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Zusammenfassung 
In Metabolic Engineering werden Stämme generiert, die bestimmte Stoffwechselprodukte 
überproduzieren. Dazu werden bestehende Stoffwechselwege von jeglicher transkriptioneller, 
translationeller und post-transkriptioneller Regulation befreit, was dazu führt, dass beteiligte 
Enzyme in hoher Anzahl vorliegen und unabhängig der Konzentration des Endprodukts aktiv 
sind. Eine komplette Deregulation eines Stoffwechselweges ist allerdings auch problematisch: 
Eine Reaktion auf interne oder externe Störungen ist häufig nicht möglich und der 
Gesamtmetabolismus überfordert mit der Überproduktion eines bestimmten Metaboliten, was 
dazu führt, dass die zelluläre Fitness reduziert wird und Wachstumsraten abnehmen. 
Um dieses Problem zu lösen, kann es hilfreich sein, neue Regulationsmechanismen in das 
metabolische Netzwerk und im Besonderen in den Überproduktions-Stoffwechselweg 
einzuführen. Bisher wurde dazu in der Regel vor allem die Enzymproduktion neu reguliert. Ein 
Beispiel dafür sind Zwei-Phasen-Bioprozesse, welche unterteilt sind in eine Wachstumsphase, 
in der ausreichend Biomasse akkumuliert wird, und eine Produktionsphase, in welcher die für 
die Überproduktion benötigten Enzyme hergestellt und gegebenenfalls Flüsse in konkurrierende 
Stoffwechselwege blockiert werden. Allerdings erlaubt eine Regulation der Enzymmenge keine 
schnelle Regulation innerhalb von Sekunden oder Minuten, was insbesondere in großen 
Bioreaktoren wichtig wäre, da unzureichende Vermischungen hier dazu führen, dass die 
Verfügbarkeit von Nährstoffen und Sauerstoff sehr stark schwanken kann. Dies kann zur 
Bildung von Bereichen innerhalb des Bioreaktors mit nur geringer Nährstoffversorgung, so 
genannter dead zones, führen. Zellen, in denen der Überproduktions-Stoffwechselweg 
dereguliert oder lediglich die Enzymmenge gesteuert wird, sind nicht in der Lage sich kurzfristig 
auf sich ändernde Umweltbedingungen zu reagieren, mit der Folge, dass solche Zellen in dead 
zones stärker gestresst werden und damit die Produktivität des gesamten Bioprozesses 
abnimmt. 
Eine schnellere und dynamische Kontrolle der Stoffwechselwege, beispielsweise durch 
synthetische allosterische Regulation eines an der Überproduktion beteiligten Enzyms könnte 
daher hilfreich sein. Allerdings ist die Konstruktion und Nutzung eines solchen Enzyms 
kompliziert. Ein wichtiges Ziel dieser Arbeit war deren Konstruktion und Überprüfung, ob mit 
diesen Flüsse abhängig des gewünschten Effektors kontrolliert werden können. 
Da synthetische allosterische Enzyme als eine Art „Metabolisches Ventil“ in den von ihnen 
katalysierten Reaktionen agieren und wir diese in vivo charakterisieren wollen, war unser erstes 
Ziel das Schalten von metabolischen Ventilen an Engpässen im Stoffwechsel (sogenannte 
Metabolic Bottlenecks) zu untersuchen (Kapitel 3). Dazu haben wir das Wachstum und 
metabolische Profile von Wildtypisolaten und Laborstämmen analysiert und konnten zeigen, 
dass in Laborstämmen ein zuvor beschriebenes Bottleneck in der Pyrimidin-Biosynthese 
(verursacht durch zu geringe pyrE-Expressionsraten), dafür sorgt, dass der Fluss in den 
Stoffwechselweg so gering ist, dass letztlich sogar die Wachstumsrate verringert ist.  
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Zusätzlich dazu haben wir CRISPR interference verwendet um 30 künstliche Bottlenecks in 
unterschiedliche Teile des metabolischen Netzwerks einzubringen. In 16 dieser Stämme mit 
einem solchen Bottleneck konnten wir erhöhte Substrat- und/oder reduzierte 
Produktkonzentrationen feststellen, die auf ein erfolgreich eingefügtes Bottleneck hindeuten. 
Allerdings konnten wir nur in 6 dieser 16 Stämme auch eine reduzierte Wachstumsrate 
feststellen, was unterstreicht, dass der Einfluss metabolischer Bottlenecks auf die zelluläre 
Fitness von der Stärke des Bottlenecks sowie der Reaktion, in die das Bottleneck eingeführt 
wurde, abhängig ist.  
Im zweiten Teil haben wir dann zwei Methoden evaluiert, mit denen synthetische allosterische 
Enzyme konstruiert werden können und welche beide auf dem Konzept der gerichteten 
Evolution basieren, nämlich „Split Proteins“ (Kapitel 4) und „Domain Insertion“ (Kapitel 5). Mit 
Hilfe des Split Protein-Ansatzes waren wir in der Lage, zwei Fragmente der 
Dihydrofolatreduktase (DHFR) mit den konditionell interagierenden Proteinen FRAP und 
FKBP12 zu verbinden, resultierend in einem Rapamycin-abhängigen metabolischem Enzym, 
das zur Kontrolle des Folat-Biosynthese und letztlich der Wachstumsrate genutzt werden kann. 
Mit dem Domain Insertion-Ansatzes konnten wir Chimere aus metabolischen Enzymen – 2-
isopropylmalate-Synthase (LeuA) bzw. DHFR – und dem Maltose-bindenden Protein MBP als 
regulatorischer Domäne bilden. Wir waren in der Lage funktionelle Proteine zu identifizieren, die 
ausreichend katalytische Aktivität haben um Deletionsmutanten zu komplementieren. Allerdings 
konnten is jetzt keine Varianten gefunden werden, die sensitiv zum Effektor Maltose sind. Das 
Domain Insertion-Protokoll haben wir dahingehend optimiert, dass nun Stammbibliotheken, 
bestehend aus tausenden Stämmen, die potentiell Maltose-abhängige Enzymvarianten 
exprimieren können, hergestellt werden können, sodass eine Hochdurchsatzmethode zur 
Identifikation der interessanten Stämme benötigt wurde. 
Im dritten Teil haben wir daher das Fluoreszenzprotein TIMER, das als Einzelzell-
Wachstumssensor verwendet werden kann, für seine Verwendung in E. coli und im Besonderen 
zur Anreicherung langsam wachsender Zellen aus einer großen Stammbibliothek evaluiert 
(Kapitel 6). Die darauf aufbauende Anreicherungsmethode soll in Zukunft dafür verwendet 
werden, Stämme mit Enzymvarianten, die mit Domain Insertion hergestellt wurden und in 
welche synthetische allosterische Regulation erfolgreich implementiert wurde, zu identifizieren 
und anzureichern.  
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1 Abstract 
In metabolic engineering strains are created that overproduce a certain product. For that, the 
production pathway is often released from any transcriptional, translational and post-
translational regulation, resulting in a high abundance of enzymes in the production pathway 
and enzyme variants with feedback-resistance. However, complete dysregulation has several 
disadvantages: the pathway cannot respond to internal and external perturbations and 
metabolism of the host is overloaded, resulting in a lowered cellular fitness and reduced growth 
rates. 
To circumvent this problem, it is desirable to implement new layers of regulation in the metabolic 
network and in particular in the overproduction pathway. So far, such regulation has usually 
been implemented by controlling enzyme abundance. Two-phase processes for instance are 
dividing a bioprocess in two phases, a growth phase in which a sufficient amount of biomass is 
accumulated, and a production phase. In this second phase, the expression of enzymes needed 
for overproduction is induced, often in combination with the introduction of metabolic 
bottlenecks in competing pathways. 
However, the regulation of enzyme abundances does not allow fast response at the second or 
minute time-scale. Especially in large-scale bioreactors fast response is important, because of 
fluctuating availabilities of nutrients and oxygen caused by insufficient mixing which leads to the 
formation of microenvironments and dead-zones. Cells in which the overproduction pathway is 
either dysregulated or regulated only by implemented control of enzyme abundance are not 
able to adjust their metabolic networks according to fast changing microenvironments, leading 
to stressed and therefore unproductive strains which might negatively affect the stability and 
durability of bioprocesses. 
This highlights the need for faster acting dynamic control of metabolic pathways, for example 
through enzymes with synthetic allosteric regulation. However, the creation and usage of such 
enzymes is very challenging. A major goal of this work was to create such enzymes with 
synthetic allosteric regulation and to test their ability to control fluxes through their pathway. 
Synthetic allosteric enzymes are ‘metabolic valves’ that implement bottlenecks in the reaction 
they are catalyzing and we sought to characterize functioning of these valves in vivo. Therefore, 
our first goal was to examine functioning of these valves, resulting metabolic bottlenecks and 
their impact on the general fitness (Chapter 3). For that, we analyzed growth and metabolic 
profiles of wildtype isolate and laboratory strains and could show that in laboratory strains a 
previously reported bottleneck caused by low pyrE gene expression causes insufficient fluxes 
through the pyrimidine biosynthesis pathway and subsequently lowered growth rates. 
In addition to that, we used CRISPR interference to introduce artificial bottlenecks in 30 
reactions in different parts of the metabolic network. In 16 of the resulting 30 strains we were 
able to detect elevated substrate or lowered product concentration, indicating a metabolic 
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bottleneck. However, only 6 of these 16 strains also had a reduced growth rate, underlining that 
the impact of metabolic bottlenecks on the growth rate is generally dependent on the reaction 
and strength of the bottleneck. 
In the second part, we then evaluated two methods to create synthetic allosteric enzymes, both 
of which are based on the concept of directed evolution: Split Proteins (Protein Fragment 
Complementation, Chapter 4) and Domain Insertion (Chapter 5). With the Split Protein 
approach we were able to couple two fragments of a split dihydrofolate reductase (DHFR) to the 
conditionally interacting proteins FRAP and FKBP12, resulting in a rapamycin-dependent 
metabolic enzyme that can be used to control the folate biosynthesis pathway and consequently 
the growth rate.   
With the Domain Insertion approach, we created enzyme-regulatory domain chimera consisting 
of 2-Isopropylmalate synthase (LeuA) and murine DHFR as enzymes and the maltose binding 
protein MBP as regulatory domain. We isolated functional proteins, but could so far not identify 
a variant that is sensitive to the effector. We optimized the protocol to an extent that libraries of 
thousands of strain variants expressing potentially switching enzymes can be generated and the 
screening for strains of interest became the limiting factor. 
In a third part of this work we therefore evaluated the fluorescent single cell growth rate reporter 
TIMER for its utilization in E. coli and especially to enrich slow growing cells out of large genetic 
variant strain libraries in a high-throughput manner using fluorescence-activated cell sorting 
(Chapter 6). The herewith developed enrichment method is planned to be applied in the future 
to strain libraries created with the Domain Insertion library approach.  
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2 Introduction 
2.1 Structure and regulation of metabolic networks 
The metabolic network of Escherichia coli is very complex and consists of numerous 
metabolites, reactions and enzymes catalyzing these reactions. The components of this network 
seem to be known for the most parts: For instance, by combining genome, transcriptome, 
proteome and metabolome data sets, a comprehensive model of the metabolic network of E. 
coli K-12 MG1655, called iML1515 1, has recently been constructed, including 1515 in 
metabolism involved genes, 1192 metabolites and 2719 metabolic reactions. Interactions 
between the different components, i.e. metabolites and proteins 2,3, metabolites and 
transcription factors 4 or metabolites and RNA 5,6 on the other hand are more difficult to identify 
and therefore presumably still unknown, highlighting that our knowledge about the metabolic 
network of E. coli is, despite decades of research, still limited. 
As a consequence of the complexity and the large metabolic capabilities as well as the need to 
use valuable nutrients in the most economic manner, one of the key characteristics of metabolic 
networks is that they are tightly regulated through controlled expression and activity of involved 
metabolic enzymes. 
4 levels of metabolic pathway control exist, 2 levels on which enzyme abundance is regulated 
and 2 levels on which enzyme activity can be controlled (Figure 1): Enzyme abundance is 
usually controlled by transcriptional and translational regulation. For Mycobacterium 
tuberculosis, enzyme abundance is also controlled by the post-translational modification 
pupylation which, similar to ubiquitination in eukaryotes, tags enzymes for targeted protein 
degradation 7. However, such a mechanism is not known for E. coli and only synthetic 
mechanisms for targeted protein degradation have been reported 8. Enzymatic activity is 
controlled through post-translational modifications and allostery. 
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Figure 1: Levels on which metabolic pathways can be controlled. 
Metabolic pathways can be controlled on four levels: (1) transcriptionally by transcription factors and alternative sigma 
factors, (2) translationally by ribozymes and riboswitches, (3) by various post-translational modifications and (4) through 
allostery. These regulation levels are ordered hierarchically from regulation that acts globally and relatively slow to fast 
acting regulation with effects on only a limited number of components of the metabolic network. 
 
Transcriptional regulation is the highest level in the regulatory hierarchy and is achieved by two 
mechanisms, alternative sigma factors and transcription factors.  
Many, if not most metabolic pathways are controlled by transcription factors that repress or 
activate transcription of specific genes by binding promoters or regulatory elements on the DNA 
and as a consequence either block access or recruit the RNA polymerase holoenzyme to the 
transcription start site of specific genes. The database RegulonDB computationally predicts the 
existence of 304 transcription factors in E. coli K12 MG1655 9, the existence of 184 has been 
shown experimentally. Some, such as CRP 10 or Cra 11 act as global transcription factors that 
possess a large regulon and consequently have a strong impact on large fractions of the 
metabolic network. CRP for instance has been shown to control the expression of at least 200 
metabolic genes, mainly coding for enzymes involved in secondary carbon source catabolism 
12, nitrogen metabolism 13, iron metabolism 14 or osmoregulation 15. Other transcription factors 
control only a very small regulon, like RhaS that controls the expression of only the genes of the 
rhamnose operon 16 or LacI with 3 target genes of the lac operon 17. Often, transcription of 
genes and operons are controlled by several transcription factors in parallel, coupling gene 
expression to multiple input signals. For instance, the lac operon is regulated by CRP and LacI, 
which couples gene expression to the availability of the preferred carbon source glucose as well 
as lactose. 
Alternative sigma factors can also be used to control transcription of metabolic genes. While 
under normal growth conditions the majority of genes is transcribed from promoters that are 
recognized by the housekeeping sigma factor σ70 18, two other, alternative sigma factors are 
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directly involved in metabolism as well: σN recognizes promoters of nitrogen-related genes, half 
of which are important for nitrogen-assimilation 19,20, σ19 controls genes involved in ferric citrate 
uptake in response to presence of periplasmic Fe(III)-dicitrate 21. 
The next level in the control of enzyme abundance acts on the level of translation. Three 
mechanisms are known to control translation of metabolic genes: riboswitches 22, small RNAs 23 
or ribozymes 24 which all usually have a repressing effect on translation, often by preventing 
binding of ribosomes to the mRNA. 
After enzymes are produced, their activity is often regulated either through post-translational 
modifications or allosteric binding of regulatory metabolites. 
Post-translational modifications are covalent modifications of enzymes after their biosynthesis 
usually with the purpose to control the enzymatic activity. In E. coli, several modifications are 
known to control metabolic enzymes of which phosphorylation and acetylation are the most 
common ones. For the enzymes involved in the central carbon metabolism regulation by post-
translational modifications has been examined systematically and several contributing 
modification methods could be identified 25. Other pathways have been examined less 
extensively, primarily because a systematic mapping of post-translational modification sites 
became only possible in recent years due to advanced and sensitive mass-spectrometry-based 
proteomics methods 26. 
Allosteric regulation is the second mechanism to control enzymatic activity and can be 
considered to be the fastest level in the hierarchy of regulatory mechanisms of metabolic 
pathways. Allosteric regulation is defined as the regulation of an enzyme through binding of an 
allosteric effector molecule at a regulatory site that is not the catalytic active site. Binding of an 
effector to the allosteric site leads to altering of the properties of the distinct catalytic site of the 
enzyme. In opposite to post-translational modifications, no modifying enzymes are required for 
allosteric regulation of enzymes. Most metabolic pathways are assumed to be regulated 
allosterically, often to create feedback loops. A classic example of an allosteric feedback 
regulation is the regulation of the N-acetylglutamate synthase ArgA. ArgA catalyses the first 
reaction in the L-arginine biosynthesis pathway. In order to regulate the flux through the 
pathway, the product of the pathway, L-arginine, binds and inhibits ArgA 27. 
Apart from negative feedback, feedforward regulation of metabolic pathways is also known, 
although less frequent. For instance, the glycolytic enzyme PfkA of Bacillus stearothermophilus 
is activated upon binding of GDP 28, which signals an increased demand for energy. 
Although many enzymes are known to be regulated allosterically, a systematic identification of 
all metabolite – protein interactions has not been possible yet because the examination of 
allosteric regulation relied so far on biochemical examinations of purified enzymes. High-
throughput approaches combining metabolomics and modelling 29 could help in the future to 
discover novel allosteric regulations. 
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2.2 Biological function of different regulation levels 
In most cases, metabolic pathways are regulated on at least two levels: First, one mechanism to 
regulate enzyme abundance, and second, one mechanism to regulate fluxes through the 
pathway by controlling enzyme activity. All above-mentioned regulation levels have important 
and distinct roles in this process. 
Regulation on the level of transcription and translation is the slowest of all regulation levels with 
adaption times (times to sense a need for adaption to the actual adaption) on the timescale of 
minutes. It is also the most energy and resource cost intensive regulation mechanism. However, 
transcriptional and translational control of metabolic pathways enables global and long-term 
adaptions of the metabolic network in response to the cellular demand for building blocks and 
energy and the availability of nutrients. Transcriptional and translational control also defines the 
metabolic capacities of a cell. 
Compared to transcriptional and translational regulation, post-translational modifications and 
allostery cannot change the metabolic capabilities of a cell. Instead, their function is to regulate 
the fluxes trough metabolic pathways within the network by regulating the activity of already 
produced enzymes and by that, limiting fluxes on a short timescale to the required level 26. Post-
translational modifications usually require two sets of modifying enzymes (activating and 
deactivating) and compounds that are added to the metabolic enzymes, thereby consuming a 
modest amount of resources. Allosteric regulation on the other hand does not require any 
modifying enzymes and only binds its allosteric effector molecule and thereby, consumes 
neither resources nor energy. Allosteric regulation also acts more direct and therefore faster 
than regulation through post-translational modifications. These differences are reasoned by the 
different tasks, post-translational modifications and allostery have for regulating metabolic 
pathways: Allosteric regulation is generally pathway-specific and therefore responsive to only 
the direct precursors or products of the regulated pathway. Post-translational modifications on 
the other hand often control several pathways and are therefore needed for more global but fast 
acting adaptions of metabolic networks 30. 
2.3 Dysregulating metabolism and its impact on fitness 
and productivity 
2.3.1 Classical overproducers 
An important approach in metabolic engineering of strains is dysregulation of overproduction 
pathways on the level of enzyme abundance and activity. For example, by replacing a 
feedback-regulated promoter with a constitutive promoter or, as an alternative, deleting the 
transcriptional regulator or its binding sites, enzyme abundance can be decoupled from 
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substrate and product concentration. In addition, removal of allosteric feedback inhibition 
maintains high enzyme activity in the presence of high end-product concentration.  
An example of this concept is a L-arginine overproducing E. coli strain 31 (Figure 2). To create 
high titers of arginine both strategies were combined: Enzyme abundance was elevated by 
deletion of the transcription factor ArgR that normally represses the expression of all enzymes 
of the arginine biosynthesis pathway in presence of arginine. In addition, the arginine binding 
site of the transcription factor ArgP had been removed which led to the overexpression of the 
arginine exporter ArgO. Next, enzyme activity was uncoupled from product concentration by 
removal of allosteric feedback regulation of the first enzyme in the arginine pathway, ArgA. 
These actions combined resulted in an overproduction of up to 11.64 g/L arginine but as a 
consequence of that, the growth rate dropped to 0.04 h-1, indicating a severe metabolic burden.  
 
 
Figure 2: L-arginine biosynthesis pathway of E. coli and genetic modifications for the 
creation of an overproduction strain. 
The L-arginine biosynthesis pathway consists of 9 enzymes catalyzing 8 reactions and an exporter (ArgO). In its native 
state, the production of L-arginine is regulated by two feedback loops: First, ArgR is a transcription factor repressing the 
expression of all 9 genes in dependence of the concentration of L-arginine. Second, the activity of the first enzyme of 
the pathway, ArgA (blue) is regulated by allostery. In order to create an L-arginine overproduction strain, 31 uncoupled 
the expression of the pathway enzymes and the activity of ArgA from the L-arginine concentration and increased the 
efflux of excessive L-arginine into the periplasm by overexpressing the arginine exporter ArgO. 
 
This highlights a key problem of metabolic engineering: Unregulated overproduction negatively 
correlates with the fitness of the cell. In general, the higher the flux into one metabolic pathway, 
the less resources are available for the remaining parts of the metabolic network, indirectly 
leading to metabolic bottlenecks in pathways competing with the overproduction pathways for 
precursors (Figure 3). This can ultimately cause a reduction of the growth rate. 
In addition to the reduced fitness resulting from the excessive consumption of metabolites, 
overproduction can also cause reduced growth rates due to cofactor imbalance 32 or the 
accumulation of cytotoxic intermediates 33,34.  
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Figure 3: Key problem of unregulated overproduction. 
Simplified illustration of the key problem of unregulated overproduction: In wildtype strains metabolic pathways are 
tightly controlled in order to produce only as much as needed of a certain metabolite (left), in unregulated 
overproduction strains a significant ratio of the metabolic flux is redirected into the production pathway, leading to an 
extensive demand and consumption of precursors that cannot be utilized in competing metabolic pathways required for 
growth. 
 
In order to solve the problem of reduced fitness when overexpressing certain products, 
an introduction of a novel regulation of the overproduction pathways might be beneficial 
to ensure both, fitness of individual cells and overproduction. 
2.3.2 Two phase bioprocesses 
The most simple and direct way to control a bioprocess is to separate growth and production 
phases (Two-phase bioprocess, Figure 4). During the growth phase a certain biomass is 
produced in the bioreactor, which usually requires that that fluxes into the overproduction 
pathway are low. In a second phase, overproduction is induced, usually by overexpressing 
metabolic feedback-resistant enzymes35, and reducing fluxes into competing pathways 36.  
The overexpression can be controlled either externally or internally. The classical approach to 
externally initiate the production phase is the induction of gene expression by inducer 
molecules, such as IPTG. However, such inducer molecules are expensive and therefore not 
suitable for industrial applications. As a consequence, other systems have been developed that 
use for instance light 37, oxygen 38, pH shifts 39 or temperature 40 to externally control the shift 
from growth to production phase. 
An alternative strategy is to autonomously induce overproduction. For instance, recently a 
system has been developed in which a heterologous quorum sensing system had been used to 
repress transcription of glycolysis genes, allowing a biomass-dependent switch from the growth 
to the production phase 41. In a later publication 42, this system has been combined with a 
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biosensor-based system that switches overproduction on in presence of a sufficient 
concentration of a precursor of the overproduction pathway.  
 
 
Figure 4: Two-phase bioprocess. 
In two-phase bioprocesses, the bioprocess is divided in two phases, a growth phase (blue) in which biomass is 
accumulated without devoting resources for the overproduction. When enough biomass is accumulated, the production 
phase is started (green) by inducing the overproduction pathway and/or repressing competing pathways, leading to an 
increase of the product concentration (red). As the metabolic fluxes are redirected into the overproduction pathway, in 
many cases the metabolic network is drained, leading to a significant decrease of the growth rate. 
 
However, it should be noted that although all these approaches have shown to enable more 
efficient overproduction compared to unregulated, static overproduction, many of these systems 
have to be regarded as inflexible on-off control that ignores the physiological states of individual 
cells: Usually, once the production process is started, the cells usually keep producing until they 
either escape the growth burden by mutations or they die because they are not able to maintain 
the physiological state that would be needed to repair damages, e.g. in DNA or cell envelope. 
This will subsequently lead to decreasing productivity and limits the duration of a bioprocess. 
2.3.3 Continuous control of overproduction pathways 
An alternative to this strategy is dynamic and continuous control of metabolic pathways 34. 
Continuous control of overproduction pathways allows the autonomous and permanent sensing 
of certain signals and regulating gene expression accordingly.  
One of the first described examples for continuous control is the coupling of lycopene 
overproduction in E. coli to the glycolytic flux by expressing pathway enzymes under the control 
of Ntr, a global transcription factor which is regulated by the concentration of acetyl phosphate 
43. 
Another example of has been presented recently for the overproduction of biofuels which are 
often toxic to the producing cell. The low titers caused by the toxicity of the final product could 
be increased by developing and overexpressing efflux pumps 44 to transport the toxic 
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compounds out of the cells. However, overexpression of the efflux pumps led to a growth 
burden. Therefore, the benefit of sensing the product concentration and regulating the 
expression of the efflux accordingly has been evaluated 45 and implemented in E. coli 46. 
In order to solve the problem of decreasing productivity as a result of the growth burden caused 
by overexpression, continuous control of overproduction pathways could be used. For instance, 
overexpression could be directly coupled to the availability of nutrients or the general fitness 
state of the cell. One such a system has been developed recently which introduces burden-
sensing feedback regulation to control the overexpression of genes of interest 47. For that, a 
promoter that is responsive to the metabolic burden caused by excessive gene expression has 
been identified and used to control the expression of a guide RNA (gRNA). This gRNA is part of 
the CRISPR interference system 48 that allows targeted repression of transcription and has 
been designed to target the overexpressed gene of interest, leading to a gene expression 
repression when the metabolic burden caused by the gene expression is too high.  
All the above mentioned examples show that a continuous control on the level of enzyme 
abundance is beneficial for the stability and productivity of bioprocesses. However, for 
bioprocesses continuous control on the level of enzyme activity might have additional 
advantages as a result of shorter reaction times.    
The reason for this are the environmental conditions, cells face within a bioreactor 49. Especially 
in large bioreactors, insufficient mixing causes the formation of gradients of glucose, pH or 
oxygen and, as a consequence, the formation of areas with very different environmental 
conditions. Problematic for overproducing cells are in particular areas in which the concentration 
of required nutrients is insufficiently low, so called ‘dead zones’ 50. Cells in a such a zone with 
low nutrient availability will be unproductive and stressed 51, whereas in areas with high nutrient 
availability unwanted acetate overflow metabolism can be observed 52.  
To avoid these negative effects, it might be beneficial to introduce positive feedforward 
regulation to control overproduction. For instance, one could develop a system that enables 
sensing of the environmental conditions an individual cell is facing, i.e. the nutrient availability or 
the general fitness state, and control the fluxes through an overproduction pathway accordingly 
(Figure 5). As the environmental conditions within a bioreactor can change on a very short time 
scale and keeping in mind that transcriptional control of metabolic pathways reacts very slowly 
and requires resources to produce new enzymes, feedforward regulation of overexpression 
pathways should be not implemented on the level of enzyme abundance but instead on the 
level of enzyme activity, e.g. by introducing synthetic allosteric regulation into enzymes of the 
overproduction pathway. 
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Figure 5: Dynamic feed forward regulation of overproduction pathways. 
As an alternative to deregulated overproduction, the activity of an enzyme of an overproduction pathway could be 
coupled to the availability of nutrients or the concentration of fitness state indicators. By that, metabolic fluxes through 
the overproduction pathway could be limited to a level that allows overproduction while keeping a basal level of fluxes 
into competing pathways required to maintain the fitness state of the cell. 
 
 
So far, only a very limited number of enzymes with synthetic allosteric regulation to control 
overproduction pathways have been developed. We therefore sought to construct metabolic 
enzymes with synthetic allosteric regulation.  
2.4 Engineering switchable enzymes 
Engineering switchable proteins and enzymes, especially with synthetic allosteric regulation, is 
of great interest for many fields of biology, medicine and chemistry, as they can be used for a 
wide range of applications such as in vivo metabolite sensors 53, as allosteric drugs with 
improved target specificity 54, in synthetic biology to create orthogonal switches for synthetic 
circuits 55 or – as in our case – to control metabolic pathways in metabolic engineering. The high 
demand can be explained by the immediate reaction of switchable enzymes on effectors and 
that no resources have to be invested for modulation of activity 56. On the other hand, the 
introduction of synthetic transcriptional regulation is often preferred to synthetic allosteric 
regulation. The reason for this is that knowledge about allosteric regulation of proteins of 
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interest is often limited and very challenging to (re-)engineer. However, a few strategies to 
engineer such enzymes have been developed, that either base on the concept of rational 
design or directed evolution 57. 
2.4.1 Engineering allosteric regulation 
2.4.1.1 Rational Design approaches 
Rational design-based methods rely on the comprehensive knowledge about the structural 
properties of the enzyme of interest and, in particular, of structural changes upon binding of 
allosteric effectors so that, in consequence, the enzymes of interest can be modified very 
targetedly.  
Several groups used rational design approaches to introduce new allosteric binding sites into a 
protein of interest or to re-engineer the allosteric binding site to be responsive to alternative 
allosteric effectors. In one application, hotspots on the surface of the dihydrofolate reductase 
DHFR have been identified in which light-sensing LOV2 domains have been inserted targetedly, 
resulting in light-controlled DHFR enzymatic activity 58. 
An example for the rational design of an allosteric binding site in the context of metabolic 
engineering was the creation of a L-lysine-responsive homoserine dehydrogenease (HSDH) of 
Corynebacterium glutamicum 59. For that, first the allosteric binding site was identified by 
random mutagenesis, followed by reengineering of the allosteric binding site to bind solely L-
lysine instead of the natural inhibitors L-threonine and L-isoleucine. This enzyme variant can be 
used in a lysine overexpression strain to repress the flux into the homoserine biosynthesis 
pathway. 
Generally, methods for rational design of allosteric regulation are emerging 60 but still limited 
due to the incomplete understanding of how allostery works 61,62 and lacking knowledge about 
the structural properties of many enzymes – ideally in both states, when bound to an allosteric 
effector and unbound – and many regulatory domains. 
2.4.1.2 Directed Evolution approaches 
As for many proteins of interest, the knowledge about structural properties is limited and the 
consequences of modifications on enzyme function on a rational basis is difficult to predict, in 
many cases, methods based on directed evolution are preferred over rational design 
approaches as these methods allow the re-engineering of allosteric regulation into proteins of 
interest without prior knowledge about their structural properties. Among a wide-range of 
methods 56,57,63, two strategies could successfully applied by several groups to engineer proteins 
with novel allosteric regulation: Split/Fusion Proteins 64 and Domain Insertion 65 (Figure 6). 
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Figure 6: Two strategies to create switchable enzymes with directed evolution-based 
approaches. 
Left: Split Proteins consist of two regulatory proteins (orange and red) which only interact in presence of an effector 
(green). Fused to the regulatory proteins are fragments of a split enzyme. When separated, none of the fragments is 
catalytically active. Only when brought into close proximity, both fragments reassemble and form a functional enzyme. 
Right: Domain Insertion of an enzyme (blue) into a regulatory domain (red), resulting in an enzyme-regulatory domain 
fusion protein. The regulatory domain undergoes a conformational change upon binding of an effector (green) which is 
transmitted to the fused enzymatic domain which changes its activity upon. 
Fusion and Split Proteins 
Fusion proteins are simple end-to-end fusions of a protein of interest with a regulatory protein, 
often connected via a linker 63. One example of a fusion protein is a β-lactamase (BLA) that was 
fused to a nanobody, a fragment of an antibody so that only when bound to cancer cells, the β-
lactamase was catalytically active 54. This protein fusion acts as a proof of concept for the 
development of site-selective drugs. 
For many proteins, due to structural reasons a simple fusion with a regulatory domain will not 
lead to a switching protein. In these cases, an alternative could be to use split proteins (Figure 
7). 
Split proteins are proteins or enzymes that have been divided into two fragments. The individual 
fragments themselves are not enzymatically active; only when brought in close proximity, the 
fragments reassemble and form a functional protein or enzyme. Such proteins have been 
created by several groups and employed mainly as reporter proteins in Protein 
Complementation Assays (PCA). Protein complementation assays allow the analysis of protein-
protein interactions by fusing two potentially interacting proteins of interest to the fragments of a 
split protein. Only in case of an interaction of both proteins, the fused protein fragments 
reassemble to form a functional reporter enzyme for which split GFP 66, murine dihydrofolate 
reductase (mDHFR, 67), adenylate cyclase (AC, 68) and β-lactamase (BLA, 69) are commonly 
used. For instance, in a recent study by fusing potentially interacting proteins to two fragments 
of split mDHFR 2770 protein-protein interactions in Saccharomyces cerevisiae have been 
identified 70.  
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Figure 7: Construction of Split Proteins. 
Left: A monomeric enzyme of interest (blue) is split in two fragments. Center: The genes coding for the enzyme 
fragments are fused to the genes of regulatory proteins often with sequences encoding linkers in between. Right: the 
resulting split proteins consist each of an enzyme fragment (blue) and one of the regulatory proteins (orange and red). 
In presence of an effector (green), the two regulatory proteins interact, bringing the fused enzyme fragments into close 
proximity. Only then both fragments reassemble to a functional enzyme.  
 
The concept of Split Proteins can also be applied for other purposes. In a recent application, 
catalytically deactivated Cas9 (dCas9) had been split into two fragments and fused to different 
regulatory proteins, allowing artificial control of dCas9 activity and by that condition-dependent 
transcription regulation of targeted genes 71. 
In this work, we sought to apply the concept of Split Proteins to create enzymes with synthetic 
regulation to control metabolic pathways and eventually growth (Chapter 4).  
Domain Insertion 
The second method based on directed evolution is called Domain Insertion. The concept of this 
method is to randomly insert a protein of interest into a regulatory domain, resulting in a 
chimeric protein with two domains that both are intended to be still functional.  
For that, the gene of a regulatory domain is randomly cut by sequence-independent nucleases 
such as S1 nucleases or DNase I, the gene of the enzyme of interest is then inserted into the 
  Chapter 2 - Introduction 
 
19 
cut site, resulting in a gene fusion consisting of two fragments of the regulatory domain and the 
enzymatic domain (Figure 8). When this gene fusion is expressed, a protein chimera consisting 
of an enzymatic domain fused into a regulatory domain is produced. This chimera ideally has at 
least two modes of enzymatic activity, an ON state and an OFF state. Upon binding of an 
allosteric effector to the regulatory domain, the regulatory domain changes its conformation and 
transduces this change to the fused enzymatic domain which activity is altered upon.  
 
 
Figure 8: Domain Insertion Overview. 
(A) For Domain Insertion, a regulatory domain gene is randomly split into two parts, e.g. by sequence independent 
nucleases. In this cut site the gene of an enzyme of interest is inserted. The enzyme gene has been amplified without 
start or stop codons but including linker coding sequences at both ends. (B) Ligation product consisting of two fragments 
of a regulatory domain and an enzymatic fragment in between. (C) Resulting enzyme – regulatory domain fusion. Both 
regulatory domain fragments form a functional protein domain that is responsive to an effector (green). Conformational 
changes upon binding of the effector are transduced to the enzymatic domain, altering its activity. 
 
This approach has been applied successfully to create several proteins and enzymes with 
synthetic allosteric regulation (Table 1). One of the earliest examples was the insertion of 
calmodulin receptor proteins into GFP, resulting in a fluorescence protein that is responsive to 
Ca2+ ions 72. In another study, a maltose-dependent β-lactamase has been created using 
Domain Insertion of the β-lactamase gene into the gene of the maltose-binding protein MalE 
73,74. Later, the maltose binding protein has been replaced by structurally similar binding proteins 
for ribose 75, glucose and xylose 76. 
Applications of Domain Insertion to construct enzymes with synthetic allosteric regulation to 
control metabolic pathways are rare. The insertion of DHFR into an estrogen receptor resulted 
in a switchable metabolic enzyme which however has only been used as biosensor, and not 
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with the purpose to artificially control the folate biosynthesis pathway or even growth rates 77. In 
a very recent example, Domain Insertion has been used to construct a ferredoxin-estrogen 
receptor to control a synthetic electron transfer pathway and subsequently the growth rate 
dependent on the effector 4-hydroxytamoxifen (4-HT). However, to our knowledge no further 
application to create condition-dependent metabolic enzymes to control pathways and 
subsequently growth has been reported so far. One of our goals was therefore to evaluate the 
Domain Insertion approach to create such enzymes (Chapter 5). 
 
Table 1: Proteins and regulatory domains that have been used as components of enzyme 
switches created by Domain Insertion. 
Regulatory 
Domain 
Enzyme/ 
Protein 
Effector Reference 
Calmodulin Green fluorescent protein 
(GFP) 
Ca2+ 72 
Estrogen receptor Dihydrofolate reductase 
(DHFR) 
4-hydroxytamoxifen  
(4-HT) 
77 
Maltose binding 
protein (MBP) 
β-lactamase (BLA) Maltose 73 
Maltose binding 
protein (MBP) 
Green fluorescent protein 
(GFP) 
Maltose/Trehalose 78 
Ribose binding 
protein (RBP) 
β-lactamase (BLA) Ribose 75 
Glucose binding 
protein (GBP) 
β-lactamase (BLA) Glucose 76 
Xylose binding 
protein (XBP) 
β-lactamase (BLA) Xylose 76 
Maltose binding 
protein (MBP) 
Green fluorescent protein 
(GFP) 
Maltose/Trehalose 79 
Estrogen receptor Ferredoxin 4-hydroxytamoxifen  
(4-HT) 
80 
Estrogen receptor (CRISPR)-associated 
protein Cas9 
4-hydroxytamoxifen  
(4-HT) 
81 
 
Domain Insertion has, compared to other approaches, one important advantage: As the 
enzymatic gene is inserted randomly, no knowledge about the structural properties of involved 
proteins is required – the protocol is therefore also applicable to proteins that were not 
extensively characterized. However, past applications showed that only a small portion of 
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created enzyme–regulatory domain chimera result in functional enzymes of which again only a 
minority shows condition-dependent enzymatic activity. For instance, for the construction of 
maltose-controlled β-lactamases (BLA), only 0.8% of all strains possessed a functional enzyme 
of which again only 10 % also possessed a still functional maltose-binding regulatory domain. 
For Domain insertion, it is therefore key to create large libraries of enzyme-regulatory domain 
variants with many combinations of connecting linkers and insertion sites and to subsequently 
screen these libraries for enzymes with the desired phenotype. Hence, as a consequence of the 
library sizes, another important factor is the existence of an effective screening or selection 
method to identify enzyme variants with the desired functions. 
2.4.2 Techniques to identify and isolate enzymes with synthetic 
allosteric regulation 
In order to identify and subsequently isolate enzymes with synthetic allosteric regulation, 
several techniques can be used.  
The conventional approach is the screening of candidate enzymes by in vitro assays. For that, 
enzyme candidates are purified and reactants measured by spectrophotometry or mass 
spectrometry, enabling the determination of kinetic properties of enzymes 82, e.g. in presence 
and absence of an allosteric effector. The purification of enzymes is very laborious and time 
consuming, hence, for the screening of larger libraries of enzymes with potentially synthetic 
allosteric regulation, such in vitro assays are ineligible. 
Instead, methods are required that allow the screening of many enzymes with a high throughput 
and without the need to purify enzymes in advance, i.e. in vivo measurements of enzymatic 
outputs are preferred to in vitro assays. 
2.4.2.1 Biosensor-based screening for enzymes with synthetic 
allosteric regulation 
One successfully applied strategy for the in vivo screening for enzymes with synthetic allosteric 
regulation is based on the usage of genetically encoded biosensors. Biosensors are systems 
that enable sensing of certain input signals, e.g. metabolite concentrations, which result in 
changes of a measurable output signal, e.g. fluorescence, luminescence or antibiotic 
resistance. Biosensors can be classified in three groups: sensors based on Förster resonance 
energy transfer (FRET), riboswitches and transcription-factor based sensors. Although FRET- 83 
and riboswitch-based 84 biosensors have been successfully designed and applied, the most 
common strategy to create biosensors is based on transcription factor – reporter gene 
combinations. In these a transcription factor that is responsive to a specific signal molecule (e.g. 
the product or substrate of an enzyme of interest) is used to control the expression of a gene 
encoding for instance a fluorescence reporter. Two factors contribute to the popularity of 
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transcription factor-based biosensors: First, they consist of only two components that can easily 
be exchanged. Second, transcription factors responsive to a large variety of effector molecules 
are highly abundant in pro- and eukaryotes. E. coli possesses 200 – 300 transcription factors 85 
with different effector molecules that could be used for biosensor construction. In addition, a 
utilization of heterologous transcription factors has been shown 86, as well as the construction of 
novel transcription factors 87,88, so that the pool of usable transcription factors even further 
extends. 
An application of transcription factor-based biosensors to screen for enzymes with desired 
phenotypes has already been shown recently in which the NADPH-responsive transcription 
factor SoxR of E. coli has been utilized to control the expression a fluorescence protein in 
presence of low NADPH concentrations 89. This biosensor system has then be used for the in 
vivo screening of a library of NADPH consuming alcohol dehydrogenase from Lactobacillus 
brevis (LbAdh) variants to identify versions with a high enzymatic activity. 
Though, not for every metabolite and in particular not every intermediate of biosynthetic 
pathways are biosensors available and the construction of novel transcription factors is – 
despite recent advancements 90 – still challenging.  
A less specific approach to identify switchable enzymes in a high-throughput manner could 
therefore be not to measure specific output signals (such as product concentrations) but instead 
to couple enzymatic activity to a general output such as the physiological state, i.e. the growth 
rate.  
2.4.2.2 Growth-based methods for screening of enzymes with 
synthetic allosteric regulation 
In order to identify and isolate switchable enzymes with growth-based assays, it is crucial that 
the activity of the enzyme of interest defines the growth rate of the host cell. This is the case 
when the enzymatic activity is essential in the given environmental conditions but in addition so 
low that any change in enzymatic activity has an altering effect on the growth rate. In this case, 
strains with switchable enzymes have high growth rates in one (e.g. presence of the effector) 
and low growth rates in the other (e.g. absence of the effector) environmental condition. In 
contrast, non-functional enzyme variants will not support growth, whereas active enzyme 
variants in which the implementation of allosteric regulation was not successful will result in high 
growth rates independent of the presence of the allosteric effector (Figure 9). In order to identify 
and isolate switchable enzymes with growth-based assays, therefore two rounds of selection or 
screening are required: First, a positive selection round to screen for functional enzymes and to 
exclude non-functional enzymes from the pool of candidate enzyme variants, and second, a 
negative selection or screening round in which all strains are sought to be identified in which a 
conditionally inactive enzyme leads to lowered growth rates. 
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Figure 9: Growth-based screening and selection of enzyme switches. 
3 types of enzyme variants result from directed evolution-based enzyme switch construction methods: (1) Switches that 
are active in one condition (here: presence of the effector) and inactive in the second condition (absence of the effector), 
(2) enzyme variants that are active independent of the effector and (3) enzyme variants that are catalytically inactive 
independent of the effector. In order to identify enzyme switches (1) with growth-based approaches, two rounds of 
selection are required: First, a positive selection to enrich all strains that possess a functional enzyme variant (1 and 2) 
and to deplete all strains without functional enzyme variants (3). Second, a negative selection in which all strains with 
conditionally inactive enzymes (1) should be enriched and distinguished from all strains with active enzyme variants (2). 
 
Classical approaches to measure growth rates and by that, screen for strains with certain 
growth phenotypes are based on growth assays in bioreactors, shake flasks or microtiter plates 
91–93. Although they would enable an accurate determination of the growth characteristics in both 
growth conditions (presence and absence of the effector), such assays are limited in the 
number of individual strains that can be screened in parallel. For the screening of libraries of 
enzyme variant expressing strain libraries, the throughput is too low.  
A higher throughput can be reached when strain libraries are pooled prior to growth 
measurements. Pooled competition assays enable the identification of strains with certain 
growth rates 94,95. For that, a pooled strain library is grown for several generations. Before and 
after culturing samples are taken for next generation sequencing (NGS), allowing the 
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comparison of library compositions and thereby the identification of strains with higher and 
lower growth rates. By comparing compositions of the library grown in presence of the effector 
with the library grown in absence of the effector, one could therefore identify strains that 
possess switching enzymes. However, that necessitates the retrospective re-engineering of 
switches which is a very laborious process. 
A simpler solution would therefore be to select for strains with condition-dependent enzymes. 
For that, strains have to be identified and enriched out of a pooled strain library according to the 
desired phenotype in both presence and absence of the effector.  
The enrichment of fast growing cells out of pooled libraries can easily be reached by pooled 
competition in which the ratio of slow growing strains within the library is decreasing over time. 
By that, one can enrich strains with catalytically active enzyme variants and remove 
dysfunctional enzyme variants from the library.  
The negative selection for strains with conditionally inactive enzymes by enriching slow growing 
cells on the other hand is very challenging. Only a few methods to do so have been described. 
2.4.2.3 Techniques to enrich slow growing cells 
One strategy is based on reducing the well growing population by short phases of incubation in 
presence of cytotoxic antibiotics 96. Whereas fast growing bacteria are susceptible to the 
antibiotics and effectively killed, slow and non-growing bacteria are less susceptible and more 
likely to survive the treatment. We initially evaluated a similar approach for this project but 
rejected it because of its complexity (optimal antibiotic concentration and duration of treatment). 
Other methods are based on the utilization of fluorescent reporters, allowing a high-throughput 
enrichment of slow growing cells using flow cytometry. 
One such method called FitFlow has been developed for yeast 97. It is based on a strain with a 
knocked out gene encoding the chitinase CtsI. In wildtype cells this chitinase is responsible for 
the degradation of the linkage between mother and daughter cell upon cytokinesis. The 
chitinase knockout therefore results in the formation of microcolonies. Prior to the growth assay, 
the cells are briefly sonicated for separation of cells. Next, the cells are incubated for several 
generations, resulting in microcolonies, each derived from a single strain. By using a histone-
GFP fusion protein, the microcolonies can then be separated with flow cytometry according to 
the microcolony sizes which are directly reflecting the growth rates of the cells. By isolating 
small microcolonies, cells with impaired growth rates can be specifically enriched and 
subsequently analyzed in more detail. Although this method has been proven to efficiently 
separate slow from normal and fast growing strains, this method has also several 
disadvantages: The most important one is that this method is limited to yeast strains with the 
particular chitinase knockout. It is imaginable that it could be applied to other yeast strains or 
microorganisms with similar cell division. However, in bacteria such as E. coli, this system 
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cannot be applied due to differences in the mode of cell division 98. Another problem might arise 
from potentially different physiologies of cells with a chitinase deletion and without. Particularly, 
cells in microcolonies compete with each other for nutrients stronger than isolated single cells 
would do, possibly influencing the fitness state of the cells. 
A similar method which also uses the formation of microcolonies to separate strains with 
different fluorophore expression patterns has been developed 99. In their approach, single cells 
are encapsulated in small gel beads. When incubated, microcolonies deriving from these single 
cells form in the gel beads which theoretically could later be sorted according to the microcolony 
sizes that would again directly reflect the growth rates of the individual strains. Compared to 
‘FitFlow’, the big advantage of this method is that it allows the enrichment of slow growing 
strains independent of the cell’s genotype and is therefore applicable to many different 
microorganisms. However, this method has the same drawback that cells within microcolonies 
might have a different physiology compared to single cells. In addition to that, cells within gel 
beads might be potentially supplied worse with nutrients than cells with direct contact to the 
surrounding medium. It is also be worth noting that the sorting of gel beads according to the 
growth rates has been discussed in their publication but not shown yet. 
Therefore, as all these methods are not applicable for our project, we decided to develop our 
own method to enrich slow growing cells out of pooled strain libraries using the fluorescent 
single cell growth reporter TIMER. 
2.4.2.4 TIMER 
TIMER is a fluorescent reporter protein that bases on the Discosoma red fluorescent protein 
dsRed 100. Due to two introduced point mutations it has the exceptional feature of appearing 
green when freshly expressed but it also maturates with a time delay to its second, red form 
(Figure 10). This characteristic enabled its use as a single cell growth rate sensor 101: In slow 
growing cells, TIMER has time to maturate, resulting in cells with partially green and red 
fluorescent variants. In fast growing cells on the other hand, the fraction of maturated TIMER is 
diluted with every cell division and the pool of TIMER proteins inside the cell replenished with 
freshly expressed and therefore green appearing TIMER.   
This feature has been used in Salmonella species in infected mice tissues to examine 
resistance of slow growing cells against treatment with antimicrobials 102. In another study, 
TIMER has been used to visualize E. coli cells with different growth rates in biofilms 101. 
However, although both studies have shown that TIMER can be used to distinguish fast from 
slow growing cells – a characteristic that might be of interest for many fields of biology and 
metabolic engineering –, other applications of this reporter have not been described yet. 
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Figure 10: Principle of TIMER as a growth rate sensor.  
When freshly expressed, TIMER appears green and refolds spontaneously over time to a red fluorescent form. Slow 
growing cells (bottom) therefore accumulate the red fluorescent form and appear less green than fast growing cells. In 
fast growing cells (top), the fraction of already expressed and partially maturated TIMER gets diluted with every cell 
division while the TIMER pool is replenished with freshly expressed, green appearing TIMER. Faster growing cells 
therefore appear greener. 
 
 
 
For the screening of strain libraries of strains with enzymes with synthetic allosteric regulation, 
we intend to use TIMER as a tool to enrich slow growing cells in presence or absence of the 
intended allosteric effector. We therefore sought to verify first how good TIMER can display the 
growth rate in E. coli batch cultures and subsequently tried to enrich slow growing strains out of 
a pooled library of genetic variant strains (Chapter 6).  
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2.5 Goal of this work 
The major goal of this work was to create metabolic enzymes with synthetic allosteric regulation 
to control metabolic pathways with directed evolution methods. The process to obtain such 
enzymes can be illustrated by an engineering cycle as depicted in Figure 11: First, method and 
components (enzymes, regulatory domains and linkers) have to be evaluated and selected. 
Next, libraries of potentially switching enzymes are constructed. These libraries have then to be 
screened for enzymes with successfully implemented regulation. Identified enzymes can then 
be further analyzed and evaluated for their usage in an application or for further rounds of re-
engineering. 
  
 
Figure 11: Creation of enzymes with synthetic allosteric regulation.  
 
For this project we worked on 3 parts of this engineering cycle as highlighted in Figure 11: 
Part 1 – Understanding the impact of metabolic bottlenecks on the general state 
of fitness (Chapter 3) 
To create metabolic enzymes with artificial regulation, we decided to focus on essential 
enzymes that would affect growth rates in their OFF states, i.e., enzymes which, when having a 
lowered activity as a result of their synthetic allosteric regulation, limit fluxes through an 
essential biosynthetic pathway, subsequently leading to impaired growth rates. For that 
purpose, in the first part of this project, we sought to better understand the impact of flux limiting 
metabolic bottlenecks can have on the metabolic network and the overall fitness, represented 
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by the growth rate. As a starting point we therefore examined metabolism and growth rates of 
72 E. coli wildtype isolates and 5 laboratory strains to identify rate-limiting steps and bottlenecks 
(Chapter 3.1). Next, we introduced metabolic bottlenecks on the transcriptional level using 
CRISPR interference to elucidate which physiological responses we can expect when 
decreasing enzymatic activity (Chapter 3.2 and 3.3). 
 
Part 2 – Construction of enzymes with synthetic allosteric regulation (Chapters 4 
and 5) 
In the second part, for the construction of enzymes, we evaluated two techniques that are both 
based on directed evolution: Split Proteins (Chapter 4) and Domain Insertion (Chapter 5). With 
the Split Protein approach, we created a rapamycin-dependent DHFR variant and evaluated its 
impact on the growth rate of an expressing E. coli strain. For the Domain Insertion approach, we 
defined guidelines for the choice of components (Chapter 5.1), tested the expression plasmid 
(Chapter 5.2), and were able to create complementing enzyme variants with an optimized 
Domain Insertion protocol (Chapter 5.3). 
 
Part 3 – High-throughput selection of switchable enzymes (Chapter 6) 
As the abovementioned techniques to create enzymes with synthetic allosteric regulation 
usually involve the construction of large strain libraries with potentially switching enzymes, in 
third part of this work we devised a strategy to enrich strains that express switchable enzymes. 
As screening of single strains expressing candidate enzymes is not feasible with sufficient 
throughput, we evaluated and validated the single cell growth rate reporter TIMER to specifically 
enrich slow growing cells out of complex genomic variant strain libraries (Chapter 6).  
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3 Understanding the impact of metabolic 
bottlenecks on the general state of 
fitness  
 
In this work, metabolic enzymes with synthetic allosteric regulation were planned to be created 
that are supposed to work as metabolic valves, i.e. to introduce condition-dependent metabolic 
bottlenecks in single reactions of interest. We were wondering how metabolic networks are 
affected by metabolic bottlenecks in single reactions and decided therefore to examine the 
prevalence of metabolic bottlenecks and their impact on the fitness states in genetically not 
modified wildtype and laboratory strains.  
3.1 Metabolic bottlenecks in E. coli wildtype and 
laboratory strains 
The EcoR collection is a set of 72 E. coli wildtype strains isolated from a large variety of 
mammalian host organisms from different locations 103. Our initial assumption was that, 
dependent on host and isolation location, the E. coli strains faced different environmental 
conditions such as available nutrients and should have therefore adapted their metabolic 
network to the respective specific environments. Such an adaption can lead to a loss of 
metabolic capabilities and misregulations as a consequence of mutations which however have 
no impact on the fitness in their natural environment. 
We were interested if we could identify metabolic bottlenecks in single reactions that might even 
impair the general fitness of the cells in conditions that differ from the natural growth conditions.  
For that, we compared the growth rates of the 72 strains of the EcoR collection in M9 minimal 
medium with glucose as carbon source and under aerobic conditions and incubated at 37°C. In 
addition to these strains we also analyzed the growth of 5 commonly used laboratory strains (E. 
coli MG1655, W3110, MDS42, BW25113, EMG-2) (Figure 12). 
We found that a majority (66 of 77) of all strains had similar growth rates of 0.6 h-1 and higher, 
whereas a group of 11 strains had lower growth rates. To our surprise, all laboratory strains 
were found to belong to this group with growth rates between 0.41 ± 0.04 h-1 (MG1655) and 
0.47 ± 0.18 h-1 (MG1655). 
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Figure 12: Growth rates of 72 wildtype isolates and 5 laboratory strains. 
Blue bars indicate growth rates of wildtype isolates from the EcoR collection 103, red bars of laboratory strains. Shown 
are the mean growth rates measured in three independent growth experiments.  
 
 
To test if the reduced fitness can be linked to metabolic bottlenecks in single reactions we 
measured the concentrations of 94 metabolites of central carbon metabolism, nucleotide 
metabolism, amino acid metabolism and other parts of the metabolic network in all 77 strains 
(Figure 13) using high-throughput metabolomics techniques 104.  
We noticed that all laboratory strains had a similar metabolic profile, which differed from the 
wildtype isolates. Specifically, we observed a markedly higher abundance of three intermediates 
of the pyrimidine pathway, N-carbamoyl-L-aspartate, dihydroorotate and orotate (Figure 13b + 
c). On the other hand, the concentration of UMP, a later intermediate of the same pathway, was 
relatively low. These results indicate a metabolic bottleneck in a reaction between orotate and 
UMP and can indeed by explained by a reported frameshift mutation in the gene upstream pyrE, 
rph 105. This frameshift leads to lower expression rates of pyrE which codes for the orotate 
phosphoribosyltransferase, an enzyme that utilizes orotate and PRPP to convert it to the direct 
precursor of UMP, orotidine 5'-phosphate. Remarkably, the strain MDS42 possesses a minimal 
genome with over 700 genes deleted 106. However, compared to the other laboratory strains, no 
difference in growth rate or metabolite pattern could be determined. 
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Figure 13: Concentration of 94 metabolites in 72 E. coli wildtype isolate and 5 laboratory 
strains and metabolites of the pyrimidine biosynthesis pathway. 
(A) Clustered heatmap with all 94 metabolites on the Y-axis and all tested strains on the X-axis. The blue and red bars 
underneath the strain labels mark laboratory strains (red) and wildtype strains (blue). The colors in the heatmap indicate 
an up to 10 fold increase (yellow) or decrease (blue) of metabolite concentrations compared to MG1655. On the upper 
part strains are clustered that share a similar metabolic profile. In red all laboratory strains are marked. On the left side 
metabolites with a similar appearance in the different strains are clustered together. The three rows at the bottom are 
the intermediates of the pyrimidine biosynthesis pathway. (B) Overview over the pyrimidine biosynthesis pathway. All 
intermediates that we were able to measure are marked. (C) Metabolite concentrations of the 4 intermediates 
normalized to MG1655. Blue bars indicate the concentrations measured in wildtype isolate strains, red bars in the 
laboratory strains (from left to right: MDS42, W3110, BW25113, EMG-2, MG1655). 
 
In the natural isolate strains, linkages between growth phenotypes and metabolic bottlenecks 
were less apparent. 
In EcoR51, one of the slowest growing strains, we could measure the highest levels of PEP. 
PEP is substrate and product of several metabolic reactions in E. coli, it is therefore unclear in 
which reaction is limited as a result of a metabolic bottleneck. However, we speculate that as a 
result of the general importance of these pathways for the generation of energy and precursors 
for amino acid biosynthesis, metabolic bottlenecks in central carbon metabolism 
(dephosphorylation of PEP to pyruvate catalysed by pyruvate kinase), or anaplerosis 
(carboxylation of PEP to oxaloacetate, catalysed by PEP carboxylase) could not just result in 
the accumulation of PEP but might also result in reduced growth rates.  
For three other slow growing natural isolates - EcoR23, 29 and 52 - we could not identify any 
specific metabolic bottleneck. However, all of those show a similar metabolic profile that was 
very distinct to all other strains, suggesting that all these strains possess a similar metabolic 
network and possibly the same metabolic bottlenecks. 
For the slow growing strains EcoR8 and 49 we could also not identify a metabolic bottleneck. 
Instead, we found that their metabolic profiles were similar to those of the faster growing strains 
EcoR27 and EcoR42 – both with growth rates above 0.7 h-1. 
It should be noted that only 94 of 1192 metabolites 1 and therefore only a tiny fraction of 
metabolites could be measured here. Hence, it is possible that in the strains of which we 
observed reduced growth rates but could not identify a particular metabolic bottleneck like 
EcoR8 or 49, bottlenecks might exist in reactions of which we can measure neither product nor 
substrate. In addition, also the contribution of several bottlenecks to the growth reduction is 
imaginable as well as a limitation of transport capabilities which could limit the growth rate 
without causing a measurable accumulation of specific metabolites in the cell. 
We decided to examine the contribution of the pyrE bottleneck to the reduced growth rates in 
the laboratory strains in more detail. For that, we analyzed the growth rates of two laboratory 
strains (MG1655 and W3110) and 3 natural isolates (EcoR18, 42 and 46) when growing in M9 
minimal medium in presence and absence of 100 mM uracil (Figure 14). Uracil can be taken up 
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by the cell and transferred to UMP, thereby bypassing the metabolic bottleneck. We found that 
uracil addition did not affect the growth rates of the natural isolate strains, whereas the growth 
rates of both laboratory strains increased by 15% (MG1655) and 18% (W3110), respectively. 
This suggests that the pyrimidine bottleneck indeed reduces the growth rates of the laboratory 
strains. It should be noted that the growth rates were not restored to the level of the wildtype 
cells, though. This could be due to insufficient uptake of uracil from the medium as well as a 
contribution of one or more other metabolic bottlenecks that are limiting the growth rates under 
the given growth conditions.  
 
Figure 14: Uracil supplementations 
Top: Uracil can be imported and converted to UMP, thereby bypassing the PyrE bottleneck. Bottom: Growth rates of 3 
wildtype strains and 2 laboratory strains, grown in presence (yellow bars) and absence (blue bars) of 100 mM Uracil, 
measured in 3 independent cultivations.  
 
Next, we examined the pyrimidine bottleneck further by artificially introducing it into one of the 
wildtype isolate strains, EcoR18, which naturally does not have a metabolic bottleneck in the 
pyrimidine biosynthesis pathway. For the introduction of the bottleneck, we used CRISPRi for 
transcriptional downregulation of pyrE. 
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3.2 Inhibition of pyrE transcription with CRISPR 
interference 
CRISPR interference (CRISPRi) is a method for targeted repression of gene expression, 
consisting of a catalytically deactivated version of the DNA endonuclease Cas9 that acts as a 
steric hindrance for RNA polymerases to bind DNA or proceed transcription and a guide RNA 
that specifies the target site of dCas9 48.   
For transcriptional silencing of pyrE in E. coli EcoR18, we designed 4 guide RNAs, 3 of which 
bind within the pyrE gene and one without a target sequence that acts as a control guide RNA. 
It has previously been shown that the binding sites of guide RNAs define the transcriptional 
repression strength 48. In order to create bottlenecks of different strengths, we therefore 
designed the 3 pyrE targeting guide RNAs to bind at different parts of the gene, binding either 
the promoter region (sgRNA1), at the beginning (sgRNA2) or the end of the gene (sgRNA3) 
(Figure 15a).  
 
Figure 15: Introduction of a metabolic bottleneck into the pyrimidine pathway using 
CRISPRi. 
(a) Designed guide RNAs and target sites. (b) Growth rates of constructed strains in M9 minimal medium with glucose. 
(c) Concentrations of all four measurable intermediates of the pyrimidine pathway. NC is the negative control with a non-
DNA binding sgRNA. 
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We found that compared to the control, all three strains showed elevated levels of orotate and 
its precursors and no significant impact on UMP concentrations (Figure 15c). This is in line with 
the metabolite profile we observed in the tested laboratory strains, indicating that we 
successfully introduced bottlenecks in the reaction catalyzed by PyrE. We also found different 
levels of the three precursors in the three bottleneck strains. The strain with the guide RNA 
targeting the beginning of the gene (sgRNA2) resulted in the highest accumulation of 
precursors, whereas the guide RNA targeting the promoter region (sgRNA1) led to a 
comparably low accumulation. In addition to the metabolomics experiment we also examined 
the general fitness of the strains and observed similar growth rates for the control stain (NC) 
and the strains expressing guide RNAs 1 and 3 (Figure 15b). The strain expressing the 
strongest sgRNA, sgRNA2, however had an about 50 % lowered growth rate, indicating that the 
growth reduction is dependent on the strength of the metabolic bottleneck. 
 
3.3 Systematic introduction of metabolic bottlenecks in 
E. coli 
Encouraged by the successful introduction of a metabolic bottleneck in pyrE we were interested 
how bottlenecks introduced in different parts of the metabolic network of E. coli influence the 
physiology of the cell. Thus, we designed 30 sgRNAs targeting different metabolic genes across 
the metabolic network and expressed these in the E. coli laboratory strain NCM3722. This strain 
is known not to possess the abovementioned metabolic bottleneck in the reaction catalyzed by 
PyrE. Moreover, NCM3722 grows exceptionally fast compared to other laboratory strains, 
indicating that this strain is not severely influenced by metabolic bottlenecks, thus making it a 
good host strain for the experiment. 
The resulting 30 strains have been again analyzed in two ways: First, we measured the growth 
rates of all strains to identify the strains with impaired growth. Second, we measured the 
concentrations of the substrates and/or product of the targeted reactions to see if the bottleneck 
can be observed on the metabolite level. 
We found that about half of the strains, including the wildtype and control (i.e. non-targeting 
sgRNA expressing) strains, had growth rates between 0.6 and 0.65 h-1, suggesting that in these 
strains CRISPRi did not affect growth. Other strains however had reduced growth rates, with the 
lowest growth rates measured for strains expressing gRNAs targeting aroL and ilvC (0.41 h-1) 
(Table 2). In addition, we analyzed the metabolic profiles of all strains. For 16 of these strains 
we noticed an at least 2 fold increase of the substrate concentration and/or decrease of product 
concentration. 9 strains showed no measureable effect on product and substrate 
concentrations, whereas for 5 strains we could measure neither substrate nor product due to 
technical limitations of the used method. 
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Table 2: Target genes of designed sgRNAs 
The table is sorted by the measured growth rates. ++ = more than 3 fold change of substrate or product concentration 
compared to the control, + = 2 to 3 fold change of substrate or product concentration, - = less than 2 fold or no change 
of substrate or product concentration measurable, * = substrate and product due to technical reasons not measurable. 
Target 
gene 
Metabolic pathway Metabolic pathway class Growth Rate 
(h-1) 
Change of Substrate 
or Product 
Concentrations  
pyrE pyrimidine biosynthesis nucleotide biosynthesis 0.66 ++ 
gadA L-glutamate degradation stress response 0.65 - 
gshB glutathione biosynthesis Cofactor biosynthesis 0.65 ++ 
panC Pantothenate biosynthesis Cofactor biosynthesis 0.65 + 
glmS UDP-GlcNAc biosynthesis Cell wall components 0.65 + 
purM purine biosynthesis nucleotide biosynthesis 0.65 ++ 
ddlA peptidoglycan biosynthesis Cell wall components 0.64 ++ 
LuxS AI-2 biosynthesis quorum sensing 0.64 - 
dapD lysine biosynthesis amino acid biosynthesis 0.64 + 
nrdA pyrimidine biosynthesis nucleotide biosynthesis 0.64 - 
NC   0.63  
pyrB pyrimidine biosynthesis nucleotide biosynthesis 0.63 ++ 
cysE cysteine biosynthesis amino acid biosynthesis 0.63 - 
WT   0.62  
ArgA arginine biosynthesis amino acid biosynthesis 0.62 ++ 
leuA leucine biosynthesis amino acid biosynthesis 0.61 - 
mtn AI-2 biosynthesis quorum sensing 0.60 ++ 
dapE lysine biosynthesis amino acid biosynthesis 0.59 - 
metK methionine biosynthesis amino acid biosynthesis 0.59 - 
pheA phenylalanine and tyrosine 
biosynthesis 
amino acid biosynthesis 0.58 * 
proB proline biosynthesis amino acid biosynthesis 0.57 * 
metA methionine biosynthesis amino acid biosynthesis 0.57 + 
murB peptidoglycan biosynthesis Cell wall components 0.53 * 
hisB histidine biosynthesis amino acid biosynthesis 0.51 + 
coaD coenzyme A biosynthesis Cofactor biosynthesis 0.50 * 
ArgE arginine biosynthesis amino acid biosynthesis 0.49 + 
folA tetrahydrofolate biosynthesis Cofactor biosynthesis 0.49 ++ 
nadA NAD biosynthesis Electron carrier biosynthesis 0.49 * 
purB purine biosynthesis nucleotide biosynthesis 0.49 - 
metE methionine biosynthesis amino acid biosynthesis 0.43 + 
aroL chorsimate biosynthesis amino acid biosynthesis, 
Cofactor biosynthesis 
0.41 - 
ilvC isoleucine biosynthesis amino acid biosynthesis 0.41 + 
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When comparing growth rates with measurable changes of substrate and product 
concentrations we found that 10 of 15 strains with a wildtype-like growth rate (>0.60 h-1) had 
either an elevated substrate or lowered product concentration compared to the wildtype strain, 
both indicating successfully established bottlenecks, without an effect on the growth rate. One 
example is the strain targeting purM which had both elevated substrates as well as reduced 
product concentrations (Figure 16) but one of the highest observed growth rates (0.65 h-1). In 
only 5 of these strains we could not measure any significant differences in substrate or product 
concentrations. 
 
Figure 16: Substrate and Product concentrations of the PurM bottleneck strain. 
Concentration of the substrate (left) and the product (right) of the reaction catalyzed by PurM, each displayed as a fold 
change to the concentration measured in the negative control strain (non-targeting plasmid). 
 
Of the 15 strains with a growth rate lower than 0.59 h-1, in 5 strains we were not able to 
measure substrate or product concentrations. Of the remaining 10 strains, 6 had measureable 
alterations of product or substrate concentrations, whereas in 4 strains we could not observe 
any differences. 
We therefore concluded that no clear correlation between introduction of a bottleneck and 
impaired growth could be determined. Instead, the effects of bottlenecks can be very different: 
Whereas a few resulted in lowered growth rates (e.g. folA, metE, ilvC), other strains like the 
abovementioned sgRNA:purM expressing strain showed no growth reduction. This might be 
due to two reasons: First, the results indicate that some metabolic bottlenecks might be 
compensated by sufficiently high enough final product concentrations. Metabolic bottlenecks in 
these reactions might lower the flux through them and consequently lower the availability of the 
end product, however not to an extent that the lower concentration is limiting the growth rate. 
This finding is of importance for the design of metabolic enzymes with synthetic regulation that 
should act as conditional bottlenecks: In order to reduce the growth rate, the activity of such an 
enzyme must be the growth limiting factor. This can only be ensured when the expression rates 
are so low that any changes of enzymatic activity have direct consequences for the end product 
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concentration. When the expression rate is too high, an introduction of a metabolic bottleneck 
might reduce the fluxes through the pathway but not to an extent that the end product 
concentration is so low that it is limiting the growth rate. 
Connected to that is a second possible reason for the observation of strains with metabolic 
bottlenecks that could not impair the growth rate: Metabolic bottlenecks introduced by CRISPRi 
are not just dependent on the targeted genes but also on the efficiency of the guide RNA as well 
as the induction of the CRISPRi system. Optimizing the guide RNAs as well as inducing dCas9 
expression might result in stronger bottlenecks and more severe phenotypes than observed 
here, highlighting again that bottlenecks introduced by enzymes with synthetic regulation must 
be strong enough to result in growth impairment.  
3.4 Summary and consequences for the creation of 
switching enzymes 
The consequences metabolic bottlenecks in single reactions have for the metabolic pathway, 
network and general fitness state can be very diverse and is dependent on the targeted 
reaction. 
Whereas a metabolic bottleneck in the reaction catalyzed by pyrE has a large impact on the 
fitness as shown for commonly used laboratory strains as well as in an E. coli wildtype isolate 
upon artificial introduction of the bottleneck, in other reactions, metabolic bottlenecks do not 
necessarily reduce the growth rate when they are not strong enough.  
For the design of switching proteins and their identification with a growth-based screening 
method that means that it is crucial that the enzymes must not be overabundant and a reduction 
of enzymatic activity has to be so severe that the product concentration is reduced to a level 
that the growth rates are consequently also reduced. 
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4 Creation of switchable enzymes using 
the Split Protein approach 
 
Besides Domain Insertion (see Chapter 5), Split Proteins is one of two techniques which are 
based on directed evolution and which we evaluated in this work to create metabolic enzymes 
with synthetic regulation. As a proof of concept, we decided to combine two systems commonly 
used for protein fragment complementation assays, mDHFR, split in the fragments mDHFR1,2 
and mDHFR367 and rapamycin-dependent FRAP/FKBP12 107.  
4.1 mDHFR-FRAP/FKBP12 
4.1.1 Design and Construction 
DHFR is a monomeric enzyme of the folate biosynthesis pathway and catalyzes the reduction of 
dihydrofolates (DHF) to tetrahydrofolates (THF) which are important C1 group carriers needed 
in many different metabolic pathways, such as for the synthesis of purines, thymine, serine, 
methionine and glycine 108–110. mDHFR has already been used to examine protein-protein 
interactions and for this purpose split into two fragments 67.  
FRAP, commonly known as mTOR (mechanistic target of rapamycin) is a protein kinase 
involved in different eukaryotic cellular processes, FKBP is a protein folding chaperon. Both 
proteins do usually not interact; only in presence of rapamycin, a macrolide used as 
immunosuppressor, both FRAP and FKBP form a protein complex 111. It has been shown 
previously that a small fragment of FRAP (105 of 2850 amino acids), the FRB domain, is 
sufficient for binding of rapamycin and the desired interaction with FKBP12 107 so that we 
decided to use only this fragment for the creation of the protein switches. 
As linkers we chose very long flexible linkers of the composition (GGGGGS)2 which were 
supposed to enable the correct folding of adjacent proteins as well as an easier interaction of 
the fused proteins with their respective interaction partners.  
The individual fragments have been amplified by PCR, assembled together using CPEC (112, 
see Chapter 8.4.5.4) and cloned onto two expression plasmids. In addition to the potentially 
rapamycin-dependent fusions FRB-mDHFR1,2 and FKBP12-DHFR3, two controls have been 
created as well (Figure 17):  
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Figure 17: Created split mDHFR variants. 
 
As a positive control, we fused the mDHFR fragments to leucine zippers 113. Leucine zippers are 
oligopeptides that form α-helices. Two of these zippers can interact with each other and form 
coiled coil structures. Originated from eukaryotic transcription factors, in which leucine zippers 
mediate the interaction of two transcription factors to form oligomers, leucine zippers can also 
be utilized as domains to bring two fused proteins into close proximity. 
As a negative control, we fused the mDHFR fragments to two proteins that are not only not 
interacting with each other but are, in addition, supposed to act as a steric hindrance of random 
interaction of the fused enzyme fragments. For that, we used a combination of the two fusion 
proteins FRB-mDHFR1,2 and ZIP-mDHFR3. 
A crucial factor for the creation of split proteins is the order within the fusion proteins. When a 
protein is split, two new termini, a C-terminus at the first fragment and an N-terminus at the 
second fragment is created. Usually, the regulatory proteins are fused to these termini. In this 
case it is necessary that the fused regulatory proteins have an antiparallel orientation to each 
other. Neither for the leucine zippers, nor FRB/FKBP12 is this the case (Figure 18a + b). To 
solve this problem, in one of the fusion proteins the enzyme domain has to be connected to the 
regulatory domain to another terminus as depicted in Figure 18d. Usually, this requires an 
extended flexible linker connecting both domains of this fusion protein. 
In our case fortunately the N- termini of both fragments of DHFR are in very close proximity 
(Figure 18c) so that FRB and FKBP12 could be fused at these ends.   
The resulting three strains have then been examined for rapamycin-dependent growth and 
metabolism. 
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Figure 18: Structures of the used regulatory proteins and split enzyme. 
(A) Structure of FRB (green) and FKBP12 (blue) in presence of rapamycin (centre) (PDB: 1NSG, 114). The C-termini of 
both proteins are accessible and relatively close to each other positioned so that split proteins are usually fused at these 
termini. The N-termini are less accessible and therefore less favoured for the fusion of other proteins. (B) Structure of 
leucine zippers (PDB 2ZTA, 113). Two leucine zippers form a coiled coil structure consisting of two α-helices. Both 
termini are accessible but as a consequence of the rigidity of α-helices, split proteins must be both connected either at 
the N- or the C-terminus. (C) Structure of split mDHFR (PDB: 3D80, 115). mDHFR is split between L105 and A106. L105 
forms the C-terminus of mDHFR1,2 (blue), whereas A106 forms the new N-terminus of mDHFR3 (green). In order to 
maintain the structure, split proteins are usually connected through these new termini with the regulatory proteins. (D) 
Dilemma of dimer orientation. Whereas both used regulatory proteins have a parallel dimer orientation so that a 
connection at either both N- or both C-termini is favoured, split proteins have an anti-parallel orientation (connection to 
regulatory proteins ideally through the new N- and C-termini). In case two pairs of proteins with different orientations 
should be connected, one protein has to be connected at the less favourable terminus by an often extended linker 
(dashed line). In case of split mDHFR-leucine zippers and split mDHFR-FRB/FKBP12 the C-termini of the regulatory 
domains have been connected to the N-termini of both mDHFR fragments (corresponds to lower dashed line). The 
distance between both N-termini (8.8 Å) can easily be bridged by the long linkers used here (up to 36 Å per linker in a 
stretched conformation). 
 
 
  Chapter 4 - Creation of switchable enzymes using the Split Protein approach 
 
43 
4.1.2 Evaluation of FRAP/FRB-mDHFR 
To test the rapamycin dependency of the created FRAP/FRB-mDHFR split protein fusion, we 
first performed a growth experiment (Figure 19a). For that, we started LB precultures from 
glycerol stocks. This preculture had then been used to inoculate main cultures in M9 minimal 
medium supplemented with glucose, casamino acids to reduce the metabolic burden caused by 
the overexpression of the split proteins, and IPTG to allow expression of the proteins of interest. 
Furthermore, to this culture we also added 10 µM trimethoprim to inhibit bacterial DHFR so that 
the cells have to rely on the activity of the split mDHFR. At last, rapamycin has been added in 
different concentrations for the reassembly of FRB and FKBP.  
 
 
 
Figure 19: Growth rates and substrate concentrations.  
(A) Maximum growth rates of the strain expressing FRB-mDHFR1,2 and FKBP12-DHFR3 (D81, blue), the positive 
control strain expressing Zip-mDHFR (green) and the negative control strain expressing FRB-mDHFR1,2 and ZIP-
mDHFR3 (red) growing M9-Glucose-Casamino acids-IPTG-trimethoprim and varying concentrations of rapamycin. 
Shown are the results of biological triplicates. (B) Substrate and product of DHFR. (C) Concentration of the most 
abundant substrate of the reactions catalyzed by DHFR, 7,8 dihydrofolic acid. Metabolite samples were taken from D81 
and both control strains in mid-exponential growth phase (OD600nm = 0.5). Samples of three independent cultures were 
taken and analyzed. 
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We found that, as expected, the addition of rapamycin to the medium had no significant impact 
on the growth rates of the negative and positive control strain (Figure 19a). The positive control 
strain (mDHFR fragments connected to leucine zippers) had the highest growth rates of about 
0.7 h-1 in presence and absence of rapamycin. The negative control strain (FRB-mDHFR1,2; 
ZIP-mDHFR3) on the other hand had the lowest growth rate of about 0.5 h-1 with a slightly 
decreased growth rate in presence of rapamycin.  
In contrast, the strain expressing FRB-mDHFR1,2 and FKBP12-DHFR3 (D81) showed a 
rapamycin dependency: In presence of low rapamycin concentrations (0, 0.1 and 1 µM) in the 
medium, we observed similar growth rates compared to the negative control. The addition of 10 
µM rapamycin to the medium however led to an increase of the growth rate to 0.65 h-1 which is 
a growth rate that was almost as high as that of the positive control.  
As the tested strains shared the same genetic background with the exception of the expressed 
split mDHFR variants, we hypothesize that the differences in growth rates have to be explained 
with different activities of mDHFR.  
To test this, we performed a metabolic analysis for which we measured the concentration of the 
substrate of mDHFR, 7,8-dihydrofolic acid in all three strains at mid-exponential phase (OD600nm 
= 0.5) (Figure 19c). The product of the reaction, tetrahydrofolate, is usually polyglutamylated 
and various C1 groups added to it so that over 30 different variants of tetrahydrofolate exist 
within the cell. These variants are all very low abundant so that we were not able to measure 
them. 
Compared to the 7,8-dihydrofolic acid levels measured in the positive control strain, we found 3-
fold elevated levels in the negative control strain, indicating a metabolic bottleneck in the 
reaction caused by insufficient mDHFR activity. In both strains no impact of rapamycin to the 
7,8-dihydrofolic acid levels could be determined. The strain expressing FRB-mDHFR1,2 and 
FKBP12-DHFR3 on the other hand showed again a rapamycin dependency: Whereas in 
absence of rapamycin a 2.5-fold increased 7,8-dihydrofolic acid level compared to the positive 
control could be measured, the level was significantly lower (1.7 fold higher than in the positive 
control strain) in presence of 10 µM rapamycin. This suggests that the addition of rapamycin 
leads to the partial removal of a metabolic bottleneck in this reaction. 
In conclusion, the here presented data suggests that the created split mDHFR variant fused to 
FRB/FKBP12 is a rapamycin dependent enzyme switch and can therefore be regarded as our 
first created metabolic enzyme with synthetic regulation which allows us the – in this case: 
external – control of a metabolic pathway and as a consequence, the growth rate. 
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4.2 Discussion and Outlook 
Although the created split mDHFR variant can be regarded as our first switchable metabolic 
enzyme, it is quite apparent that it does not represent an optimal switch. For instance, we 
observed a high basal growth rate in both, the negative control strain as well as the FRB-
mDHFR1,2 and FKBP12-DHFR3 expressing strain when grown in absence of rapamycin. This 
is probably due to an interaction of the mDHFR fragments independent of the fused regulatory 
proteins. Although we did not expect the observed extent of complementation as a result of 
random interactions, it could be explained by the structural properties of split proteins. Many 
proteins, including mDHFR, contain hydrophobic amino acids in their catalytic center. When 
split, these amino acids are in contact with the cytosol, which is energetically unfavored 116. In 
contrast, when reassembling as a consequence of an interaction of fused regulatory proteins or 
random interactions, the hydrophobic residues of the two fragments will interact as well, 
resulting in a stable, energetically more favored state. We can therefore assume that random 
interactions occur and that once reassembled split proteins will have certain robustness against 
a re-separation. 
In addition, three other factors may have contributed to the observed high basal growth rate: 
First, it might be that the mDHFR variants were overabundant as a consequence of very high 
gene expression levels. The higher the copy numbers of split mDHFR variants are within the 
cell, the higher is the likelihood of random interactions of both fragments. A reduction of gene 
expression by reduced addition of IPTG might lead to a lower basal activity but would 
presumably also reduce the growth rates. As the growth rates and 7,8-dihydrofolic acid levels of 
D81 did not even reach the levels of the positive control in presence of IPTG and 10 µM 
rapamycin, a reduction of IPTG might only be advisable when the enzyme switch is further 
optimized. 
In addition to that, it should be noted that the addition of casamino acids to the medium reduces 
the need for functional DHFR as folates are amongst others required for the biosynthesis of 
serine, methionine and glycine which can be taken up from the surrounding medium. 
Finally, it might be that the linker sizes and compositions are not optimal. As mentioned above, 
the linker was primarily designed to allow both, the enzyme and the fused proteins, to fold 
correctly and has therefore been chosen to be long and flexible. It might be that the linkers are 
too long and flexible so that a random interaction of both mDHFR variants is not sufficiently 
prohibited. Shorter or rigid linkers could improve the switches by reducing unwanted random 
interactions between enzyme fragments. However, such linkers bear also the risk that folding of 
adjacent proteins or interaction of proteins with their counterparts might be impaired.  
Both, optimal gene expression strengths and linker compositions are planned to be subjects in 
future rounds of re-design, creation, (possibly) screening and evaluation. 
Similar to the assumed unfavored reversibility of assembly of the mDHFR fragments, it has 
been shown that the dimerization of FRB and FKBP12 is most likely irreversible as well 107. In 
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case a reversibly switching enzyme should be created, one therefore either has to use ligands 
such as FK506 which compete with rapamycin to bind to FKBP12 117 or use an alternative 
regulatory protein with a higher tendency to dissociate in absence of its effector. 
In addition to these limitations, as rapamycin is a very expensive compound, its usage as 
inducer molecule in bioprocesses is not eligible, a usage of FRAP/FRB to control 
overproduction pathways is therefore not possible.  
Despite the disadvantages of this existing switch, we would like to use it in the future as a 
platform to create new switches. For instance, we plan to replace the two mDHFR fragments 
with enzymes of more biotechnological relevance such as ArgA, LeuA or GPD1 of the glycerol 
production pathway of S. cerevisiae. It should be noted though that these enzymes are in 
contrast to mDHFR not active as monomers but instead form oligomers in order to be active. 
Instead of fragment reassembly we would therefore try to control in these cases the 
oligomerization and in that way the activity of the enzymes through the fused regulatory 
domains (Figure 20).  
 
 
Figure 20: Control of oligomerization. 
Many proteins that could potentially be used as regulatory proteins (red) are forming oligomers and only change their 
conformation upon binding of an effector (green). This conformational change can be used to control either reassembly 
of split proteins or to control the oligomerization of full length proteins that need to form oligomers in order to be active. 
Oligomer forming enzymes might form oligomers independent of the fused regulatory domain. In such cases, enzymatic 
activity is controlled through conformational changes upon binding of an effector. 
 
As the linker composition might be important in these cases as well, we hope to profit from the 
experiences that we will hopefully gain from the experiments about the optimization of the 
linkers connecting the mDHFR fragments with FRB and FKBP12. 
We will also try to replace FRB/FKBP12 with other regulatory proteins. In particular, we are 
interested in regulatory domains that sense and are active dependent on growth condition 
indicators in bioreactors. For example, through the effector binding and oligomerization domain 
of the transcription factor Cra we could try to control the oligomerization of enzymes such as 
ArgA and by that, couple the overexpression of biotechnological relevant products to the state 
of the glycolytic flux. It should be noted though that regulatory domains of transcription factors 
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such as Cra usually form oligomers independent of the presence or absence of the effector. In 
contrast to FRB/FKBP1,2, split proteins with effector binding domains of transcription factors as 
regulatory domains might therefore interact constantly and enzyme activity will not be controlled 
by protein assembly but through a transmission of the conformational change the fused 
regulatory domains undergo upon binding of their effectors. 
We already tried to construct of an oxygen-dependent mDHFR version by fusing both mDHFR 
fragments to the oxygen-binding domains of the transcription factor FNR. So far, with the 
chosen linkers and in the given growth conditions, no complementation of the DHFR knockdown 
phenotype could be observed. 
Planned adaptions of the created split protein are depicted in Figure 21. 
 
 
 
Figure 21: Planned adaptions and optimizations based on the created mDHFR-
FRB/FKBP12 split protein switch. 
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5 Creation of switchable enzymes using 
the Domain Insertion approach 
 
The second directed evolution-based method that we evaluated in this work to create metabolic 
enzymes with synthetic allosteric regulation is Domain Insertion in which an enzyme of interest 
is randomly inserted into a regulatory domain which changes its conformation upon binding of 
an allosteric effector 65,73.  
Proteins that are intended to be used as regulatory domains or metabolic enzymes can be 
differently suited for Domain Insertion. Our first goal was therefore to define guidelines for the 
choice of components. 
5.1 Guidelines for the choice of components 
5.1.1 Regulatory Domains 
We defined following 4 criteria for the choice of regulatory domains in Domain Insertion: 
First, a crucial characteristic of regulatory domains is their existence as self-contained proteins 
or domains. In many enzymes, the allosteric binding site is not formed by an isolated domain. 
Instead, amino acids at different positions within the primary structure of the protein are needed 
for effector binding and signal transduction, as for instance described for LeuA 118. Such 
allosteric binding sites are difficult to isolate and transfer and therefore not suited for Domain 
Insertion. Second, regulatory domains are preferred that undergo a large conformational 
change upon binding of their allosteric regulator. The larger a conformational change is, the 
more likely it is that this change can be transmitted to the fused enzymatic domain and thereby, 
the more likely is it that the enzymatic activity can be modulated. Third, we preferred regulatory 
domains and proteins that act as monomers. The reason for this it that enzymatic domains 
inserted into oligomer forming regulatory domains could sterically impede their oligomerization 
and consequently their functionality. The fourth criterion is the allosteric effector. Whereas in 
later applications, this criterion will be one of the most important ones as the allosteric effector 
defines the function of the resulting enzyme – regulatory domain fusion, for a first test of 
concept, the identity of the allosteric effector is less important. 
Based on these criteria, for our first attempts regulation we chose to work with the maltose-
dependent MBP. MBP acts as the periplasmic substrate-binding component of the maltose ABC 
transporter and is as such involved in the import of maltose. We chose it as regulatory domain 
because it fulfills the first three criteria best: First, it can be used in its entirety, making it easy to 
work with. Second, it is active as a monomer thus avoiding problems that can arise from the 
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insertion of proteins into parts required for the oligomerization. And third, similar to other 
periplasmic sugar binding proteins, the protein consists of two separate domains with a groove 
between them which contains the sugar binding site. It has been shown previously that MBP 
undergoes a large conformational change when binding maltose 119,120 (Figure 22). Moreover, 
MBP has already been used as regulatory domain in other applications of Domain Insertion 
73,78,79. 
 
Figure 22: Conformational change of MBP upon binding of maltose. 
Alignment of structures of MBP in the unbound, open form (blue, PDB 1JW4, 121) and when bound to maltose (green) in 
a closed form (red, PDB 1ANF, 122). Upon binding of maltose, the clamp shaped structure closes. The hinge angle 
increases as a result of this motion by 35° 119. 
 
5.1.2 Enzymatic domains 
For enzymatic domains in parts similar guidelines apply as for regulatory domains: First, 
monomeric enzymes are preferred to enzymes that have to oligomerize in order to form 
catalytically functional enzymes. The reason for this is that an insertion into a regulatory domain 
might sterically hinder the enzymes’ ability to form oligomers. Second, in later applications, 
enzymes will be mainly chosen to control certain reactions. For our first attempts to create 
metabolic enzymes with synthetic regulations this criterion is less important. In addition to these 
criteria, two other rules apply for enzymatic domains: One is that N- and C-terminus of the 
enzymes are ideally in as closest proximity as possible. The idea behind that is that the 
insertion of the enzymatic domain separates the two fragments of the regulatory domain with 
the same distance as the distance between the N- and the C-termini of the enzymatic domain. 
The longer this distance is, the less realistic is a successful folding as well as a functional 
reassembly of both fragments of the regulatory domain. The second additional rule is that the 
enzymatic activity has to result in a measurable phenotype, e.g. fluorescence 72, antibiotic 
resistance 73 or changes in growth rates. 
Based on these criteria, for our first attempts to create metabolic enzymes with synthetic 
allosteric regulation we selected murine dihydrofolate reductase mDHFR (folate biosynthesis) 
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and 2-isopropylmalate synthase LeuA (leucine biosynthesis) as our enzymes. Furthermore, the 
usage of ArgA (arginine biosynthesis) and HisG (histidine biosynthesis) has been evaluated.  
mDHFR had been chosen because of its relatively simple structure. It acts as a monomer and 
possesses termini that are in very close proximity (murine DHFR: 14.8 Å, see Figure 23), 
allowing the insertion of DHFR in regulatory domains with relatively small linkers. In addition, 
mDHFR has already been used in Domain Insertion although with a more targeted approach 
and with DHFR as acceptor domain 77. For us, DHFR has in addition the advantage that we also 
used it as Split Protein (Chapter 4). 
 
Figure 23: Structure of mDHFR. 
PDB 3d80 123. Marked is the distance between both termini. 
 
 
 
LeuA has been chosen for its higher relevance for biotechnology 124,125 but has also the 
advantage of having a relatively simple structure consisting of an N-terminal catalytic domain 
and a C-terminal regulatory domain, connected through a subdivided linker structure 118 (Figure 
24). LeuA forms dimers and although both N-terminal domains of a dimer form independent 
catalytic sites, the C-terminal domain is required for catalytic activity, presumably by ensuring 
protein dynamics 126. We therefore decided to work with the full length LeuA and assume 
chimera with LeuA as enzymatic domain will form oligomeric complexes. 
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Figure 24: Domain Structure of LeuA 126. 
LeuA consists of 3 domains, a N-terminal catalytic domain (green), a C-terminal regulatory domain (purple) and a linker 
structure in between which consists of two subdomains (blue and red). LeuA forms homodimers with two catalytic sites 
and one leucine binding site. 
5.2 Complementation of gene knockout and knockdown 
phenotypes 
Metabolic enzymes with synthetic allosteric regulation are intended to work as metabolic valves 
with two states of activity: In one condition (e.g. presence of an effector), the enzyme is 
intended to be active, thereby not limiting fluxes. In the second condition (e.g. absence of the 
effector), the enzyme has a lowered activity. In order to ensure that the lowered activity also 
results in a reduced flux through the pathway, it is crucial that the abundance of the enzyme 
switch is sufficiently low since less active but overabundant enzymes would allow for 
maintaining high fluxes through the pathway. As a consequence, the expression of the enzyme 
switch genes must be tightly regulated.  
To ensure that, an expression plasmid was required that allows very low gene expression rates. 
Hence, we decided to work with the plasmid pSB4A5, a low copy plasmid (origin of replication: 
pSC101, 4-5 copies per cell) with an arabinose-inducible PBAD promoter to control the 
expression of the gene of interest (Figure 25). 
 
Figure 25: Expression plasmid pSB4A5 
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In this work, we would like use these enzymes to not just to control metabolic fluxes but 
consequently also to control the growth rates of the enzyme expressing strains. To reach that, it 
is important that the activity of the enzyme switch limits the growth rate. Hence, we have not just 
to ensure low gene expression rates but also that the genes are expressed in genetic 
backgrounds in which the enzymatic activity is required for growth. 
As mentioned above, we are interested in the metabolic enzymes ArgA, HisG, LeuA and 
mDHFR. We amplified their genes and cloned them on the selected expression plasmid 
pSB4A5. The resulting plasmids were then transformed in the respective knockout strains. As 
no knockout strain is available for folA (encoding DHFR), the plasmid has been transformed into 
E. coli MG1655 and incubated the resulting strain in presence of trimethoprim which specifically 
inhibits the native bacterial DHFR. 
With the resulting strains, we performed a complementation experiment. For that, we incubated 
the strains and E. coli MG1655 as negative control in M9 glucose minimal medium and varied 
gene expression rates by the addition of arabinose in different concentrations (Figure 26).  
For all complementation strains, we expected limited growth in absence of arabinose as a result 
of low gene expression and increasing growth rates with higher arabinose concentrations.  
For the ΔargA complementation strain, we observed this behavior: while low arabinose 
concentrations resulted in low growth rates between 0.11 h-1 (0 g/L arabinose) and 0.45 h-1 (0.5 
g/L), indicating insufficient argA expression rates, we observed a growth rate of 0.58 h-1 in 
presence of 5 g/L arabinose, suggesting high ArgA abundance. For Domain Insertion we will 
incubate the cells with limited arabinose concentrations, e.g. with 0.5 g/L arabinose. This 
concentration allows on the one hand substantial growth; on the other hand, we can assume 
that with this arabinose concentration the ArgA abundance is growth limiting so that any change 
in enzymatic activity would also affect the growth rate. 
For the ΔhisG, ΔleuA and DHFR knockdown complementation strains, the highest growth rate 
was not reached with the highest concentration of arabinose (5 g/L). Instead, we assume that 
the full induction of the PBAD promoter leads to an overexpression of the enzyme genes and 
consequently to a growth burden. For Domain Insertion the strains will be incubated in presence 
of arabinose concentrations that are slightly below the optimal concentration. HisG and mDHFR 
variant expressing strains will be incubated in total absence of arabinose as the basal activity of 
the promoter already leads to sufficient hisG and mDHFR expression rates. LeuA variant 
expressing strains will be incubated with 0.1 g/L arabinose.  
The growth rates of the negative control strain E. coli MG1655 were not significantly affected by 
added arabinose, showing that increased growth rates of the complementing strains in 
presence of arabinose are not caused by the availability of a second carbon source but rather a 
result of higher gene expression rates and improved complementation.  
 
  Chapter 5 - Creation of switchable enzymes using the Domain Insertion approach 
 
53 
 
Figure 26: Complementation of gene knockouts and knockdowns using pSB4A5 
as expression plasmid. 
Shown are the growth curves and maximum growth rates of 5 strains grown each in presence of 4 different 
concentrations of arabinose, the inducer of the PBAD promoter that controls the expression of the enzyme gene required 
for complementation. Top row: ΔargA complementation strain, second row: ΔhisG complementation strain, third row: 
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ΔleuA complementation strain, fourth row: E. coli MG1655 strain complementing the bacterial DHFR inhibition 
phenotype, fifth row: E. coli MG1655 as control strain. Dark green: 0 g/L Arabinose, light green: 0.1 g/L, yellow: 0.5 g/L, 
orange: 5 g/L Arabinose.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3 Construction of libraries and optimization of the 
Domain Insertion protocol 
We then sought to apply the Domain Insertion for the creation of metabolic enzymes with 
synthetic allosteric regulation. For that, we selected mDHFR as enzymatic domain, linkers of the 
composition (GGGGS)2 and the maltose binding MBP as regulatory domain, and followed the 
Domain Insertion Protocol 74 which consists of 4 parts as depicted in Figure 27: In the first part 
(Part A) an expression plasmid with the regulatory domain gene is randomly linearized and 
repaired, resulting in a library of plasmids with different insertion sites. In the second part (Part 
B), the enzyme gene of interest is amplified. In the third part (Part C), the plasmid library is 
constructed by ligation of previously prepared linearized plasmids and enzyme genes. And 
finally, after pooled transformation in the enzyme gene knockout strain, the resulting strain 
library can be screened for conditionally active enzyme variants (Part D).  
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Figure 27: Overview over the original Domain Insertion protocol. 
The protocol is divided in four parts. Part A: Preparation of the plasmid harboring the gene for the regulatory domain. 
The plasmid is randomly linearized with the sequence-independent nuclease DNaseI. Sticky ends are blunted as well as 
nicks sealed in the next step by T4 polymerase and T4 ligase. As only a fraction of the plasmids is linearized by DNaseI, 
this fraction is isolated by gel electrophoresis and gel extraction in the next step. Finally, the linearized plasmids are 
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dephosphorylated to prevent self ligation. Part B: Preparation of the enzyme gene fragment. The enzyme gene is 
amplified without start and stop codons and with linker sequences on one or both ends if needed and subsequently 
purified. Part C: Library generation and screening. Enzyme genes and linearized plasmids are ligated first to create a 
pooled plasmid library. Dependent on the site the plasmid was linearized by DNAseI the gene is inserted at different 
posititions within the plasmid. Next, the plasmids are transformed into a enzyme gene knockut strain to create a pooled 
strain library. Part D: To find enzymes with synthetic allosteric regulation, two steps of screening are necessary. First, 
the strains are tested for functional enzyme activity by incubating them in minimal medium. Plasmid in which the gene is 
inserted inside the regulatory domain but out of frame, in the wrong direction or when the insertion site is not suitable to 
allow the formation of a functional enzyme variant (3rd plasmid), plasmids in which the enzyme gene inserts outside of 
the open reading frame of the regulatory domain (4th and 5th plasmid) or religated plasmids (6th plasmid) will not result in 
functional enzymes and therefore will not support growth. Next, the complementing strains are screened in a second 
round for condition-dependent enzymes. For that, cells are incubated for example in presence of an effector. A majority 
of the complementing enzymes will be unaffected by the effector, resulting in normal growth (2nd plasmid). We are 
interested in enzymes with impaired activity in presence of the effector which will subsequently cause lowered growth 
rates (1st plasmid). 
 
 
Part A: Preparation of the acceptor plasmid 
Prior to Domain Insertion we cloned the MBP coding malE gene on the expression plasmid. To 
obtain sufficient amounts of plasmids, 120 mL cultures of the E. coli strain harboring the plasmid 
have been used for plasmid preparation. 60 µg of plasmids could be isolated and used for the 
following steps. 
For the linearization of the plasmid we initially used the sequence-independent nuclease 
DNaseI. First, we determined the optimal concentration of DNaseI for the digest. The targeted 
concentration allows a linearization of a substantial part of the plasmids while simultaneously 
overdigestion is prevented. We found that with a concentration of 10-4 U/µg DNA a significant 
ratio of the plasmids was linearized (Figure 28b) and used this concentration for the further 
digests. Lower concentrations do not result in linearized plasmids, whereas higher 
concentrations lead to an overdigest. The determined concentration has been used for the 
random linearization of the in the first step prepared plasmids. 
After linearization, the plasmids were repaired for which T4 DNA ligase was used for sealing of 
nicks and T4 DNA polymerase for blunting of sticky ends. We then isolated the fraction of 
linearized plasmids. For that, we loaded the plasmids on a TAE agarose gel and extracted the 
band formed by linearized plasmids which migrate faster than nicked circles and slower than 
supercoiled DNA (Figure 28a).  
At last, in order to prevent self-ligation in the subsequent ligation step, the ends of the linearized 
plasmids have been dephosphorylated using Antarctic phosphatase. After a last DNA 
purification step, about 1 µg of randomly linearized, repaired, blunted and dephosphorylated 
plasmid was obtained which could be used for ligation.  
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Figure 28: DNaseI digestion 
(A) Digest of plasmids leads to the formation of fractions of linear DNA, nicked/relaxed plasmids and still undigested, 
supercoiled DNA. These fractions can be separated by gel electrophoresis. (B) Determination of an optimal DNaseI 
concentration. Linear plasmids are marked with a black box. A concentration of 10-1 and 10-2 U/µg DNA leads to a 
complete digestion, whereas a concentration of 10-5 U/µg DNA and lower does not result in a sufficient linearization. A 
concentration of 10-3 and 10-4 U/µg DNA resulted in a sufficient amount of linear plasmids. 
 
Part B: Preparation of the enzyme gene 
For the preparation of the enzyme gene, mDHFR without start and stop codons had 
been amplified with phosphorylated primers and subsequently purified. To the 5’ ends 
of both primers, sequences coding for long flexible glycine linkers of the composition 
(GGGGS)2 were added. 
 
Part C: Library construction 
Linearized plasmids containing malE and insert consisting of mDHFR and linkers sequences at 
both ends were ligated in a blunt end ligation reaction. Following the original protocol we used 
T4 DNA ligase and PEG-6000 which was added to increase the likelihood of interactions of 
blunt ends in the reaction mix. After purification, the plasmids were transformed into chemically 
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competent E. coli NCM3722 cells and plated on M9 minimal medium agar plates with glucose 
as carbon source and Trimethoprim to inhibit bacterial DHFR. 
We found that the original protocol resulted in insufficient library sizes. For instance, after 
plating of E. coli NCM3722 strains with plasmids constructed following the original Domain 
Insertion protocol, we obtained only 11 strains. 
In addition, by sequencing some of these strains we noticed an overdigestion of the acceptor 
plasmid, resulting in the deletion of parts of the regulatory domain gene. Resulting enzyme 
variants may therefore be functional but usually do not possess a functional maltose binding 
domain.  
To increase library sizes and reduce the number of overdigested plasmids, we therefore sought 
to optimize the Domain Insertion protocol. 
 
Optimizations of the protocol in order to increase library sizes 
In order to increase the number of transformants with candidate enzyme variants, we evaluated 
and optimized almost all steps in several rounds of Domain Insertion. All adaptions to the 
protocol that led to an increase of library sizes are summarized in Table 3. 
 
Table 3: Adaptions to the Domain Insertion protocol 
 
Step Change Remarks 
Linearization DNaseI   
S1 Nuclease 
Avoiding over-digestion as S1 nuclease 
cuts only circular, not linear DNA. Also 
used by Tullman, Guntas, Dumont, & 
Ostermeier (2011) 
Repair T4-Ligase  
T7-Ligase 
Avoiding re-ligation of linearized plasmids. 
Dephosphory-
lation 
Increased Incubation time, 
different enzymes tested 
Avoiding plasmid re-ligation in the 
subsequent ligation reaction 
Ligation Different protocols, 
suppliers, enzymes and kits 
tested 
Increasing the number of successful 
ligations while avoiding multiple ligation 
events.  
Transformation Different transformation 
protocols and suppliers of 
competent cells tested 
Increasing the number of transformants 
after transformation of the ligation mix 
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As mentioned above, we noticed that the usage of DNaseI to randomly linearize plasmids often 
led to an overdigestion of plasmids, resulting in the deletion of parts of the regulatory domain 
gene and often to frameshifts. Resulting enzyme variants may therefore be functional but 
usually do not possess a functional maltose binding domain. To solve this problem and by that 
enhance the quality of produced libraries, we therefore sought to replace DNaseI with S1 
nuclease which has been shown to linearize specifically supercoiled double stranded DNA and 
already been used for Domain Insertion 75.  
We evaluated S1 nuclease for its usage in Domain Insertion. In particular, we were interested if 
S1 nuclease can linearize a sufficient fraction of the plasmids and if the linearization is 
sequence-independent. To test this, we followed the suggested reaction conditions 75 and found 
that compared to DNaseI, a larger fraction of the plasmids in the reaction had been linearized 
(Figure 29a) which is beneficial for the desired increase of library sizes.  
 
 
Figure 29: Digestion of plasmids with S1 nuclease. 
(A) Comparison of DNaseI and S1 nuclease digestion. The digestion of plasmids with S1 nuclease leads to a higher 
yield of linearized plasmids. Note that here a boric-acid based agarose gel buffer has been used, leading to linearized 
plasmids to migrate fastest through the gel. (B) Evaluation of the sequence dependency of S1 nuclease. Shown is the 
undigested plasmid (1), the S1 digest (3) and as comparison the plasmid linearized with a restriction enzyme (2). The 
linearized plasmids of the S1 digest have been isolated (4). This fraction has then been digested with a restriction 
enzyme (5). A biased S1 digest leads to a predominant formation of certain fragments as observed here. 
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By additionally digesting the linearized plasmid with a sequence specific and single-cutting 
restriction enzyme, we tested if linearization of S1 nuclease is sequence-independent: Whereas 
a random linearization would result in many products of different sizes, in case of a preference 
for a certain sequence, the predominant formation of certain products could be observed. When 
linearizing our expression plasmid with S1 nuclease and additionally digest the linear plasmids 
with HindIII, we found that two fragments with sizes of about 2200 and 2800 bp formed, 
indicating a sequence preference od S1 nuclease (Figure 29b). Hence, although larger amounts 
of linearized plasmids could be isolated through gel extraction when digested with S1 nuclease, 
a smaller variance of insertion sites is expected.  
In addition to the replacement of DNaseI by S1 nuclease we also tested different enzymes and 
reaction conditions for subsequent protocol steps. For instance, we replaced the T4 ligase with 
T7 ligase for the repair of nicked plasmids. The reason for this is that T7 ligase is known to have 
a lower preference for blunt DNA ends and therefore reduces the likelihood of unwanted re-
circularization of previously linearized plasmids. For dephosphorylation and ligation, we found 
that Antarctic Phosphatase and a premade ligation master mix specifically developed for blunt 
end ligations (Blunt/TA ligation master mix, New England Biolabs) resulted in a higher number 
of transformants.  
We also speculated if the low number of transformants could have been caused by the direct 
transformation of the ligation reaction into the respective knockout strain and plating on minimal 
media plates which probably leads to stress the cells may not be able to cope with. We 
therefore decided to do two sequential transformations: First, the ligation reactions were 
transformed in highly electrocompetent laboratory strain cells, the resulting transformants were 
plated on rich media plates to avoid a bias in the library and reduce stress. The transformants 
were then pooled and the plasmids isolated. These isolated, amplified and purified plasmids 
were then retransformed in the final step into the enzyme gene knockout strain. 
With all abovementioned adaptions, we were able to significantly increase the quantity of strains 
within libraries. A list of all created libraries can be found in Table 4. Of most libraries we 
isolated several individual strains which were in parts further characterized in more detail by 
comparing the growth rates when growing on maltose or glucose minimal medium (Chapter 
5.4). In addition, our last constructed library with MBP as regulatory domain, linkers of the 
composition (GGGGS)2 and DHFR as enzymatic domain consisted of more than 2000 strains 
and we could have increased the number of strains even more by repeating and upscaling the 
final transformation step. For such large libraries an isolation and individual screening of single 
strains is not feasible anymore. Instead, all colonies were pooled and intended to be screened 
in pooled growth assays. 
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Table 4: Composition and sizes of created and stored Domain Insertion strain libraries. 
Library Name Plasmid 
Backbone 
Regulatory 
Domain 
Linker Enzyme Size 
pSB4A5-malE-
αH-leuA  
pSB4A5 MalE α helices LeuA 30 
pTRC99KK-
malE-GS-
mDHFR 
pTRC99KK MalE Glycine-Serine mDHFR 38 
B0031-malE-
GS-mDHFR 
pSB4A5 MalE Glycine-Serine mDHFR 543 
B0031-malE-
GS-mDHFR 
pooled 
pSB4A5 MalE Glycine-Serine mDHFR > 2000 
(pooled) 
 
5.4 Screening of constructed MBP-mDHFR libraries 
Constructed libraries were screened in two steps: First, to identify functional enzymes, strains 
were tested for the ability to complement the native enzyme gene knockout. As for DHFR such 
a gene knockout strain does not exist, we instead treated the cells with the antimicrobial 
trimethoprim that inhibits bacterial DHFR. For the complementation screen, transformants were 
plated on M9 minimal medium plates so that only strains could grow in which the enzyme gene 
has been successfully inserted into the regulatory domain gene, in frame and in the right 
direction. All strains listed in Table 3 were able to grow on minimal medium plates and thus, 
possess catalytically active enzyme variants. 
Next, we screened for strains that possess enzymes that are sensitive to maltose, i.e. that have 
a reduced enzymatic activity in either presence or absence of maltose. As mentioned earlier, to 
identify enzymes with synthetic regulation, we screen for strains which have low growth rates in 
presence or absence of the intended allosteric effector, in our case maltose. Hence, we did 
comparative growth experiments by letting library strains grow in presence and absence of 
maltose. For instance, we measured the growth rates of 38 individual strains expressing MBP-
mDHFR in M9 minimal medium with either glucose or maltose as sole carbon source and 
supplemented with trimethoprim to inhibit native bacterial DHFR activity (Figure 30). We found 
that almost all of the tested 38 strains had growth rates between 0.7 and 0.9 h-1 when growing 
on glucose and between 0.45 and 0.75 h-1 when growing on maltose. One of the strains, K21, 
however had an interesting growth phenotype: With glucose as carbon source, the growth rate 
was relatively low but comparable to the other measured strains (Figure 30a), while when 
growing on maltose, a reduced growth rate could be observed. Such a growth phenotype would 
be typical for a Mal OFF enzyme switch: While in absence of maltose, the enzyme is active, 
thereby enabling sufficient fluxes and consequently a high growth rate, in presence of the 
effector maltose, the enzyme is less active, leading to reduced fluxes and consequently reduced 
growth rates.  
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Figure 30: Screening of 38 Domain Insertion library strains and subsequent 
characterization of two strains. 
(A) 38 E. coli strains expressing potentially maltose-dependent mDHFR variants and a control strain expressing solely 
mDHFR were grown on M9 minimal medium with either glucose or maltose as carbon source. Shown are the maximum 
growth rates in both growth conditions as scatter plot. Marked in orange is a strain with a low growth rate on maltose 
while growing with an average growth rate on glucose, a phenotype expected for strains with a maltose-sensitive 
mDHFR variant (K21). As a comparison, in purple the control strain (CTRL) has been marked. (B) Growth curves and 
growth rates of K21 and the control strain on M9-Glucose and M9-Maltose. (C) Sequenced gene of malE (red) with 
inserted mDHFR gene (blue) from K21. 
 
We sequenced the expression plasmid of K21 and found that, as intended, mDHFR was 
inserted into malE. However, despite using S1 nuclease to randomly linearize the plasmid, we 
also observed that parts of malE were deleted, probably due to overdigestion. We noticed that 
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the deletion led in this case to a frameshift so that the sequence adjacent to the mDHFR gene is 
no longer coding for the second MBP fragment (Figure 30c). The MBP was as a consequence 
truncated and consisted only of the amino acids 1-239, whereas the amino acids 240-396 and 
with that, important parts of the maltose-binding pocket (W340, Y341)122 were deleted. It is 
therefore very unlikely that the resulting enzyme switch is able to bind maltose and to control 
the activity of the fused enzymatic domain upon. 
Growth experiments have been performed for most of the created strain libraries with potentially 
switching enzymes. In most cases, a few strains showed initially an interesting growth 
phenotype in one of the growth conditions. However, so far none of the strains that showed 
conditional growth impairment were also found to possess switching proteins. Instead, we 
noticed that almost all sequenced plasmids were found to be overdigested – to our surprise 
independent of whether DNaseI or S1 nuclease had been used for the linearization – so that 
often large parts of the maltose binding protein could not be expressed.  
 
5.5 Discussion and Outlook 
Domain Insertion is a promising technique to create metabolic enzymes with synthetic allosteric 
regulation as enzymes and regulatory domains of interest can be combined to create potentially 
switching enzymes without the need for detailed knowledge about the structural properties of 
the involved proteins. In this project, we apply this approach to create such enzymes with the 
purpose to implement internal control of metabolic fluxes and consequently the growth rate.  
For that, we first defined needed specifications of enzymes and regulatory domains and then 
successfully tested an expression plasmid that allows very low and consequently growth rate 
limiting gene expression rates. 
Using both as groundwork we then tried to construct first metabolic enzymes with synthetic 
allosteric regulation. However, using the original protocol 73 only an insufficient number of library 
clones could be obtained. From previous applications of Domain Insertion we know that large 
library sizes are required in order to identify enzymes with synthetic allosteric regulation. A 
reference point of how many colonies are needed in order to isolate an enzyme with synthetic 
allosteric regulation is the study of 73: Of an original library of 1.000.000 strains, only 0.8% (8000 
strains) processed a functional enzyme. 10 % of those strains (800 strains) possessed in 
addition a functional regulatory domain. These strains were next screened for condition 
dependent enzymes. Although it has not been mentioned how many of these 800 strains 
showed condition-dependent enzyme activity, it is quite clear from these observations that 
thousands, if not millions of strains have to be produced in the first place in order to find a few 
strains that express enzymes with novel regulation. 
We therefore sought to optimize the protocol in order to increase the quantity of strains with 
candidate enzymes. We spent a significant amount of time and effort on the optimization 
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process and by changing most steps we were able to significantly increase library sizes. The 
production of a first large library consisting of over 2000 strains expressing functional and 
potentially condition-dependent enzymes was already successful and by repeating the 
transformation step, thousands and even millions of strains could be produced. 
Need for improved library quality 
However, not just the quantity, also the quality of obtained strains turned out to be problematic. 
When sequencing, we found that most plasmids previously linearized with DNaseI were 
overdigested. This can be very problematic as an overdigestion can cause i.) a frame shift and 
by that the expression of dysfunctional nonsense protein fragments at the C-terminus of the 
protein chimer or ii.) simply the deletion of crucial parts of the regulatory domain. To circumvent 
this problem, we decided to work with an alternative nuclease, the S1 nuclease. This nuclease 
has been reported to solely digest supercoiled DNA so that a digest of already linearized 
plasmids should be prevented. In addition, the successful usage of this nuclease in Domain 
Insertion has already been shown 75. We found that the linearization with S1 nuclease has the 
advantage that a larger fraction of plasmids can be linearized and consequently more linear 
plasmids prepared for the subsequent ligation step. However, we also observed a clear 
preference for a certain cut site, 2200 and 2800 bp away from a HindIII cut site. This indicates 
that the preferred S1 cut site is located in the origin of replication. Indeed, such a preference for 
inverted repeats commonly found in origins of replications has been reported 127. Plasmids in 
which the enzyme gene is inserted in this plasmid region is expected not to result in a functional 
plasmid as the replication of the plasmid might be affected, as well as the inserted gene will 
presumably not be able to be transcribed and translated. As a consequence, we assume that 
the higher yield of linearized plasmids will not result in more plasmids with enzymes inserted in 
the regulatory domain gene. In addition and in contrast to previous observations 75, even for 
plasmids linearized with S1 nuclease we noticed that a majority of plasmids is still overdigested.  
We therefore conclude that although the successful applications of DNaseI and S1 nucleases 
for sequence-independent linearization of plasmids for Domain Insertion have been reported 
73,75, as a result of the observed high number of overdigested plasmids we regard both 
nucleases as not suitable for Domain Insertion. Instead, alternative linearization methods are 
required in which overdigestions are prevented. In recent publications, such alternative methods 
have been presented: One uses random transposon insertion and subsequent replacement with 
an enzyme of interest 79. In another paper – interestingly from the same laboratory that 
developed the DNaseI and S1 nuclease approach – multiplex inverse PCR has been used to 
create linearized plasmids 76. The idea of this method is to create primer pairs for each possible 
insertion site and to amplify the whole plasmids. These plasmids can then be pooled and used 
for an insertion of the enzymatic gene via blunt end ligation. The big advantage of this technique 
is that all plasmids are linearized in frame and within the regulatory domain gene so that 
insertions outside the regulatory gene and overdigestions of the regulatory domain are 
prevented. Compared to the linearization by DNaseI and S1 nuclease, an amplification of the 
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acceptor plasmid has the disadvantage of being more laborious and expensive. However, we 
regard this approach as a promising technique to increase library sizes and especially to 
improve the quality of constructed libraries and therefore decided to use multiplexed inverse 
PCR in the next rounds of Domain Insertion. 
In addition to overdigestion by both nucleases, we speculate that the observed high ratio of 
overdigested plasmids and vice versa the low abundance of plasmids in which the enzyme had 
been correctly inserted into the regulatory domain might have been caused by another factor: It 
could be that the used combinations of enzymes, regulatory domains and linkers that have been 
tested so far are not suitable for Domain Insertion. For instance, this might be the case when 
enzymes are used that cannot correctly fold when other full length regulatory proteins are 
attached to the ends. In such a case, by plating on minimal plates we select for functional 
enzymes with only fragments of the enzymes attached so that their ratio in the library is high. 
Impaired protein functionalities as a result of insertions into other proteins are dependent on 
many factors such as the selected proteins, the insertion site but also linker size and 
composition. A prediction which combinations are suited for Domain insertion is therefore 
generally difficult. Instead, it is advisable, to test many different combinations or optimize the 
components. For instance, linker compositions can be varied very easily and for the 
optimizations of enzymes, methods like circular permutation could be applied that have already 
been shown to improve existing enzyme switch variants to be more responsive to the allosteric 
effector 74. 
Components that are planned to be used in future attempts of Domain Insertion 
We plan to test more combinations of enzymes, linkers and regulatory domains. For that, we 
selected several components of each group that are going to be combined with each other 
(Figure 31).  
 
 
Figure 31: Regulatory domains, enzymatic domains and linkers that are planed to be 
used for Domain Insertion. 
We still intend to work with MBP as regulatory domain and mDHFR as enzyme domain which 
are both monomeric proteins and therefore very suitable for Domain Insertion. However, several 
other regulatory domains and enzymes might be less suited as they form oligomers but would 
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be more interesting from a biotechnological perspective. As regulatory domains, we selected 
the effector binding proteins of the transcription factors Cra, PurR and FNR. All of those are 
responsive to metabolites that are important signal molecules for bioprocesses: As previously 
mentioned, Cra is responsive to fructose-1,6-bisphosphate and by that acts as a glycolytic flux 
sensor. This means that the flux into a production pathway could be coupled to the availability of 
e.g. glucose within bioreactors. FNR binds and is dependent on oxygen so that, similar to Cra, 
the flux can be controlled according to the availability of an important nutrient. PurR on the other 
hand is activated by hypoxanthine and guanine, degradation products of purines. It has been 
shown recently, that hypoxanthine accumulates quite rapidly in starving cells, whereas in good 
growth conditions, hypoxanthine levels are low 128. Hence, hypoxanthine can act as a metabolic 
indicator for starvation so that by using the metabolite binding domain of PurR as regulatory 
domain in Domain Insertion, fluxes could be coupled to the fitness state of a host cell.  
As enzymatic domains, we selected in addition to mDHFR and LeuA two other enzymes, ArgA 
and HisG. LeuA, ArgA and HisG are all responsible for the catalysis of the first step of their 
respective amino acid biosynthesis pathways and thereby usually allosterically regulated. For 
the construction of overproduction strains, the allosteric binding sites have already been 
identified and feedback resistant mutants described. By using these enzymes, we could 
therefore test synthetic allosteric regulation in bioprocesses. As shown above, we already 
tested the complementation of the native gene deletion phenotype for all these enzymes so that 
the required growth conditions are already determined. 
Linkers are the smallest components in Domain Insertion, their sizes and compositions are 
crucial for the creation of enzymes with synthetic allosteric regulation by Domain Insertion. This 
has exemplarily been shown for a GFP-MBP switch that was only slightly maltose dependent 
before optimizing the linkers 78. The introduction of a linker library resulted in different variants 
that showed a maltose dependency that was up to 300% higher or 50% lower than the original 
biosensor. 
The reason for the crucial role linkers have in Domain Insertion is they have to fulfill two tasks: 
On the one hand linkers have a transmission role, i.e. they have to transmit the conformational 
change the regulatory domain undergoes upon binding of its allosteric effector to the fused 
enzymatic domain so that the conformation of the enzyme and consequently its activity changes 
as well. To allow this signal transmission, linkers are ideally as short and rigid as possible. On 
the other hand, linkers may not interfere with the folding of the individual domains. For that, 
linkers should be long and flexible enough. 
As linkers, we so far used only flexible glycine-serine linkers. Our intention is to use other linker 
types, such as rigid α-helical structure forming linkers of the composition A(EAAAK)nA (n= 2–5) 
129 and short random linkers of sizes 0 – 3 amino acids. 
In conclusion, with the optimized protocol we are now able to create large libraries and would 
like to further improve the method with a new plasmid linearization approach. We plan to create 
many and very large libraries by combining several enzymes, regulatory domains and linkers. 
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So far, a screening of individual strains was possible due to small library sizes. However, for 
screening of new libraries, a high-throughput screening and enrichment method is required. For 
that, we evaluated the usage of the single cell growth rate reporter TIMER. 
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6 Enrichment of slow growing cells out of 
complex strain libraries using the 
fluorescent growth reporter TIMER 
 
Parts of following chapter have been published in ACS Synthetic Biology 130: 
Beuter D, Gomes-Filho J, Randau L, Díaz-Pascual F, Drescher K, Link H (2018) Selective 
enrichment of slow-growing bacteria in a metabolism-wide CRISPRi library with a TIMER 
protein. ACS Synthetic Biology. doi: 10.1021/acssynbio.8b00379 
 
As mentioned in the previous chapter, the creation of switching enzymes with directed evolution 
methods such as Domain Insertion or Fusion/Split Proteins usually involves the generation of 
large libraries of enzyme variants that potentially act as switches., i.e. which possess catalytic 
activity that is condition dependent. Such libraries have to be screened – ideally in a high-
throughput manner – in order to identify enzymes with the desired functions. As explained in 
more detail in Chapter 2.4.2, different approaches exist to identify such enzymes of which one is 
to couple enzymatic activity to growth: By expressing enzymes in conditions in which the 
enzymatic activity is defining the growth rate, every change in metabolic activity, e.g. as a result 
of implemented synthetic allosteric regulation, will subsequently lead to changes in the growth 
rates. This can be used to screen for the screening of condition-dependent enzymes: Whereas 
unregulated enzymes will support growth in all conditions, enzymes with synthetic allosteric 
regulation are in certain conditions (presence or absence of the effector) less active, hence, the 
growth rates of the expressing cells will be reduced in this particular condition. These cells with 
reduced growth rates are planned to be identified and enriched.  
Several methods to enrich fractions of strains with low growth rates have been developed 
(Chapter 2.4.2.2) but none of those was suitable for our purposes. Instead, we decided to 
develop our own enrichment method based on the single cell growth reporter TIMER, a 
fluorescence protein that appears green when freshly expressed but that maturates over time to 
a red fluorescent form. It has previously been shown that TIMER appears red in slow growing 
cells whereas fast growing cells appear greener. However, a usage as a tool to enrich slow 
growing cells out of large strain variants growing in batch cultures has not been reported so far. 
We therefore first sought to verify how good TIMER can display the growth rate in E. coli batch 
cultures. 
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6.1 Validation of TIMER to display the growth rate in E. 
coli 
6.1.1 Dynamics of TIMER 
Our first goal was to analyze the behavior of TIMER, i.e. the ratio of green and red fluorescence 
in a batch culture over time, from the inoculation to the stationary phase. For that, we 
transformed the plasmid pBR322-C_TIMER into E. coli NCM3722. For the growth experiment, 
we first started a LB preculture which we used in the second step to inoculate a M9-Glucose 
preculture. This second preculture was incubated for 24 hours at 37°C and shaking in 
Erlenmeyer flasks to ensure full maturation of TIMER. From this preculture a main culture was 
inoculated in a multiplate reader, enabling continuous measurements of optical densities and 
levels of green and red fluorescence. Moreover, we added small doses of the antimicrobial 
trimethoprim (Tmp) in sublethal concentrations (0, 0.25 and 0.5 µg/mL) to the medium, resulting 
in cultures with different growth rates. 
We found that in E. coli batch cultures, the TIMER fluorescence ratio followed a certain pattern 
which is depicted in Figure 32b: In the first growth phase – from inoculation until early 
exponential growth phase – all three cultures behaved the same: At the beginning, the 
green/red fluorescence ratio is very low which could be expected since the cells in the M9 
preculture that had been used for inoculation were in the stationary growth phase for many 
hours and thereby not growing, so that TIMER appears mainly red. After about 3 hours we then 
observe for all cultures a sudden large increase in the green/red fluorescence ratio. The reason 
for this observation is the technical limitation of the used microplate reader which has a higher 
sensitivity for detecting green fluorescence compared to red fluorescence. At the beginning of 
the incubation, the cell density is very low so that the detector cannot measure anything but red 
background fluorescence. With increasing cell density, first green fluorescence can be 
measured accurately and only later red fluorescence, leading to the observed sharp peaks of 
green/red ratios.   
In exponential growth phase, the ratio of green to red fluorescent TIMER first suddenly drops, 
as from this time point on, red fluorescence can be detected. The ratio then increases. This 
observation is in line with the previously proposed model 102 (Figure 32a) that with every cell 
division the fraction of red fluorescent, maturated TIMER is diluted and replaced with freshly 
expressed, green fluorescent TIMER. The ratio increased further until late exponential 
growth/early stationary phase was reached when the ratio usually reaches maximum. From this 
moment on the ratio decreases with an initial fast and then slower decreasing ratio. 
Interestingly, the three cultures did not reach the same green to red ratio even many hours after 
reaching stationary phase. 
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Figure 32: Growth curves and TIMER dynamics of three cultures with different growth 
rates. 
(A) Reported appearance and behavior of TIMER in fast and slow growing strains. (B) Three cultures of E. coli 
NCM3722 pBR322-C_TIMER grown in presence of different sublethal concentrations of Trimethoprim to alter the 
growth rates. At the top, the growth curves are depicted as black lines with the time point of the maximum growth rates 
marked with black dots. At the bottom, the TIMER dynamics over time is shown with a blue line. Black dots mark the 
time point of maximum growth.  
 
Based on these and previous observations 102 and having the technical limitations at low optical 
densities in mind, we assume that at the point of inoculation, the cells all are mainly red, then 
with each cell division appear more and more green and turn red again after entering stationary 
phase. We assume that in the first phase and can show that in the stationary phase, cells with 
different growth rates cannot be distinguished by their TIMER fluorescence ratios. For the 
usage of TIMER to identify and isolate slow growing cells within libraries of strains with different 
growth rates, however, it is crucial that cells with different growth rates can be distinguished as 
easy as possible. Hence, it would be ideal if the differences of TIMER ratios between slow and 
faster growing cells would be as large as possible. One emerging question from the observed 
TIMER dynamics was therefore, at which time point is the difference of TIMER ratios largest, i.e. 
when is the optimal time point to separate slow from fast growing cells. To answer this question, 
we therefore wanted to examine the dependency of TIMER appearance from the growth rate in 
more detail and for that, compared many cultures with a high variance in growth with their 
TIMER ratio in different growth phases. 
6.1.2 Correlation of TIMER and growth rate 
To see how well the TIMER ratio correlates with the growth rate at different growth phases, we 
repeated the previous growth experiment with 22 cultures in technical triplicates growing in 
presence of different Tmp concentrations spanning from 0 to 1 µg/mL. These concentrations 
impaired growth very differently, from no growth impairment (maximum growth) in absence of 
Trimethoprim to a by 90% reduced growth rate in presence of 1 µg/mL Tmp. Of these cultures, 
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maximum growth rates were calculated as well as the green/red fluorescence ratios measured 
at three different ODs representing different growth stages: OD = 0.15 (early exponential 
phase), 0.5 (mid-exponential phase) and 0.8 (late exponential phase). We then checked how 
well the maximum growth rates correlated with the TIMER behavior at the different time points 
(Figure 33).  
 
 
 
Figure 33: TIMER appearances in strains with different growth rates at different growth 
stages. 
TIMER expressed in E. coli NCM3722 pBR322-C_TIMER grown in presence of Trimethoprim in sublethal 
concentrations between 1 and 0 µg/mL. The TIMER appearance has been compared with the maximum growth rate of 
each culture at three different growth stages: Early exponential phase (OD= 0.15; left), mid-exponential phase (OD= 0.5, 
middle) and late exponential phase (OD= 0.8; right). The calculated Pearson coefficient (R²) is displayed in the bottom-
right corners. This experiment has been performed with technical triplicates.  
 
We found that TIMER correlates well and linearly with the growth rates at all phases of 
exponential growth with coefficients of determination (R²) between 0.93 and 0.99. For the 
utilization of TIMER in the enrichment of slow growing cells, a linear correlation is desirable 
because it would theoretically enable also the enrichment of only partially growth impaired 
strains, whereas non-linear correlations (e.g. bimodal behavior of TIMER with either completely 
green or completely red cells) would only allow the separation of a limited number of fractions. 
The best correlation could be observed at mid-exponential growth (OD= 0.5), whereas in the 
late exponential growth phase, the correlation was weaker in faster growing cells. In early 
exponential phase (OD= 0.15), the difference between green/red fluorescence ratios of slow 
and fast growing strains was largest. However, we also observed a large variation in the 
fluorescence ratios. This might be due to biological noise since in early growth stages it is 
expected that a larger fraction of the whole populations is still in the lagging phase and therefore 
appearing mainly red, whereas other cells already divided so that these cells appear greener, 
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resulting in a less homogeneous population. Another factor that might contribute to the higher 
variation might be the abovementioned technical limitation to measure red fluorescence in 
cultures with low density.  
As pointed out before, for library sortings, a large variation would be desirable to allow an easier 
separation of slow and fast-growing cells. However, due to the observed variance in the TIMER 
signals and the expected biological noise at lower ODs, we think that the growth rate display at 
mid-exponential phase is more reliable and hence, sortings at mid-exponential growth would be 
more reasonable. All following experiments therefore show TIMER at mid-exponential growth.  
6.1.3 Comparison of TIMER expressed from high and low copy 
number plasmids 
For library sortings with FACS, it is desirable that TIMER reflects the growth rate with as little 
noise as possible. In detail, that means that cells with a certain growth rate are supposed to 
have as less cell-to cell variations as possible.  
For this work, two plasmids with different copy numbers were available, a low copy number 
plasmid with a pSC101 origin of replication and a high-copy number plasmid with a pBR322 
origin 102 which was edited in this work (replacement of the antibiotic resistance cassette to be 
compatible with plasmids used in enzyme switch construction).  
We transformed these plasmids into 3 different E. coli wildtype strains (MG1655, NCM3722 and 
BW25113) and examined the TIMER – growth correlation in the resulting strains. For that, we 
let the cells grow in M9 medium with different carbon sources (glucose and glycerol) and the 
antibiotics to select for strains still harboring the plasmid and measured optical densities and 
green and red fluorescences in microtiter plate readers. 
We found that the strains harboring the high-copy number plasmid had growth rates reduced by 
15-20% compared to the control strains without any plasmid (Figure 34). No growth burden 
could be observed for the strains with the low copy number TIMER plasmid. In large parts, the 
growth burden will be caused by the excessive expression of TIMER, although an additional 
growth burden caused by differing antibiotics used for the selection for plasmid carrying cells 
cannot be excluded. However, although this burden might be problematic for other applications 
of TIMER, for the screen of pooled libraries we expect no severe limitations caused by it since 
this growth burden is affecting all cells within the library similarly.  
We also tested the correlations between TIMER signal and maximum growth rates. Here we 
found that the correlation using the high copy number plasmid is stronger with less variance 
compared to the strains expressing TIMER from the low copy number plasmid. Our explanation 
for this is – again in addition to the technical limitations of measuring low fluorescence signals –, 
a presumably higher variance due to the low copy numbers of expressed TIMER inside the 
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cells: The more TIMER molecules are within a cell, the higher is the robustness of the ratio of 
green to red fluorescent TIMER ratios.  
 
 
Figure 34: TIMER expressed from high and low copy number plasmids. 
(a) TIMER expressed from a high copy number plasmid (pBR322-TIMER, left plot) and low copy number plasmid 
(pSC101-TIMER, right plot) in 3 different E. coli strains (NCM3722, BW25113, MG1655) growing in M9 minimal medium 
with Glucose or Glycerol as carbon source. (b) Maximum growth rates of TIMER expressing strains in M9-Glucose 
minimal medium compared to the not TIMER expressing wildtype strains.  
 
To test this hypothesis, we let E. coli NCM3722 expressing TIMER from either the high or the 
low copy number plasmid grow to mid-exponential phase and analyzed the TIMER ratios of 
10,000 single cells each with flow cytometry (Figure 35). As expected, we detected generally 
lower fluorescences in the cells carrying the low copy number plasmid. When comparing the 
distribution of TIMER fluorescence ratios, we observed indeed a higher variance in the 
population of cells expressing TIMER from the low copy number plasmid (CV = 19.8) compared 
to cells expressing TIMER from the high copy number plasmid (CV = 15.9). This higher variance 
could have biological reasons, i.e. the low copy number plasmid causes a higher variation of 
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growth rates of individual cells. To test the hypothesis that the higher variance of TIMER signals 
actually reflects a higher variance in growth phenotypes, one possibility would be to test the 
relation between both on the single cell level using a mother machine as recently presented 131. 
 
 
Figure 35: TIMER appearance of single cells expressing TIMER from a high and low copy 
number plasmid. 
TIMER expression from high and low copy plasmid compared on single cell level by Flow Cytometry. Embedded into the 
plot is the distribution of cells with different ratios of green/red fluorescent TIMER expressed from the high copy number 
plasmid (green) and high copy number plasmid (low). 
 
However, we think that the results presented here are sufficient to conclude that the display of 
the growth rate by TIMER is more accurate when expressed from the high copy number 
plasmid. We therefore decided that the high copy number plasmid is more eligible for library 
screens and sortings, despite the growth burden caused by the expression of TIMER from the 
high copy number plasmid. 
6.1.4 Robustness of TIMER against genetic perturbations 
Next, we were wondering how robust TIMER expression and its ability to display the growth rate 
is when the cells are perturbed genetically. The intention behind this question is that we assume 
that the growth conditions are similar for all cells within a pooled library and external factors, 
such as the influence of oxygen concentrations on the maturation rate of TMER, can therefore 
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be neglected when evaluating the ability of TIMER to display the growth rate reliably. However, 
cells within the pooled libraries vary genomically. The phenotypes caused by these variations 
can vary dramatically, from silent mutations that have no impact on the fitness, and variations 
that only cause a fitness burden under certain conditions to severely growth impairing or even 
lethal mutations. Though, an important prerequisite for the usage of TIMER to screen pooled 
libraries of genetic variant strains is the independence of TIMER to display the growth rate from 
such genetic perturbations.  
To test this, we transformed the TIMER expression plasmid into 11 strains of the KEIO 
collection 132 with knockouts of global transcription factors. These transcription factors are 
responsible for the control of expression of 31 to 513 genes. A knockout of these transcription 
factors will therefore presumably lead to a misregulation of many genes and by that impair the 
physiological state of the cells. Hence, assuming that the TIMER fluorescence ratio is not 
independent of genetic perturbations, it would be very likely to observe such a deficiency of 
TIMER to display the growth rate in genetically perturbed strains with the chosen global 
transcription factor knockout strains. 
With these strains we did another growth experiment, measuring optical density and 
fluorescences in microplate readers to determine maximum growth rates and TIMER 
fluorescence ratio at mid-exponential growth (Figure 36). 
 
 
Figure 36: TIMER expressed in transcription factor knockout strains. 
TIMER appearance (green/red fluorescence ratio) in relation to the growth rates of 11 E. coli strains of the KEIO 
collection 132 in which global transcription factors have been knocked out.  
 
The growth rates in the given growth conditions were reduced to different extents and varied 
between 0.17 and 0.68 h-1. Interestingly, the TIMER expressing E. coli wildtype strain BW25113 
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– the KEIO collection background strain – grew slower than expected and slower than the 
majority of transcription factor knockout strains. We explain this with a random mutation within 
the genome of the host strain that leads to an unusual growth reduction. TIMER, however, was 
able to display this reduced growth rate despite the random mutation. Overall, the previously 
observed clear linear correlation between growth and TIMER behavior could also be observed 
with this set of strains with a calculated coefficient of determination of 0.97. Only the ΔiscR 
strain showed a green/red fluorescence ratio that was slightly too low for the measured growth 
rate. We can only speculate why this is the case. A direct link between TIMER expression and 
the biological function of IscR which controls the expression of genes needed for the expression 
of iron-sulfur clusters is not apparent. Moreover, the deviation from the expected TIMER ratio is 
not very large and dubiously significant. 
We therefore conclude that large genetic perturbations caused by deletions of global 
transcriptions factors may have a reducing effect on the growth rate but do not impair the 
display of growth rates by TIMER. 
6.1.5 A simple mathematical model can explain the TIMER 
behavior 
Based on the previous results, we propose a simple model that is sufficient to explain the linear 
correlation of TIMER and the growth rate. The model includes the concentration of green and 
red fluorescent TIMER, the expression rate b, growth rate µ and maturation rate k (Figure 37). 
The concentration of green fluorescent protein is influenced positively by the expression rate 
and negatively by the maturation constant (maturation from green to red fluorescent TIMER) 
and dilution by growth. The concentration of the red fluorescent protein fraction itself is 
positively influenced by the maturation constant and like the green fluorescent fraction 
negatively influenced by dilution due to growth. 
Combining these two equations, we found that the TIMER fluorescence ratio ([G]/[R]) is only 
dependent on two factors, the growth rate µ and the maturation constant k. The dependency on 
the growth rate is apparent as this has been described before 102 and is also the reason why we 
chose this fluorescence reporter in the first place. Previous studies found a dependency of 
TIMER maturation from pH, temperature 100 and oxygen 102 despite unchanged growth rates. 
The fluorescence ratio is on the other hand not dependent on the expression rate b. This 
explains the similar correlation of growth rate and TIMER expressed from the high and low copy 
plasmids.  
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Figure 37: Simulation of dependency of TIMER appearance from growth and maturation 
constant. 
(a) TIMER appearance (ratio of green [g] and red [r] fluorescent TIMER) can be explained by only a small number of 
parameters: b is the expression rate of TIMER, k is the maturation constant, m is the dilution rate which is defined by the 
growth rate of the culture. Solving the steady state equation shows that the TIMER appearance is proportional to the 
growth rate m and inversely related to the maturation constant k. (b) TIMER ([g]/[r]) is linearly dependent on the growth 
rate m. Changing the maturation constant k (e.g. by growth in presence of lower oxygen concentrations) does not impair 
the linear dependency. 
 
6.1.6 Conclusions 
Based on our verification experiments we think that TIMER could theoretically be used as a tool 
to screen pooled libraries for slow growing cells. An important prerequisite for its utilization is 
that the TIMER fluorescence ratio is not influenced by genetic perturbations. Since the TIMER 
fluorescence ratio was not even impaired by knockouts of global transcription factors, we think 
that the TIMER fluorescence ratio is independent on the genetic background. We could also 
show that the best correlation between growth rates and TIMER fluorescence ratio can be 
observed when TIMER is expressed from a high copy plasmid and in mid-exponential growth 
phase.  
Our next goal was to use TIMER to specifically enrich slow growing cells out of a 
comprehensive library of genetic variants using the beforehand determined settings. 
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6.2 Selective Enrichment of slow growing cells 
6.2.1 Creation of a metabolism-wide CRISPRi library 
We sought to verify if TIMER can be used to enrich fractions of slow growing strains from 
pooled large genetic variant strain libraries. A method to create such a large library is CRISPR 
interference. As shown in Chapter 3.2, the construction of sgRNAs that target genes of interest 
is relatively simple with only a handful of design principles to follow 133 and multiplexing of DNA 
synthesis enables the construction of large and comprehensive CRISPRi libraries that target 
large sets of genes. Dependent on the essentiality of the targeted gene and the strength of the 
introduced metabolic bottleneck, it can be expected that some strains within such a CRISPRi 
strain library will have reduced growth rates under certain environmental conditions – similar to 
strain libraries expressing enzymes with potentially implemented allosteric regulation. We 
therefore regarded CRISPRi as an interesting method to create a complex strain library that can 
be used to evaluate TIMER as a tool for the enrichment of conditionally growth impaired strains 
and sought to generate such a comprehensive CRISPRi library for E. coli. 
We chose to target every metabolic gene of E. coli. According to the last metabolic network 
reconstruction, iML1515, E. coli possesses 1515 genes involved in metabolism 1. For each of 
these genes we designed 4 to 5 sgRNAs, resulting in a library of 7184 sgRNAs. The target 
sequences have been identified and selected using a Matlab script. The criteria for target 
finding were that the binding sites should be evenly distributed over the whole gene sequence 
to allow different gene expression repression strengths, and that the sgRNA should bind to the 
non-template strand as binding to this strand proved to be more efficient than binding to the 
template strand 48. The full list of designed sgRNAs can be found in our publication. 
As the plasmids used in the original CRISPRi system are not compatible with the TIMER 
plasmid, we had to use another CRISPRi expression system for which we chose to work with 
pNUT1527 (Figure 38). This plasmid has the advantage to carry both, the genes for dCas9 
under the control of a strong IPTG inducible promoter (Ptac) and the sgRNA gene under the 
control of a constitutive promoter (PJ23119).  
 
Figure 38: Plasmids used for the screening of a metabolism-wide CRISPRi library and the 
enrichment of slow growing cells. 
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For cloning of the library, the sgRNAs were ordered and received as pooled oligonucleotides 
from Agilent Technologies and then amplified in a low cycle PCR with high amounts of template 
RNA to obtain double-stranded DNA without changing the composition of the library. Next the 
plasmid backbone was amplified and after purification, we used Gibson Assembly to fuse both 
and to create the CRISPRi library plasmids (Figure 39).  
 
 
Figure 39: Design and Construction of the metabolism-wide CRISPRi library. 
 
The plasmids were then directly transformed into electrocompetent NCM3722 cells harboring 
the TIMER plasmid, the resulting transformants plated on rich medium without inducers to 
minimize the impact of CRISPRi on the growth rates. The transformation resulted in 
approximately 107 cfus, which is above the 1000x library coverage threshold. All these colonies 
have been flushed and pooled resulting in the desired comprehensive strain library.  
We next examined the composition of the strain library with Next Generation Sequencing. For 
that, we amplified 300 bp fragments consisting of the sgRNA gene and flanking regions by 
PCRs with high amounts of template and low cycle numbers. The amplified DNA was then 
cleaned up and amplified a second time to add indexes to the fragments which allow binding of 
the fragments to the NGS chip. We performed Next Generation Sequencing and analyzed the 
obtained data using Matlab. After removal of all sequences that did not map to the sgRNA 
sequences in the reference library, we obtained 430.000 analyzable reads. In these reads we 
found that 7094 out of the 7184 sgRNAs (98.7%) were present in our strain library (Figure 40). It 
must be noted that several sgRNAs had only very low read counts, a few only with a single 
read. We therefore conclude that although an analyzable read count of 430.000 is usually 
regarded as very high, it is most likely not sufficient to allow sequencing of all low abundant 
sgRNAs and that actually more or less all sgRNAs are present within the strain library. In fact, 
20 of the 90 in the original library undetected sgRNAs could be detected in other rounds of 
sequencing. In the next step, we sought to enrich a slow growing fraction out of this library using 
the TIMER protein. 
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Figure 40: sgRNA abundances in the cloned strain library. 
Read counts of sgRNAs after assembly of the CRISPRi library. 7094 of 7184 sgRNAs (98.7%) were present in the 
library (black dots), 90 sgRNAs (1.3%, red dots) were not detected. 
 
It has been recently reported that an overexpression of dCas9 can be toxic to the cells 95 which 
might result in abnormal cell morphology 134. We therefore examined the cell morphologies of 
library cells expressing TIMER, dCas9 and gRNAs using microscopy (Figure 41). We could not 
observe any of the reported morphological changes, showing that impaired growth would not be 
a result of morphological changes caused by dCas9 overexpression but in fact caused by a 
combination of both, TIMER overexpression and gene repression by CRISPRi. 
 
Figure 41: Overlay green and red fluorescence in E. coli NCM3722 pBR322-C_TIMER 
pNUT1527-sgRNA:none. 
E. coli cells expressing TIMER, dCas9 and a non-targeting guide RNA. The expression of all three does not result in any 
cell length phenotype.  
  Chapter 6 - Enrichment of slow growing cells out of complex strain libraries using the fluorescent 
growth reporter TIMER 
 
81 
6.2.2 Enrichment of cells with a metabolic bottleneck in amino 
acid metabolism 
Out of the created CRISPRi strain library, our goal was then to isolate a fraction of strains which 
are growth impaired under certain conditions using the TIMER protein, in this case amino acid 
depletion.  
For that, we separated the growth period into two phases (Figure 42): First, we started the first 
culture by inoculating M9-Glucose minimal medium supplemented with 1 mM of each amino 
acid with a defined volume of the library glycerol stock. This culture was incubated for 6 hours to 
mid-exponential growth phase. Then, the cells were vacuum-filtered, washed and resuspended 
in fresh M9 minimal medium, only this time without supplemented amino acids. Again the cells 
were incubated for 6 hours to again reach mid-exponential phase as in this phase TIMER 
correlates best with the growth rate. This culture was then used for FACS-based analysis and 
sorting to enrich slow growing cells. 
 
 
 
Figure 42: Workflow for TIMER-based enrichment of strains with bottlenecks in amino 
acid biosynthesis. 
The enrichment is divided into two growth phases and a subsequent enrichment of cells with a low green/red 
fluorescence ratio using Flow Cytometry: In the first growth phase, a culture is started by inoculation of M9 minimal 
medium with glucose and 1mM of each amino acid with a defined volume of the library cryo stock. The culture is 
incubated for 6 hours. We expect the occurrence of a non-growing fraction (1) that will be outcompeted by the non-
affected, normally growing strains (2+3). Then the cells are washed and reinoculated in fresh medium for the second 
growth phase. In this phase, cells grow in absence of amino acids. Whereas most cells will grow unaffectedly (2), cells 
that are auxotroph for amino acids as a consequence of the introduced metabolic bottleneck will be growth impaired and 
appear red (3). This fraction can then be isolated by using flow cytometry. 
 
Chapter 6 - Enrichment of slow growing cells out of complex strain libraries using the fluorescent 
growth reporter TIMER 
 
82 
With this setup, we expected the occurrence of three subpopulations with different growth 
characteristics as depicted in Figure 42: A major fraction of the population is neither growth 
impaired in the first culture with amino acids, nor in the second culture without amino acids 
(fraction 2). In many cases this is due to gRNAs targeting genes that are irrelevant for growth 
under the given growth conditions. In other cases, an insufficient silencing of transcription due 
to weak gRNAs and/or overabundance of targeted proteins could result in reduced transcription 
rates but not to an extent that would limit fluxes sufficiently to cause reduced growth rates. 
A second fraction of strains is growth impaired in both media (fraction 1). This is the case when 
the targeted gene is essential in minimal medium independent of the addition of amino acids. 
We expected that these strains will be lost already in the first culture by the other strains 
overgrowing these growth impaired strains. Indeed, we found that 80 sgRNAs that could be 
detected in the original library were not present in both experiments, neither before washing, nor 
after sorting. Targeted genes are involved in different metabolic pathways, e.g. pyruvate 
decarboxylation, ATP synthesis, folate biosynthesis, lipopolysaccharide transport, pyrimidine 
and purine biosynthesis. 
The third fraction consists of conditionally growth affected strains (fraction 3): In presence of 
amino acids these strains are not growth impaired as the bottleneck caused by CRISPRi can be 
compensated by uptake of amino acids. However, after depletion of the amino acids the genetic 
bottleneck introduced by CRISPRi results in a bottleneck in the metabolic network and 
subsequently in reduced growth. We assumed that most strains showing this behavior 
presumably have metabolic bottlenecks in pathways required for the biosynthesis of amino 
acids. It is theoretically possible that strains were enriched that are unable to grow sufficiently 
on glucose alone but a combination of both, glucose and amino acids restores that growth. For 
instance, incomplete bottlenecks in glycolysis could result in this phenotype. 
We sought to isolate and further analyze this third fraction using TIMER-based enrichment of 
slow growing cells. For that, the cells were first analyzed by flow cytometry. Similar to the 
appearance of cells expressing TIMER from high and low copy number plasmids (Chapter 
6.1.3), when comparing red and green fluorescences of individual cells, we observed that most 
cells of the whole population were within the characteristic cloud (Figure 43). However, in 
addition to this population a small subpopulation with a lower green/red fluorescence ratio – 
indicating slow growth – which had a share of about 2% of the whole population was 
observable. We isolated 100,000 cells of this fraction using a cell sorter and plated these cells 
on plates with rich medium. As a reference for strains without growth impairment, we also 
isolated and plated cells with a high green/red fluorescence ratio. These two fractions were then 
analyzed further, in a growth experiment and by NGS. To compare the reproducibility of the 
enrichment, the sorting has been performed in two independent experiments. 
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Figure 43: Sorted fraction of slow and fast growing cells. 
Left: Green and red fluorescences of E. coli NCM3722 pBR322-C_TIMER, pNUT1527-ML cells 6 hours after removal of 
amino acids from the medium. The two fractions with a high and low green/red fluorescence ratio have been marked. 
Right: Distribution of TIMER fluorescences of sorted fractions (orange and green) and the whole population (blue). (a) 
and (b) indicate both independent cultivations and sortings. 
 
6.2.2.1 Analysis of sorted and isolated strains 
Of both fractions, we picked 48 (low green/red) and 45 colonies (high green/red), respectively. 
The growth rates of these isolates were compared in a growth assay experiment in a multititer 
plate reader. In addition, three cultures of a strain with a non-targeting gRNA were used as a 
control strain. Growth of the control strain is not significantly affected by the expression of both 
CRISPRi components as shown in Figure 44. All strains from the fast growing fraction grew 
similarly and comparable to the control strain, with growth rates above 0.52 h-1 and lag phases 
shorter than 8.6 hours (Figure 45). It has been shown recently, that a CRISPRi can have a 
strong effect on the lag phases. Strains with such a delayed growth presumably were growth 
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inhibited in the first growth phase until the bottleneck can be overcome by escape mutations or 
compensatory responses 93.  
 
 
Figure 44: Growth characteristics of the CRISPRi control strain. 
Growth of the CRISPRi control strain (E. coli NCM3722 pBR322-C_TIMER pNUT1527-non targeting control; green) in 
comparison to the wildtype strain and the strains harbouring only one of the plasmids. Shown are the results of three 
independent cultures each in 96 well microtiter plates. Black dots in the growth curves indicate the time when the 
cultures reached maximum growth. Top: Growth conditions as used in the growth experiments to characterize TIMER 
(Figure 32). Bottom: Growth conditions as used for the enrichment of strains with a metabolic bottleneck upon removal 
of amino acids. 
 
As the strains isolated with a high green/red ratio are expected not to be growth 
impaired, we defined all strains with a growth rate below 0.52 h-1 and/or with a lag 
phase longer than 8.6 h as poorly growing. Of the fraction isolated with a low green/red 
ratio, 38 of the 48 isolates showed either reduced growth prolonged lag phases or both, 
showing that we indeed specifically enriched slow growing cells with TIMER.  
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Figure 45: Growth of isolated strains. 
Shown are the maximum growth rates and lag phases (time until the maximum growth rate is reached) of 45 strains 
isolated with a high green/red fluorescence ratio (reference strains; green dots), three independent cultures of the 
control strain (black dots) and of 47 strains isolated from the fraction with the lowest green/red fluorescence ratio 
(orange and red dots). Dashed lines indicate the longest lag phase and lowest growth rate observed for the strains in 
the reference strain panel. 28 of the strains with most impaired growth (lowered growth rate and/or longer lag phase) 
compared to the reference panel have been sequenced. Of those, 16 strains possessed gRNAs targeting genes directly 
involved in amino acid biosynthesis (red dots).  
 
Next, we were interested which metabolic genes have been targeted in this group of 38 growth 
impaired strains, assuming that a large fraction of those target genes are related to amino acid 
metabolism. Indeed, Sanger sequencing of the 28 most growth impaired strains showed that 11 
had gRNAs targeting genes encoding enzymes in the de novo biosynthesis of amino acids. 
Moreover, in 5 additional strains genes involved in assimilatory sulfate reduction was targeted. 
This pathway is needed for the de novo biosynthesis of cysteine. The remaining 12 strains were 
not directly involved in amino acid metabolism. However, targeted genes of this set of strains 
include genes like sdh of the TCA cycle which is producing precursors of amino acid 
biosynthesis. Perturbing the expression of a gene like sdh might therefore indirectly disturb the 
biosynthesis of amino acids. 
In addition to the growth experiment, we wanted to verify if the reduction of growth rates and 
elongation of lag phases is actually caused by reduced gene expression. We were able to show 
this indirectly by measuring the intracellular concentration of precursors of the targeted 
reactions (Figure 46). We chose three strains with gRNAs binding to genes of the amino acid 
biosynthesis pathway, hisD, aroC and argG and measured the concentration of the precursors 
of these reactions. For AroC, the direct precursor is not measurable, instead we measured the 
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concentration of the previous metabolite in the pathway, shikimate-3-P. As a control strain, we 
also measured the concentrations of these metabolites in the negative control strain. For each 
of the measured metabolites, we saw a specific accumulation in the corresponding strain with 
the metabolic bottleneck. Although this does not exclude the possibility that the growth 
impairment is also partially caused by off-target effects, i.e. the binding of the gRNAs to 
unintended targets, the accumulation of precursors proofs the successful implementation of 
metabolic bottlenecks that presumably at least contribute to the growth phenotypes. 
 
 
Figure 46: Intracellular concentrations of precursor metabolites. 
Depicted are the intracellular concentrations of 3 metabolites, Shikimate-5-phosphate, histidinol and L-citrulline, that 
were measured with LC-MS/MS and which are precursors in reactions in which metabolic bottlenecks were introduced 
with CRISPRi. Metabolite concentrations have been measured in the negative control strain as well as in the CRISPRi 
strains targeting the respective genes. LC-MS/MS parameters are shown on the left, the targeted reaction on the right. 
 
  Chapter 6 - Enrichment of slow growing cells out of complex strain libraries using the fluorescent 
growth reporter TIMER 
 
87 
We conclude from these results that our library consist of strains with different growth 
phenotypes under different growth conditions and that the isolation of growth impaired strains 
out of this library is possible with TIMER. Furthermore, Sanger sequencing of a small number of 
growth impaired strains already suggests that a large fraction of the isolated strains have 
bottlenecks in pathways directly or indirectly involved in the biosynthesis of amino acids. To 
quantify their appearances before and after enrichment more accurately, we next sought to 
analyze the library compositions with NGS.  
For that, the cells before washing and the isolated cells with a low green/red fluorescence ratio 
have been plated on rich media plates and incubated overnight. The resulting colonies have 
been flushed from the plate and minipreps have been performed on the pooled cell suspension 
to isolate the plasmids. The plasmids then have been used as the template to amplify the 
abovementioned 300 bp fragment including the guide RNA gene sequence and flanking 
regions. The fragments were then further processed as described in Materials and Methods and 
subsequently sequenced and analyzed. 
As the enrichment has been performed in two independent experiments, we first sought to 
analyze how much the enrichments differ between both experiments. We therefore compared 
the fold changes of abundances of each strain before removal of amino acids and after 
enrichment of slow growing strains (Figure 47). We found that in both experiments the majority 
of strains were comparably enriched or depleted. Particularly strains that showed a high level of 
enrichment after isolation of slow growing cells were enriched comparably in both experiments. 
Differences in the fold changes were especially observed for strains that were highly depleted in 
one of the experiments. These variations between the two experiments could be caused by very 
low numbers of sorted cells per strain, resulting in statistical errors. Another possible reason are 
differences in the gates that were set to isolate the fraction of cells with a low green/red 
fluorescence ratio so that in one of the experiments, cells with a certain, relatively low green/red 
ratio have been isolated, whereas in the other experiment, these cells were not within the gate 
and therefore have not been isolated. Nonetheless, as we are primarily interested in the strains 
with the biggest changes in abundance (i.e. cells with the highest enrichment upon isolation of 
presumably slow growing cells) and since their changes of abundances seem to be sufficiently 
robust, the observed differences of fold changes of abundances of other strains can be ignored. 
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Figure 47: Fold change of individual gRNAs in both experiments. 
Depicted are the fold changes of abundances of gRNAs after enrichment of the slow growing fraction compared to their 
abundances before removal of amino acids from the medium in both experiments. Each dot represents an individual 
gRNA. gRNAs on the black line have the same fold change of abundance in both experiments. 
 
Next, we were interested which ratio of the isolated strains with low green/red fluorescence ratio 
possessed targets in amino acid biosynthesis pathways. We found that in both experiments, 
before removal of amino acids, about 12 % of all strains within the cultures possessed gRNAs 
that are directly targeting amino acid biosynthesis pathways (Figure 48a). This ratio correlates 
very well with the theoretical ratio of amino acid biosynthesis targeting gRNAs in the library (12 
%; 837 of 7184 gRNAs) and shows that this group of gRNAs was not already enriched prior to 
washing. After removal of amino acids, incubation for 6 hours and sorting of the presumably 
slow and non-growing cells with a low green/red fluorescence ratio, we found that the fraction of 
cells with amino acid biosynthesis gene targeting gRNAs increased significantly to roughly 50% 
of the whole population. This number is in line with the previous results from Sanger sequencing 
of growth impaired isolates where also roughly half of the isolated strains possessed such 
gRNAs and already shows that the enrichment of strains with bottlenecks in amino acid 
biosynthesis pathways was successful. 
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Figure 48: Abundance of gRNAs targeting genes involved in amino acid biosynthesis. 
(a) Fraction of gRNAs within the library that target genes involved in amino acid biosynthesis. (b) Read counts of 
individual gRNAs within the library before removal of amino acids and after enrichment of slow growing cells. Orange 
dots represent gRNAs that target genes involved in amino acid biosynthesis. In red are the 6 gRNAs with the highest 
fold change marked that inhibit the expression of genes in amino acid biosynthesis. The black dashed line show a fold 
change of 1 and 10, respectively. 
 
When regarding only these strains with gRNAs targeting amino acid biosynthesis genes in more 
detail, we found that the extent of their enrichments differed strongly (Figure 48b): Some strains 
were less abundant in the isolated fraction of cells with a low green/red ratio, indicating that 
these strains possess gRNAs that are either not sufficiently strong to silence the targeted gene 
or that the knock down of transcription can be compensated. On the other hand, many strains 
with these gRNAs were highly enriched, indicating a strong difference in growth phenotypes 
before washing (sufficient growth) and after (impaired growth). These strains are expected to 
possess strong gRNAs that are sufficient to knockdown a gene that is essential in absence of 
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supplemented amino acids. 141 strains of the whole library showed a high level (more than 10 
fold) of enrichment after isolation. Of these highly enriched strains, 61% were directly linked to 
amino acid metabolism (Figure 49, blue dots). Interestingly, when comparing the different amino 
acid biosynthesis pathways we noted that of some pathways many strains were highly enriched, 
whereas in other pathways, we observed only for a small number of strains an increased level 
of abundance. For instance, of the methionine biosynthesis pathway, we noted a >10 fold higher 
abundance of 15 strains, with strains possessing gRNAs targeting metA, metB and metC 
partially being enriched >60 fold. The reason for this sensitivity of gene expression is that 
methionine biosynthesis usually operates at maximum capacity. Any disturbances of gene 
expression therefore reduce fluxes which apparently leads to lowered fitness, even when the 
gRNAs do not bind near transcription start site where repression is known to be more effective 
than downstream of the gene 48. 
 
Figure 49: Fold change of gRNA abundance by classes of metabolic pathways. 
Each dot represents the fold change of abundance of an individual gRNA after enrichment. Blue dots indicate gRNAs 
that showed a more than 10-fold higher abundance upon enrichment. Numbers above the lines show the amount of 
gRNAs with a more than 10-fold enrichment. The orange box marks all gRNAs that bind genes in amino acid 
biosynthesis pathways. 
 
On the other hand, even the strongest gRNAs targeting genes in the glutamine/glutamate 
biosynthesis pathway did not result in growth impairment to an extent that these strains were 
significantly enriched. This robustness might be a result of the central role these pathways have 
in ammonium assimilation and transamination reactions but could be also a consequence of 
high amounts of stored glutamate within the cell 104: After removal of amino acids, this pool 
might be large enough to maintain the metabolic network to a certain extent so that the 
metabolic bottleneck in glutamine and glutamate biosynthesis impairs growth only with a delay. 
When this delay is too long, the cells with such a bottleneck stop growing so late that TIMER 
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has not enough time to maturate accordingly and it will not reflect the growth rate, so that we 
will not be able to enrich these strains under the tested conditions. Instead, an increased 
incubation time after removal of amino acids would be necessary to isolate those. 
39% of the highly enriched strains were not directly linked to amino acid biosynthesis. However, 
many of these strains possessed gRNAs that target genes that are indirectly linked to amino 
acid biosynthesis. Anaplerotic reactions are for instance crucial to refill pools of TCA cycle 
intermediates that are partially used as precursors for amino acid biosynthesis. Cells with 
metabolic bottlenecks in these reactions are able to grow in presence of glucose and amino 
acids as the needed amino acids can be taken up from the medium and anaplerotic reactions 
are not needed. In absence of amino acids however, TCA cycle intermediates are utilized to 
produce amino acids de novo that cannot be replenished, leading to reduced growth as a result 
of impaired TCA cycle and amino acid biosynthesis. Similarly, several strains with bottlenecks in 
the TCA cycle and glycolysis were highly enriched after removal of amino acids from the 
medium. In presence of amino acids, these strains were able to take up all needed amino acids, 
whereas after removal of amino acids, the cells were not able to synthesize the precursors for 
amino acid biosynthesis as a result of the introduced metabolic bottleneck.  
At last, we checked if off-target effects and bad seeds might have had an impact on growth and 
subsequently the library composition after sorting.  
gRNAs with off-targets have sequences with 9 nt or more identity to other target genes than the 
intended target gene 95. We identified in our library 635 gRNAs that have off-targets in amino 
acid biosynthesis. Their appearances before and after enrichment have been analyzed for both 
experiments (Figure 50, top). In general, we found that the fraction of strains with off-targets in 
amino acid biosynthesis was not increased upon sorting of cells with low green/red fluorescence 
ratio, showing that a large majority of potential off-targeting gRNAs are not sufficiently strong to 
create a negative impact on the fitness of the cell. This observation can be confirmed when the 
appearances of strains with off-targets are compared before and after enrichment (Figure 50, 
bottom): Most strains showed a lower or similar abundance upon isolation of cells with low 
green/red fluorescence ratio, showing that for the vast majority of these strains the off-target 
effect is not strong enough to impair growth in absence of amino acids. Only three strains with 
potentially off-targeting gRNAs were enriched more than 10 fold. Their gRNAs have off-targets 
in argF, argH (arginine biosynthesis) and ilvE (isoleucine biosynthesis). However, the on-targets 
of all three gRNAs are genes involved in the biosynthesis of cofactors (metF in folate 
biosynthesis and pdxH of pyridoxal phosphate biosynthesis) that are also crucial for amino acid 
biosynthesis so that the enrichment might be also a directly caused by the on-target. 
Bad seeds are gRNA sequences that show a so far unexplained sequence-specific toxicity 
which is assumingly caused by the 5 bases next to the PAM sequence 95. To exclude that the 
bad seed-effect influenced the library composition before and after enrichment, we screened 
our library for the abundances of gRNAs with the 25 bad seed sequences that have to be 
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reported to have the most severe effect on the growth rate. We found that they were neither 
depleted before enrichment, nor were they enriched after isolation of the slow growing fraction 
of cells.  
We therefore conclude that the impact of off-targets as well as of bad seeds seems neglectable 
in this enrichment and the highly enriched strains were isolated as a consequence of the direct 
on-targets of their gRNAs.   
 
Figure 50: Off-targets in amino acid metabolism. 
Top: Normalized sequencing read counts for each sgRNA before and after enrichment. sgRNAs with off-targets in 
amino acid metabolism, and no on-target in amino acid metabolism are shown as purple dots. Bottom: Fraction of 
sgRNAs in the library with off-targets in amino acid metabolism (and no on-target in amino acid metabolism), before and 
after sorting. Shown are results of two independent experiments (Exp1 and Exp2). 
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6.3 Discussion and Outlook 
The dsRed variant TIMER is an interesting fluorescent protein that has the special feature of 
appearing green when freshly expressed but maturating to a red form. This characteristic 
enables its usage as a fluorescent growth rate reporter as shown for the visualization of growth 
rates of mouse tissues infecting Salmonella and of E. coli cells in biofilms 101. An application for 
an enrichment of slow growing cells out of pooled strain libraries however had not been 
reported so far.  
Our goal in this work was to evaluate the usage of TIMER for this application. For that, we 
verified that TIMER reflects the growth rate in E. coli batch cultures independent of used host 
strain and genetic backgrounds in a linear dependency – an important prerequisite for the 
usage of TIMER to enrich strains with a specific growth rate. 
We then tested how efficient we can enrich slow growing cells out of a large strain library using 
TIMER as it is planned for the libraries of strains expressing potentially switching enzymes 
created by Domain Insertion. As a test library we produced a large pooled CRISPRi strain 
library for which we designed 7184 sgRNAs targeting all 1515 metabolic genes of E. coli. Such 
a strain library could be used in the future to systematically examine the impact of single 
metabolic bottlenecks on the phenotype under certain environmental conditions. So far, the 
strain library that was commonly used for such examinations is the KEIO collection 132. 
However, our library has two features that make it superior to the KEIO collection: First, 
dependent on the sgRNA target site within the gene metabolic bottlenecks can also be 
introduced gradually whereas the complete gene knockout usually results in complete 
bottlenecks. Second, the possibility to induce dCas9 expression enables also the examination 
of bottlenecks caused by knockdowns of essential genes whereas with the KEIO collection a 
construction of essential gene knockout strains was not possible. A further examination of the 
CRISPRi library would be interesting but is not planned within this project. 
We could show that an enrichment of fractions of growth impaired strain under specific 
environmental conditions – in this case amino acid depletion – is possible. For that, we used 
fluorescence activated sorting of slow growing cells according to the individual TIMER 
appearances and verified the efficiency of sorting by next-generation sequencing and detailed 
growth characterization of a smaller number of enriched cells. 
The next step would be now to apply TIMER to screen for strains with switchable enzymes. 
However, TIMER-based enrichment of slow growing cells could be also interesting for various 
other fields of biology. For instance, the enrichment of slow growing strains can help examining 
persister cells with low growth rates and therefore low susceptibility to antibiotics 102. Slow 
growing cells with a high metabolic activity might be also interesting in metabolic engineering as 
host strains for overproduction of chemicals in two-phase bioprocesses 135. Moreover, an 
isolation of growth impaired strains could be helpful in synthetic biology to identify genetic parts 
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that create a growth burden to the cell 136. We plan to use TIMER in other projects that are not 
directly linked to the creation of switching enzymes. 
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7 Conclusions and Outlook 
Enzymes with synthetic allosteric regulation could be of great interest for metabolic engineering 
and synthetic biology although their construction remains challenging. Our main goal was to 
create switching enzymes for the immediate, autonomous and continuous control of metabolic 
pathways. For that, we chose creation techniques based on the concept of directed evolution. 
As already indicated in the introduction, the creation of switching enzymes through directed 
evolution involves several steps which can be illustrated with an engineering cycle (Figure 51), 
which we followed in this project. 
 
Figure 51: Creation of enzymes with synthetic allosteric regulation. 
 
Metabolic enzymes with synthetic allosteric regulation introduce conditional metabolic 
bottlenecks in the reaction catalyzed by them, and effectively cause a pseudo-auxotrophy for 
downstream products (e.g. amino acid, folic acid). At first and prior to the creation of switching 
enzymes we therefore sought to examine metabolic bottlenecks and how they influence growth 
of E. coli. We found that a metabolic bottleneck in the pyrimidine biosynthesis pathway caused 
by insufficient expression of pyrE causes upstream metabolites to accumulate and growth rates 
to be reduced. While a bottleneck in this reaction had strong effects on the fitness, bottlenecks 
in other reactions might not. One bottleneck, that we found to have no impact on the fitness was 
the strain expressing sdRNA:purM: Although the substrate level increased and the product level 
decreased, no reduction of the growth rate was observable. This is explainable by insufficient 
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bottleneck strengths that limit fluxes through the pathway but not to an extent that the final 
product concentration is growth limiting. These findings have some implications for the creation 
of switching enzymes and the growth-based screening for those that. The prerequisite is that 
the enzymatic activity is the growth limiting factor. Usually, this can be reached by expressing 
the enzyme in a strain in which the respective native gene is knocked out and letting the 
resulting strain grow in environmental conditions in which a functional enzyme is essential for 
growth. In addition to that, the expression strength has to be so low so at least when the 
enzyme switch is in the OFF state, the growth rate is reduced. For that reason, for our attempts 
to create enzyme switches we expressed candidate enzymes from low copy number plasmids 
and either in gene knockout strains or in presence of antibiotics that specifically target the native 
enzyme version. 
For the creation of enzyme switches, we evaluated two techniques: Split Proteins and Domain 
Insertion.  
With the Split Protein approach we were able to create a rapamycin-dependent mDHFR switch. 
We characterized this switch in growth and metabolomics experiments and could show that 
when expressed in an E. coli strain that is growing on minimal medium, in presence of 
trimethoprim to inhibit bacterial DHFR and in absence of rapamycin a growth rate limiting 
bottleneck is introduced that leads to an accumulation of the substrate dihydrofolate. In 
presence of rapamycin on the other hand both mDHFR fragments reassemble and form a 
functional enzyme that removes the metabolic bottleneck partially and leads to growth rates 
similar to a positive control strain in which constantly interacting mDHFR fragments are 
expressed. With this switching enzyme we could show that Split Proteins generally can control 
metabolic pathways and several optimizations of the switch are planned to create split 
enzymes, which have a higher relevance for biotechnology.  
Domain Insertion remains a difficult approach. Although we extensively optimized the method 
and are now able to create larger libraries, due to overdigestion by S1 nuclease and DNaseI 
there is still a high tendency for enzymes with partially deleted regulatory domains. With further 
adaptions to the protocol and testing more combinations of enzymes linkers and regulatory 
domains, we want to create more and larger libraries and are still confident to identify enzymes 
with switching behavior out of them.  
The high-throughput screening method required for the identification of enzyme switches has 
been successfully developed in this project. Biosensors that are active dependent on a certain 
compound (e.g. product of a reaction catalyzed by an enzyme of interest) have been proven to 
be useful tools for the identification of certain strains out of pooled libraries 82 and would have 
been a good option for the identification of enzyme switches as well. However, we plan to 
create different enzymes with synthetic allosteric regulation and a development of biosensors 
for each of the reaction of pathway products would be very laborious. Hence, we favored a 
reporter system that can be used for many enzymes of interest and therefore developed a 
growth-based screening system utilizing the growth rate reporter TIMER. This allows the 
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screening of many switching enzymes as long as their activity is limiting the growth rate of the 
cells. We have not tested the enrichment method with a Domain Insertion strain library yet but 
could already show that TIMER reflects the growth rates of E. coli batch cultures quite 
accurately and that out of pooled strain libraries fractions of slow growing cells can be enriched. 
Hence, we are confident that TIMER is also a suitable tool for the enrichment of conditionally 
slow growing cells out of Domain Insertion libraries. In addition to that, we speculate that the 
TIMER-based method for the enrichment of slow-growing cells might also be useful for many 
other fields of biology and we currently plan to use it in other projects in our group. 
After the identification of potentially switching enzymes it is planned to characterize the switch, 
especially with high-throughput metabolomics methods and potentially by determining the 
protein kinetics of purified enzymes. Enzymes that have been proven to have a high catalytic 
activity in the ON state and a substantially lowered activity in the OFF state are furthermore 
planned to be tested in an overproduction strain. By simulating changing environmental 
conditions on a very short time scale we could try to elucidate if switching enzymes have a 
beneficial effect on the fitness of the overproducing cells while ideally having only a slight 
negative effect on the production rate. 
If successful, the in this work performed experiments, optimized protocols and developed 
methods can act as a basis for the creation and identification of switching metabolic enzymes 
that have the potential to optimize many different overproduction strains and bioprocesses. One 
might speculate that in the long term a computer-aided design of synthetic allosteric regulation 
in metabolic enzymes might be possible, however until then directed evolution with the here 
presented methods seems an appropriate alternative. 
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8 Materials and Methods 
8.1 Materials, instruments and source of supplies 
8.1.1 Chemicals, kits and enzymes 
Chemicals and enzymes that have been used in this work were acquired from Bioline 
(Germany), Carl-Roth (Germany), GE Healthcare (Germany), Invitrogen (USA), Merck 
(Germany), New England Biolabs (USA), Peqlab (USA), Roche (Switzerland) and Sigma-Aldrich 
(Germany). 
8.1.2 Buffers and solutions 
De-ionized water (Purelab ultra water purification systems, ELGA, Germany) has been used to 
prepare buffers and solutions. If required, they were sterilized by autoclaving (121°C for 15 
minutes, 1 bar) or filter sterilization (pore size 0.22 µm, Merck, Germany). 
8.1.3 Media and supplements 
For E. coli pre-cultures and DNA amplification cultures LB (lysogeny broth) medium 137 has 
been used, for other cultures, M9 minimal medium 138: 
LB medium 
Tryptone 1.0 % (w/v) 
Yeast Extract 0.5 % (w/v) 
NaCl 1.0 % (w/v) 
 
M9 minimal medium 
Na2HPO4 6 g/L 42.2 mM 
KH2PO4 3 g/L 22 mM 
(NH4)2SO4 0.5 g/L 8.56 mM 
NaCl 1.5 g/L 11.34 mM 
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The following components have been added separately: 
ZnSO4 1.8 mg/L 6.3 µM 
CuCl2 1.2 mg/L 7 µM 
MnSO4 1.2 mg/L 7.1 µM 
CoCl2 1.8 mg/L 7.6 µM 
Thiamine 1 mg/L 2.8 µM 
MgSO4 246 mg/L 1 mM 
CaCl2 14.7 mg/L 0.1 mM 
FeCl3 16.2 mg/L 60 µM 
 
The resulting medium has been filter sterilized and a carbon source has been added with a final 
concentration in the medium of 5 g/L.  
For the expression of Split Proteins (Chapter 4) casamino acids with a concentration of 10 g/L 
have been added to the medium, for the enrichment of slow growing cells (Chapter 6.2) the 
medium has been supplemented with 1 mM of each amino acid, for the examination of the pyrE 
bottleneck (Chapter 3.1) 100 mM uracil. 
 
8.1.4 Antibiotics 
Where appropriate antibiotics enlisted in Table 5 have been added to the medium. 
 
Table 5: Antibiotics used in this study. 
Antibiotic Stock concentration 
mg/mL 
Final concentration 
µg/mL 
Ampicillin 50 50 
Chloramphenicol 35 35 
Kanamycin 50 50 
Gentamycin 15 15 
Tetracycline 15 15 
Trimethoprim 10 10 
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8.2 Strains and culture conditions 
8.2.1 Strains 
A list of all Strains used in this study is shown in Table 6: 
Table 6: Strains used in this work 
Strain or strain libraries Relevant features Reference 
or Source 
Escherichia coli K12 DH5α fhuA2 lacΔU169 phoA glnV44 Φ80' lacZΔM15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 
139 
Escherichia coli K12 DH10β F- mcrA ∆(mrr-hsdRMS-mcrBC)  φ80lacZ∆M15 ∆lacX74 
recA1 endA1 araD139 ∆(ara, leu)7697 galU galK λ- rpsL 
nupG /pMON14272 / pMON7124 
Invitrogen 
(USA) 
Escherichia coli MG1655 F-, λ-, rph-1 140 
Escherichia coli NCM3722 F- 141 
Escherichia coli EMG-2 F+, λ+, rpoS (Am) 
rph-1 
140 
Escherichia coli MDS42 F-, λ-, rph-1, ΔfhuACDB, ΔendA, deletion of 699 additional 
genes 
142 
Escherichia coli W3110 F−, λ−, rpoS(Am), rph-1 Inv(rrnD−rrnE) 140 
Escherichia coli BW25113 F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514 
143 
Escherichia coli BW25113 
ΔargA 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔargA 
132 
Escherichia coli BW25113 
ΔargR 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔargR 
132 
Escherichia coli BW25113 
Δcrp 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,Δcrp 
132 
Escherichia coli BW25113 
Δfnr 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,Δfnr 
132 
Escherichia coli BW25113 
ΔfruR 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔfruR 
132 
Escherichia coli BW25113 
Δfur 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,Δfur 
132 
Escherichia coli BW25113 
ΔglnG 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔglnG 
132 
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Escherichia coli BW25113 
ΔhisG 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔhisG 
132 
Escherichia coli BW25113 
ΔiscR 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔiscR 
132 
Escherichia coli BW25113 
ΔleuA 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔleuA 
132 
Escherichia coli BW25113 
Δlrp 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,Δlrp 
132 
Escherichia coli BW25113 
ΔnagC 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔnagC 
132 
Escherichia coli BW25113 
ΔphoB 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔphoB 
132 
Escherichia coli BW25113 
ΔpurR 
F-, Δ(araD-araB)567, lacZ4787Δ::rrnB-3, λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514,ΔpurR 
132 
EcoR wildtype isolates Various 103 
 
8.2.2 Culture conditions 
Liquid E. coli cultures were incubated either in shake flasks, culture tubes or microtiter plates. 
For that, usually a preculture was started by inoculating LB medium with bacteria from a glycerol 
stock and incubated for 6 hours at 37°C, constantly shaking. Next, a M9 preculture has been 
started by rediluting the LB preculture 1:200 in M9 minimal medium. This culture has been 
incubated overnight at 37°C, constantly shaking. These precultures were then used in the next 
morning to start M9 main cultures by re-diluting the M9 preculture 1:200 in fresh M9 minimal 
medium. 
Upon transformation, cells were incubated on solid medium plates with either LB or M9 medium 
and 1.5% (w/v) agar-agar over night or up to 72 hours at 37°C. 
For long-term storage of strains, stationary cultures were mixed with glycerol to a final 
concentration of 50% (v/v) and stored in cryo tubes, 96 well plates or 15 mL volume falcon 
tubes, 
8.2.3 Transformation 
3 different methods for plasmid transformation in E. coli cells have been used in this work: TSS 
transformation, transformation in chemically competent cells and transformation in 
electrocompetent cells.  
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8.2.4 TSS transformation 
For TSS transformation 144, a culture has been started by inoculating 5 mL LB medium with 50 
µL from an overnight preculture or cryo stock and incubated at 37°C. When an OD of 0.5 to 0.8 
is reached, 200 µL of the culture is mixed with 200 µL of the TSS solution (20 % (w/v) 
Polyethylenglycol 6000, 100 mM MgSO4, 10% (v/v) DMSO in LB medium) and 1 µL of the 
plasmid. The suspension is incubated on ice for 30 minutes, then at 37°C for 45 minutes and 
finally plated on LB agar plates. 
8.2.5 Preparation of chemically competent cells 
For the preparation of chemically competent cells the protocol described by 145 had been 
followed. For that, a 1 L flask with 100 mL LB medium has been inoculated from cryo stock and 
incubated overnight or for 8 hours until an optical desity of 0.6 is reached. Then, the cells are 
placed on ice for 10 minutes, pelleted by centrifugation (10 minutes, 4°C, 2500 x g), 
resuspended with 50 mL ice cold TB buffer, incubated on ice for 15 minutes, pelleted again and 
resuspended in 12 mL TB buffer. To the cell suspension 900 µL DMSO has been added, briefly 
mixed and incubated for 10 minutes on ice. Then, 150 µL aliquots could be created which have 
been immediately quick frozen in liquid nitrogen and stored at -80 °C until further usage. 
For the transformation of plasmid DNA, aliquots have been thawed on ice, 100 ng plasmids 
added per aliquot and the resulting mixture have been incubated on ice for 30 minutes. Next, 
cells were heat shocked for 30 seconds in a water bath at 42°C. Upon the heat shock, cells 
were incubated on ice again for 5 minutes. Then, 800 µL LB medium without antibiotics was 
added and the cultures incubated shaking for 1 hour at 37°C. Finally, cells were pelleted by 
centrifugation (3 minutes, 3000 x g), the pellet resuspended in about 100 µL remaining 
supernatant and plated on LB agar plates. 
8.2.6 Preparation of electrocompetent cells 
For the preparation of electrocompetent cells the protocol published on the NEB website 
(https://international.neb.com/protocols/2012/06/21/making-your-own-electrocompetent-cells) 
has been followed. Briefly, cells are grown to an optical density of 0.5 – 0.7, washed twice with 
10% glycerol and resuspended in small volume of residual supernatant. The resulting dense cell 
suspension was aliquoted (100 µL per tube) and stored at -80°C until needed. 
For electroporation, 1 µL of plasmid solution has been added to the cell suspension, briefly 
mixed and used for electroporation using a BioRad MicroPulser (Bio-Rad Laboratories, USA).  
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8.3 Plasmids and Oligonucleotides 
SeqBuilder (DNASTAR, USA) and Benchling (https://benchling.com) have been used to design 
oligonucleotides used for PCR reactions and sequencing reactions. Oligonucleotides were 
purchased from Eurofins (Germany) and Invitrogen (USA) and ThermoFisher (USA). The 
pooled oligonucleotide library (Chapter 6.2.1) was purchased from Agilent (USA). 
A list of all oligonucleotides used in this work can be found in Table 7- Table 10, a list of all used 
and constructed plasmids in Table 11 - Table 14. A list of all oligonucleotides that have been 
purchased for the metabolism-wide CRISPRi library can be found in the appendix. 
 
Table 7: Primers used for the construction of plasmids used to introduce metabolic 
bottlenecks with CRISPRi (Chapter 3.2) 
Name Sequence Purpose 
sgRNA 
pyrE001 
TACTTTTCTACAGACAAAAAAAGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Introduction of base pairing 
region to sgRNA, target: 
Intergenic region  
(-46), coding strand 
sgRNA 
pyrE002 
GCTAAGCGCAAATTCAATAAACGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: pyrE +21, non-coding 
strand 
sgRNA 
pyrE003 
TTAAGGCCTATCGCGAAGAGTTGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: pyrE +632, non-coding 
strand 
sgRNA 
CTRL 
GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGC Non targeting  
sgRNA 
gshB 
CTTGATGTTGATGTTTGCGATGGTTTTAGAGCTAGAA
ATAGCAAGTTAAAATAAGGC 
Target: gshB 
sgRNA 
gadA 
ACGTGAATCGAGTAGTTCTGAGGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: gadA 
sgRNA 
glmS 
CAGACGACGTAAACCTTCAAGAGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: glmS 
sgRNA 
panC 
ATTTGCTGACGCAGCAGCGGCAGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: panC 
sgRNA 
purM 
CCGGCATCTTTGTAGCTAAGAGGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: purM 
sgRNA 
LuxS 
CGACTGTGAAGCTATCTAACAAGTTTTAGAGCTAGAA
ATAGCAAGTTAAAATAAGGC 
Target: LuxS 
sgRNA 
dapD 
ATCTCGGCACGGCGTTCAAAAGGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: dapD 
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sgRNA 
ddlA 
ACGTCGAAGCGACTTTTATCAAGTTTTAGAGCTAGAA
ATAGCAAGTTAAAATAAGGC 
Target: ddlA 
sgRNA 
cysE 
CAGTCCGCCAGCGTTCTGGCTTGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: cysE 
sgRNA 
pyrB 
AAATGATATGTTTCTGATATAGGTTTTAGAGCTAGAA
ATAGCAAGTTAAAATAAGGC 
Target: pyrB 
sgRNA 
nrdA 
TGCCGCCCAATCCAGAACGCGAGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: nrdA 
sgRNA 
mtn 
ACCTCGGTTCCATTCAGTTGGCGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: mtn 
sgRNA 
ArgA 
GTATTGATATAGGGAACCGAATGGGTTTTAGAGCTA
GAAATAGCAAGTTAAAATAAGGC 
Target: ArgA 
sgRNA 
leuA 
GCCTGTTCACCGTCGCGCAATGGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: leuA 
sgRNA 
metK 
GGATGCCCTTCAGAGACGGACTGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: metK 
sgRNA 
dapE 
CTGTTGTGTCAGCTCAATAACCGTTTTAGAGCTAGAA
ATAGCAAGTTAAAATAAGGC 
Target: dapE 
sgRNA 
pheA 
TTTCTCTCGCAGCGCCAGTAACGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: pheA 
sgRNA 
murB 
TGTGTTCCAGGGTTTTAAGGAGGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: murB 
sgRNA 
metA 
CTTCACGCAAGAAATTGACGGCGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: metA 
sgRNA 
proB 
GCCGAGTTTTACCACCAGCGTCGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: proB 
sgRNA 
hisB 
TCACTCGGCGGTTCGCTAATCAGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: hisB 
sgRNA 
coaD 
TGGTAATGGGATCGAAAGTACCGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: coaD 
sgRNA 
ilvC 
CGCGCCATCGGCGAATTCATCGGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: ilvC 
sgRNA 
pyrE 
GCTAAGCGCAAATTCAATAAACGTTTTAGAGCTAGAA
ATAGCAAGTTAAAATAAGGC 
Target: pyrE 
sgRNA 
aroL 
CCCGAGGCCCGATCAGAAAAAGGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: aroL 
sgRNA GGAAAGGATAAATCGCCGTGTCGTTTTAGAGCTAGA Target: nadA 
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nadA AATAGCAAGTTAAAATAAGGC 
sgRNA 
purB 
ACAGGGGAAACGGCGGTCAGTGGTTTTAGAGCTAG
AAATAGCAAGTTAAAATAAGGC 
Target: purB 
sgRNA 
ArgE 
tttttcattgttgacacacctcGTTTTAGAGCTAGAAATAGCAAG
TTAAAATAAGGC 
Target: ArgE 
sgRNA 
folA 
TCGGCAGGCAGGTTCCACGGCAGTTTTAGAGCTAGA
AATAGCAAGTTAAAATAAGGC 
Target: folA 
Ec-R ACTAGTATTATACCTAGGACTGAGCTAGC Reverse primer to amplify the 
sgRNA plasmid 146 
Ec-F-
colony 
GGGTTATTGTCTCATGAGCGGATACATATTTG- Colony PCR and sequencing 
primer for the sgRNA plasmids 
146 
Ec-R-
colony 
CGCGGCCTTTTTACGGTTC Colony PCR and sequencing 
primer for the sgRNA plasmids 
146 
 
 
Table 8: Primers used for the construction of plasmids and sequencing primers used for 
the development of Split Proteins (Chapter 4) 
Name Sequence Purpose 
pT18 FWD gaggtggaggctcaggaggaggtggtggttcaGCC
GCCAGCGAG GCCACG 
Amplification of pT18 and 
overhangs for CPEC 
pT18 REV TTTTCCGGGATCAAGCTTGGCGTAATC
ATGG 
Amplification of pT18 and 
overhangs for CPEC 
DHFR3 pT18 FWD GTCTACGAGAAGAAAGACtaactaagtaata
tggtgcactctc agtacaa 
Amplification of DHFR3 and 
overhangs for CPEC 
DHFR3 pT18 REV AAACCATGTCTACTTTACTtgaaccaccacc
tcctcct 
Amplification of DHFR3 and 
overhangs for CPEC 
DHFR(3) for FKBP12 
FWD 
GGAGCTTCTAAAACTGGAAggaggaggtg
gaggctca 
Amplification of pT18-DHFR(3) 
and overhangs for CPEC 
DHFR(3) for FKBP12 
REV 
GCACTCCCATagctgtttcctgtgtgaaattgtt Amplification of DHFR(3) and 
overhangs for CPEC 
FKBP12 gene FWD acaggaaacagctATGGGAGTGCAGGTGG
AA 
Amplification of FKBP12 and 
overhangs for CPEC 
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FKBP12 gene REV ctcctccTTCCAGTTTTAGAAGCTCCACAT
C 
Amplification of FKBP12 and 
overhangs for CPEC 
pT25 for FRB FWD GAACAACCGGAATTGACTCTAGAGGAT
CCCCGG GT 
Amplification of pT25 and 
overhangs for CPEC 
pT25 for FRB REV GAATCAGCTCTTCcatagctgtttcctgtgtgaaa
ttg 
Amplification of pT25 and 
overhangs for CPEC 
FRB gene FWD ggaaacagctatgGAAGAGCTGATTCGAGT
AGCCA 
Amplification of FRB and 
overhangs for CPEC 
FRB gene REV tcctcctgagcctccacctcctccTAGCTGCTTGG
AGATCCGT C 
Amplification of FRB and 
overhangs for CPEC 
DHFR12 for FRB FWD gaggtggaggctcaggaggaggtggtggttcaGTTC
GACCATTGA ACTGCATC 
Amplification of DHFR1,2 and 
overhangs for CPEC 
DHFR12 for FRB REV TCCTCTAGAGTCAATTCCGGTTGTTCA
ATAAGTC TTA 
Amplification of DHFR1,2 and 
overhangs for CPEC 
Cut at linker FWD ggaggaggtggaggctca Amplification of pT18-DHFR3 and 
overhangs for CPEC 
Cut at Lac REV CATagctgtttcctgtgtgaaattg Amplification of pT18-DHFR3 and 
overhangs for CPEC 
Make zip + linker FWD gataacaatttcacacaggaaacagctATGATCCA
GCGTATGA AACAGCTG 
Amplification of leucine zippers 
and overhangs for CPEC 
Make Zip + linker REV tgaaccaccacctcctcctgagcctccacctcctccAC
GTTCACCCA CCAGTTTTTT 
Amplification of leucine zippers 
and overhangs for CPEC 
Lac promoter T18/25 
FWD 
tatgcttccggctcgtatgt  Colony-PCR and sequencing 
primer 
Seq primer T25 REV gttttcccagtcacgacgtt Colony-PCR and sequencing 
primer 
Seq primer T18 REV ctggcttaactatgcggcat Colony-PCR and sequencing 
primer 
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Table 9: Primers used for the construction of plasmids and sequencing primers used for 
the development of enzymes with synthetic allosteric regulation using the Domain 
insertion approach (Chapter 5) 
Name Sequence Purpose 
malE stop BamHI ggtcGGATCCttaCTTGGTGATACGAGTCTGC Amplification of malE for 
construction of pTRC99KK-malE  
malE start XhoI cgccCTCGAGatgAAGATCGAAGAAGGTAAAC
TG 
Amplification of malE for 
construction of pTRC99KK-malE 
leuA_f_noATG_5G ggtggcggaggtggcAGCCAGCAAGTCATTATTTT
CG 
Amplification of leuA with GGGGS 
linker 
leuA_r_nostop_5G tccaccacctcctccCACGGTTTCCTTGTTGTTTTC
G 
Amplification of leuA with GGGGS 
linker 
DHFR 05 f ggtggtggagggtctGTTCGACCATTGAACTGCAT
CGTC 
Amplification of mDHFR with 
GGGGS linker 
DHFR 05 r accgccaccaccagaGTCTTTCTTCTCGTAGACT
TCAAACTTATACTTGATGCC 
Amplification of mDHFR with 
GGGGS linker 
mDHFR fwd 3X NNNNNNNNNGTTCGACCATTGAACTGCATC Amplification of mDHFR with NNN 
linker 
mDHFR rev 3X NNNNNNNNNGTCTTTCTTCTCGTAGACTTC
AAACTTATAC 
Amplification of mDHFR with NNN 
linker 
pSB cra OH r TCACAAGACCcatactagtggtttcctgtgtgActc Amplification of pSB4A5 for the 
insertion of cra with CPEC 
pSB cra OH f AGCCGTAGCtaataactgcaggagtcactaaggg Amplification of pSB4A5 for the 
insertion of cra with CPEC 
cra pSB OH f accactagtatgGGTCTTGTGATCCCC Amplification of cra for the 
insertion into pSB4A5 with CPEC 
cra pSB OH r tgcagttattaGCTACGGCTGAGCAC Amplification of cra for the 
insertion into pSB4A5 with CPEC 
pSB malE OH r CCTTCTTCGATCTTcatactagtggtttcctgtgtgActc Amplification of pSB4A5 for the 
insertion of malE with CPEC 
pSB_malE_OH_f GACTCGTATCACCAAGtaataactgcaggagtcacta
aggg 
Amplification of pSB4A5 for the 
insertion of malE with CPEC 
malE pSB OH f cactagtatgAAGATCGAAGAAGGTAAACTG Amplification of malE for the 
insertion into pSB4A5 with CPEC 
malE pSB OH r cagttattaCTTGGTGATACGAGTCTGC Amplification of malE for the 
insertion into pSB4A5 with CPEC 
pSB purR OH r ACCGATAGACTTcatactagtggtttcctgtgtgActc Amplification of pSB4A5 for the 
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insertion of purR with CPEC 
pSB_purR_OH_f ACTATCGTCGTtaataactgcaggagtcactaaggg Amplification of pSB4A5 for the 
insertion of purR with CPEC 
purR pSB OH f aaccactagtatgAAGTCTATCGGTTTGCTG Amplification of purR for the 
insertion into pSB4A5 with CPEC 
purR_pSB_OH_r ctgcagttattaACGACGATAGTCGCG Amplification of purR for the 
insertion into pSB4A5 with CPEC 
pSB_fnr_OH_r TTTCCGGGATcatactagtggtttcctgtgtgActc Amplification of pSB4A5 for the 
insertion of fnr with CPEC 
pSB_fnr_OH_f TCATCTACtgataactgcaggagtcactaaggg Amplification of pSB4A5 for the 
insertion of fnr with CPEC 
fnr_pSB_OH_r tcctgcagttatcaGTAGATGAATGCAGCC Amplification of fnr for the 
insertion into pSB4A5 with CPEC 
fnr_pSB_OH_f cactagtatgATCCCGGAAAAGC Amplification of fnr for the 
insertion into pSB4A5 with CPEC 
pSB_BB_fwd taactgcaggagtcactaaggg Amplification of pSB4A5 for the 
insertion of several enzyme genes 
with CPEC 
pSB_BB_rev catactagtggtttcctgtgtgAc Amplification of pSB4A5 for the 
insertion of several enzyme genes 
with CPEC 
hisG_OH_SB_f gTcacacaggaaaccactagtatgACAGACAACACT
CGTTTACGC 
Amplification of hisG for the 
insertion into pSB4A5 with CPEC 
hisG_OH_SB_r ccttagtgactcctgcagttaCTCCATCATCTTCTCAA
TCG 
Amplification of hisG for the 
insertion into pSB4A5 with CPEC 
argA_OH_SB_f gTcacacaggaaaccactagtgtgGTAAAGGAACGT
AAAACCGAG 
Amplification of argA for the 
insertion into pSB4A5 with CPEC 
argA_OH_SB_r ccttagtgactcctgcagttattaCCCTAAATCCGCCAT
C 
Amplification of argA for the 
insertion into pSB4A5 with CPEC 
pSB_BB_rev_ARG cacactagtggtttcctgtgtgAc Amplification of pSB4A5 for the 
insertion of argA with CPEC 
leuA_OH_SB_f gagTcacacaggaaaccactagtatgagccagcaagtcatta
ttttc 
Amplification of leuA for the 
insertion into pSB4A5 with CPEC 
leuA_OH_SB_r cccttagtgactcctgcagttattacacggtttccttgttgttttc Amplification of leuA for the 
insertion into pSB4A5 with CPEC 
leuA M38L M43L r GGCCAGCGCAATTTGCAG Amplification of leuA to remove 
two potential start codons 
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leuA M38L M43L f CTTGAGCGTttaGGTGTTGACGTGttaGAAGT
CG 
Amplification of leuA to remove 
two potential start codons 
pTRC99KK_fwd catcataacggttctggcaa pTRC99KK sequencing primer 
pTRC99KK_rev aaaatcttctctcatccgcc pTRC99KK sequencing primer 
pSB4A5 seq rev aagggaagttttagtcaaaagc pSB4A5 sequencing primer 
pSB4A5 seq fwd cggatcctacctgacg pSB4A5 sequencing primer 
 
 
Table 10: Primers used for the construction of plasmids and sequencing primers used 
for the development of a method to enrich slow growing strains using a TIMER protein 
(Chapter 6) and primers required for next generation sequencing. 
Name Sequence Purpose 
pBR_CMP_BB_F 
 
gacgtctaagaaaactgtcagaccaagtttactcatatatac 
 
Amplification of pBR322_TIMER 
for exchange of the resistance 
cassette 
pBR_CMP_BB_R 
 
tggtgagaatccaaaatgtatttagaaaaataaacaaaagag 
 
Amplification of pBR322_TIMER 
for exchange of the resistance 
cassette 
Cmp_pBR_fwd 
 
ctaaatacattttggattctcaccaataaaaaacg 
 
Amplification of Cmpr for 
exchange of the resistance 
cassette in pBR322_TIMER 
Cmp_pBR_rev 
 
ggtctgacagttttcttagacgtcaggtggc 
 
Amplification of Cmpr for 
exchange of the resistance 
cassette in pBR322_TIMER 
   
kdo1740 gaaaatgagacgtccagttcaccgacaaacaacag amplification of Addgene #44251  
kdo1742 tatagcggccgcaataggcgtatcacgaggcaga amplification of Addgene #44251  
kdo1741 tcggtgaactggacgtctcattttcgccagatatcgac amplification of Addgene #44249  
kdo1739 gcgcttaattaaagcgagtcagtgagcgagg amplification of Addgene #44249  
kdo1737 gcgcttaattaacagtaatgacctcagaactccatctgg amplification pNUT1270 
kdo1736 tctagaagcggccgcgaattc amplification pNUT1270 
kdo1860 ccagatatcgaccaagcgagctctctagacgcca amplification of lacIQ1 
kdo525 tttagacctccttagctcctgaattccta amplification of lacIQ1 
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OH_amp_fwd 
 
taaggatgatttctggaattctaaag 
 
Amplification of pooled 
oligonucleotides 
OH_amp_rev 
 
gtgccactttttcaagttgataac 
 
Amplification of pooled 
oligonucleotides 
EcF_forward 
 
gttttagagctagaaatagcaagttaaaataaggc 
 
Amplification of pNUT1527 for 
Gibson Assembly with amplified 
pooled oligonucleotides 
EcF_reverse 
 
actagtattatacctaggactgagctagc 
 
Amplification of pNUT1527 for 
Gibson Assembly with amplified 
pooled oligonucleotides 
NGS_F2_adapter TCGTCGGCAGCGTCAGATGTGTATAAGAG
ACAGcgcaataggcgtatcacgagg 
Amplification of a 150 bp 
fragment of pNUT1527 including 
the sgRNA  
NGS_R2_adapter GTCTCGTGGGCTCGGAGATGTGTATAAGA
GACAGcgacggcgctattcagatcc 
Amplification of a 150 bp 
fragment of pNUT1527 including 
the sgRNA 
   
Custom_N701 CAAGCAGAAGACGGCATACGAGATTCGCC
TTAGTCTCGTGGGCTCGG 
I7 oligo 
 
Custom_N702 CAAGCAGAAGACGGCATACGAGATCTAGT
ACGGTCTCGTGGGCTCGG 
I7 oligo 
 
Custom_N703 CAAGCAGAAGACGGCATACGAGATTTCTG
CCTGTCTCGTGGGCTCGG 
I7 oligo 
 
Custom_N704 CAAGCAGAAGACGGCATACGAGATGCTCA
GGAGTCTCGTGGGCTCGG 
I7 oligo 
 
Custom_N705 CAAGCAGAAGACGGCATACGAGATAGGAG
TCCGTCTCGTGGGCTCGG 
I7 oligo 
 
Custom_N706 CAAGCAGAAGACGGCATACGAGATCATGC
CTAGTCTCGTGGGCTCGG 
I7 oligo 
 
Custom_S502 AATGATACGGCGACCACCGAGATCTACAC
CTCTCTATTCGTCGGCAGCGTC 
I5 oligo 
 
Custom_S503 AATGATACGGCGACCACCGAGATCTACAC
TATCCTCTTCGTCGGCAGCGTC 
I5 oligo 
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Table 11: Plasmids used for the introduction of metabolic bottlenecks using CRISPRi 
(Chapter 3.2) 
Name Genotype Reference 
pdCas9-bacteria p15A, pLtetO-1-dCas9, Cmpr 48 
pgRNA-bacteria pUC19, pBBa_J23119-sgRNA, Ampr 48 
pgRNA-pyrE001 pUC19, pBBa_J23119-sgRNA:pyrE001, Ampr This study 
pgRNA-pyrE002 pUC19, pBBa_J23119-sgRNA:pyrE002, Ampr This study 
pgRNA-pyrE002 pUC19, pBBa_J23119-sgRNA:pyrE003, Ampr This study 
pgRNA-gshB pUC19, pBBa_J23119-sgRNA:gshB, AmpR This study 
pgRNA-gadA pUC19, pBBa_J23119-sgRNA:gadA, AmpR This study 
pgRNA-glmS pUC19, pBBa_J23119-sgRNA:glmS, AmpR This study 
pgRNA-panC pUC19, pBBa_J23119-sgRNA:panC, AmpR This study 
pgRNA-purM pUC19, pBBa_J23119-sgRNA:purM, AmpR This study 
pgRNA-LuxS pUC19, pBBa_J23119-sgRNA:LuxS, AmpR This study 
pgRNA-dapD pUC19, pBBa_J23119-sgRNA:dapD, AmpR This study 
pgRNA-ddlA pUC19, pBBa_J23119-sgRNA:ddlA, AmpR This study 
pgRNA-cysE pUC19, pBBa_J23119-sgRNA:cysE, AmpR This study 
pgRNA-pyrB pUC19, pBBa_J23119-sgRNA:pyrB, AmpR This study 
pgRNA-nrdA pUC19, pBBa_J23119-sgRNA:nrdA, AmpR This study 
pgRNA-mtn pUC19, pBBa_J23119-sgRNA:mtn, AmpR This study 
pgRNA-ArgA pUC19, pBBa_J23119-sgRNA:ArgA, AmpR This study 
pgRNA-leuA pUC19, pBBa_J23119-sgRNA:leuA, AmpR This study 
pgRNA-metK pUC19, pBBa_J23119-sgRNA:metK, AmpR This study 
pgRNA-dapE pUC19, pBBa_J23119-sgRNA:dapE, AmpR This study 
pgRNA-pheA pUC19, pBBa_J23119-sgRNA:pheA, AmpR This study 
pgRNA-murB pUC19, pBBa_J23119-sgRNA:murB, AmpR This study 
pgRNA-metA pUC19, pBBa_J23119-sgRNA:metA, AmpR This study 
pgRNA-proB pUC19, pBBa_J23119-sgRNA:proB, AmpR This study 
pgRNA-hisB pUC19, pBBa_J23119-sgRNA:hisB, AmpR This study 
pgRNA-coaD pUC19, pBBa_J23119-sgRNA:coaD, AmpR This study 
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pgRNA-ilvC pUC19, pBBa_J23119-sgRNA:ilvC, AmpR This study 
pgRNA-pyrE pUC19, pBBa_J23119-sgRNA:pyrE, AmpR This study 
pgRNA-aroL pUC19, pBBa_J23119-sgRNA:aroL, AmpR This study 
pgRNA-nadA pUC19, pBBa_J23119-sgRNA:nadA, AmpR This study 
pgRNA-purB pUC19, pBBa_J23119-sgRNA:purB, AmpR This study 
pgRNA-ArgE pUC19, pBBa_J23119-sgRNA:ArgE, AmpR This study 
pgRNA-folA pUC19, pBBa_J23119-sgRNA:folA, AmpR This study 
 
 
Table 12: Plasmids used for the construction of Split Proteins (Chapter 4) 
Name Genotype or purpose Reference 
pT18 Expression plasmid, AmpR, Plac Gift from Prof. Dr. Daniel 
Ladant 
pT25 Expression plasmid, KanR, Plac Gift from Prof. Dr. Daniel 
Ladant 
pKT25-zip Template for amplification of leucine zippers BATCH EUROMEDEX 
pMT3-FKBP(full-length)- 
DHFR[3] 
Template for amplification of FKBP1,2 and 
DHFR(3) 
Gift from Prof. Dr. 
Stephen Michnick 
pcDNA3-DHFR[1,2:F31S]-
FRAP 
Template for amplification of FRB and 
DHFR1,2 
Gift from Prof. Dr. 
Stephen Michnick 
pT18-FKBP1,2-DHFR(3) AmpR, Plac-FKBP1,2-DHFR(3) This work 
pT25-FRB-DHFR1,2 KanR, Plac-FRB-DHFR1,2 This work 
pT18-Zip-DHFR(3) AmpR, Plac-Zip-DHFR(3) This work 
pT25-Zip-DHFR1,2 KanR, Plac-Zip-DHFR1,2 This work 
 
 
Table 13: Plasmids used for the construction of enzymes with synthetic allosteric 
regulation using the Domain Insertion approach (Chapter 5) 
Name Genotype or purpose Reference 
pTRC99KK pBR322 origin, AmpR, Ptrc Gift from Karl 
Kochanowski 29 
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pTRC99KK-malE pBR322 origin, AmpR, Ptrc-malE This work 
pSB4A5 pSC101 origin, AmpR, PBAD 147 
pSB4A5-malE pSC101 origin, AmpR, PBAD-malE This work 
pSB4A5-cra pSC101 origin, AmpR, PBAD-cra This work 
pSB4A5-fnr pSC101 origin, AmpR, PBAD-fur This work 
pSB4A5-purR pSC101 origin, AmpR, PBAD-purR This work 
pSB4A5-mDHFR pSC101 origin, AmpR, PBAD-mDHFR This work 
pSB4A5-argA pSC101 origin, AmpR, PBAD-argA This work 
pSB4A5-leuA pSC101 origin, AmpR, PBAD-leuA This work 
pSB4A5-hisG pSC101 origin, AmpR, PBAD-hisG This work 
 
 
Table 14: Plasmids used for the development of a method to enrich slow growing strains 
(Chapter 6) 
Name Genotype or purpose Reference 
pSC101_TIMER Tetr, TIMER in pSC101 102 
pBR322_TIMER Ampr, TIMER in pBR322 102 
pBR322-C_TIMER Cmpr, TIMER in pBR322 This study 
   
pNUT1527 Gentr, Ptac-dCas9, pJ23119-sgRNA This study 
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8.4 Molecular working with DNA 
8.4.1 Plasmid preparation 
For plasmid preparations kits from different suppliers (Thermo Scientific, Qiagen, Macherey-
Nagel, Zymo Research) have been used following the manufacturers’ instructions. 
8.4.2 PCR 
Polymerase chain reactions (PCR) were used to amplify DNA. For reactions in which low error 
rates were crucial, Q5 polymerase (NEB) was used; for Colony-PCRs Taq polymerase (NEB) 
has been used. The annealing temperatures were defined by the composition of primers as well 
as the used polymerase and calculated with Benchling (https://benchling.com). As template 
either defined amounts of plasmid DNA or chromosomal DNA has been used. For the 
preparation of chromosomal DNA, small amount of a colony of the strain of interest has been 
re-solubilized in 100 µL H2O and heated for 5 minutes at 90°C. 1 µL of this suspension than had 
been used as template.  
8.4.3 Electrophoresis 
For gel electrophoresis usually 1% agarose gels were used. As buffer system TAE buffer has 
been used. For the isolation of linearized plasmids in some cases 0.8% LB (Lithium Bromide) 
agarose gels were used.  
8.4.4 Purification 
For DNA clean up upon ligation and kits from Thermo Scientific, Qiagen and Zymo Research 
have been used. 
8.4.5 Enzymatic modification 
8.4.5.1 Restriction Digests 
Enzymes from NEB have been used for DNA restriction, following the manufacturer’s 
instructions. High fidelity enzymes were preferred and used when available. 
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8.4.5.2 Ligation 
For ligations of genes into plasmid backbones usually an insert/plasmid-ratio of 1:3 has been 
chosen. The needed amounts of plasmids and inserts have been calculated with the “Ligation 
Calculator” (http://www.insilico.uni-duesseldorf.de/Lig_Input.html, Universität Düsseldorf). Prior 
to ligation in some cases the ends of the plasmid backbone have been dephosphorylated using 
Antarctic Phosphatase (NEB).T4 ligase (NEB, Thermo Scientific) has been used for the ligation, 
the reaction mix was incubated overnight at room temperature. Ligated plasmids were 
subsequently purified using DNA Clean & Concentrator Kit (Zymo Research) in case they were 
planned to be transformed into electrocompetent cells. 
8.4.5.3 Gibson Assembly 
As alternative method to construct plasmids, Gibson Assembly and CPEC have been used. For 
Gibson Assembly 148 multiple DNA fragments with overlapping sequences at their ends are 
required. A 5’ exonuclease partially digests the 5’ ends of double stranded DNA, the resulting 
sticky ends of different DNA fragments anneal and can be covalently joined by a polymerase 
and ligase. We designed fragments in a way that they have overlapping sequences between 20 
and 40 nt and used a Gibson Assembly Master mix from NEB. 
8.4.5.4 CPEC 
Circular polymerase extension cloning (CPEC, 112) also requires overlapping end sequences of 
DNA fragments that are supposed to be connected with each other and includes several rounds 
of denaturation, annealing and extension. First, the DNA fragments are denatured by heat to 
create single strands. Single strands of different DNA fragments can anneal at the overlapping 
sequences from which a polymerase is then synthesizing the missing second strand. 
Overlapping sequences had a length between 20 and 35 nt and where designed to have a very 
similar melting temperature (Tm). As polymerase Q5 polymerase (NEB) had been used, the 
extension time was defined by the length of the longest fragment to assemble. 
8.5 Domain Insertion 
The creation of plasmid libraries with Domain Insertion 73,149 is divided in 6 parts as depicted in 
Figure 52: In addition to the preparation of the insert gene (1), the acceptor plasmid is linearized 
randomly (2), repaired (3), isolated (4) and dephosphorylated (5). Finally, both the linearized 
plasmids and insert genes are ligated together (6).  
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Figure 52: Domain Insertion.  
Domain Insertion can be divided in 6 steps: Amplification of the enzyme gene with phosphorylated primers (1), 
Linearization of the expression plasmid carrying the gene coding for the regulatory domain with a sequence 
independent nuclease (2), repair of the linearized plasmid (3), isolation of the linear plasmids through gel extraction (4), 
dephosphorylation of the ends to prevent re-ligation (5) and ligation of both, plasmids and enzymes (6). Optimized steps 
are highlighted in green. 
 
8.5.1 Preparation of the insert gene 
For the amplification of the insert gene, Q5 polymerase (NEB) and primers that were 
phosphorylated at the 5’ end with T4 polynucleotide kinase (NEB) following the manufacturer’s 
instructions were used. 
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8.5.2 Random Linearization 
8.5.2.1 Determination of the optimal DNaseI concentration 
Needed components: 
• 40 µg plasmid DNA 
• DNaseI (1U/µL)  (Thermo Scientific) 
• Diluent solution:  25 mM Tris-HCl pH7.5, 1mM MnCl2, 6 µL 100x BSA 
(has to be prepared freshly and kept at room temperature) 
• 1.0 M EDTA 
• 0.8% Agarose gel, alternatively 1% 
 
Experimental procedure: 
1) Preheat Thermo Block at 75°C 
2) Preparation of 100 mL 50mM Tris stock: 
(0.6057 mg Tris, pH7.5 with HCl) 
3) Preparation of an agarose gel 
4) Preparation of 500 µL Diluent Solution  
(250 µL Tris-HCl, 5 µL 100 mM MnCl2, 2.5 µL 100x BSA, ad 500 µL H2O) 
(Attention: BSA is pretty viscous!) 
5) Preparation of 800 µL Diluent Solution with plasmid DNA 
(400 µL Tris-HCl, 8 µL 100 mM MnCl2, 4 µL 100x BSA, X µL plasmid DNA (40 µg), ad 800 
µL H2O) 
6) Dilution series of DNaseI: 
Serial dilution of DNaseI: 1:10 dilutions, 8 steps, each 20 µL (2 µL DNaseI or previous 
dilution step  +  18 µL Diluent Solution). Keeping DNaseI on ice. Mixing by pipetting the 
whole reaction volume (20 µL) up and down three times. 
7) Aliquoting 8x 95 µL of the Diluent Solution with plasmid DNA 
8) To each aliquot 5 µL of the DNaseI dilution series added, then mixed by pipetting the whole 
reaction volume (100 µL) up and down three times. 
9) Incubation for exact 8 min at room temperature 
10) Stopping the reaction by adding 1.2 µL. Mixing by pipetting the whole reaction volume 
(102.4 or 124 µL) up and down three times. 
11) Heat inactivation of DNaseI by incubation at 75°C for 10 min 
12) Determination of the optimal DNaseI concentration by loading about 10 µL of the reaction 
products on the agarose gel. The optimal DNaseI concentration is the one that results in a 
sharp band for linearized plasmid without producing a “smear” caused by multiple 
digestions.  
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8.5.2.2 DNaseI digestion 
Needed components: 
• 60 µg Plasmid-DNA  
• DNaseI (1U/µL) (Thermo Scientific) 
• Diluent solution:  25 mM Tris-HCl pH7.5, 1mM MnCl2, 6 µL 100x BSA 
(has to be prepared freshly and kept at room temperature) 
• 1.0 M EDTA 
• PCR Purification Kit 
• Agarose gel (0.8% or 1% agarose in LB or TAE buffer) 
 
Experimental procedure: 
1) Preheating  Thermo Block to 75°C 
2) Preparation of 100 mL 50mM Tris stock  
3) Preparation of an agarose gel (if planned to proceed with repair and isolation of linear 
plasmids after linearization) 
4) Preparation of 500 µL Diluent Solution  
(250 µL Tris-HCl, 5 µL 100 mM MnCl2, 2.5 µL 100x BSA,   ad 500 µL H2O) 
Preparation of 1200 µL Diluent Solution with plasmid DNA 
(600 µL Tris-HCl, 12 µL 100 mM MnCl2, 6 µL 100x BSA,   X µL plasmid DNA (60 µg) 
ad 1200 µL H2O) 
Aliquot 12x 95 µL of the Diluent Solution with plasmid DNA. Incubate for 10 minutes at 
room temperature. 
5) DNaseI: 
Preparation of a serial dilution of DNaseI in 1:10 dilution steps until your previously 
determined optimal concentration of DNaseI is reached. 60 µL DNaseI-Solution are 
required for digestion.  
6) Adding 5 µL of the DNaseI solution to each aliquot of plasmid DNA. Mixing by pipetting the 
whole reaction volume (100 µL) up and down three times.  
7) Incubation for exact 8 min at room temperature 
8) Stopping the reaction by adding 1.2 µL 1M EDTA 
9) Mix by pipetting the whole reaction volume up and down three times. 
10) Heat inactivation of DNaseI by incubation at 75°C for 10 min 
11) 3 times: Combining the contents of 4 tubes to one tube and purification of the DNA using a 
DNA purification kit. 
12) Combining all 3 eluates. 
13) Storing at -20°C or proceeding with repairing (Step 3) 
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8.5.2.3 S1 nuclease digestion 
Needed components: 
• 50 µg Plasmid-DNA  
• S1 Nuclease + Buffer  (as provided by Promega) 
• PCR Purification Kit 
 
Experimental procedure: 
1.) Preheating a heat block to 37°C 
2.)  (25x) 
X µL (2 µg) plasmid DNA,  
2.5 µL 10x S1 Nuclease Buffer,  
0.5 µL S1 Nuclease (10U) 
22 – X µL H2O 
3.) Incubation for 20 min at 37°C 
4.) Stopping the incubation by pooling all reactions and adding DNA binding buffer of a 
DNA purification kit 
5.) Purification of the DNA and elution in H2O. Concentration in Speedvac if needed. 
6.) Storing at -20°C or proceeding with repairing (Step 3) 
 
Either: Proceed with Part 3 
Or: Store the DNA at -20°C 
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8.5.3 Repair of linearized DNA 
Needed components: 
• Linearized plasmid DNA   
• 1 Agarose gel (0.8% in LB buffer) 
• Gel Extraction Kit 
• T7-Ligase 
• T4-Polymerase 
• dNTPs, Ligase Buffer, BSA 
• DNA purification kit 
• Gel Extraction Kit 
• 1.0 M EDTA 
• Antarctic Phosphatase 
 
Experimental procedure: 
1) Preparation of a small agarose gel 
2) Preheating a Thermo Block to 75°C 
3) Cooling down a second Thermo Block to 12°C 
4) Determining the concentration of the Plasmid DNA with a NanoDrop or similar. 
5) Loading 200-500 ng on an agarose gel to analyze the quality of the linearization.  
6) Preparation of a T7-Ligase and T4-Polymerase-Reaction-Mix for repairing the linearized 
plasmids: 
T7-Ligase (160U/1 µg linearized DNA), T4-Polymerase (1U/1 µg linearized DNA), 1.5 µL 
dNTPs (200µM final concentration), 7,5 µL T4-Ligase Buffer (10x), 0.75 µL BSA (100x, 
stored in our freezer) and up to 75 µL your linearized plasmid DNA 
Incubation in multiple tubes with each 75 µL reaction volume. 
7) Incubation for 20 minutes at 12°C 
8) Stopping the reaction by adding 15 µL 50 mM EDTA, mixing by pipetting up and down 
gently and heat inactivating the enzymes for 15 minutes at 75 °C 
9) Letting the solution cooling down to room temperature and isolating the DNA using a PCR 
Purification Kit. Usage of multiple tubes to prevent overloading the columns is 
recommended. 
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8.5.4 Isolation of linearized plasmids and dephosphorylation 
Needed components: 
• Linearized and repaired plasmid DNA   
• 1 Agarose gel (0.8% in LB buffer) 
• Gel Extraction Kit 
• Antarctic Phosphatase 
• DNA purification kit 
 
Experimental procedure: 
1) Pool the isolated DNA and load it on a large agarose gel. As a comparison it is 
recommended to load some plasmid DNA linearized by a restriction enzyme. The by 
DNAseI or S1 nuclease linearized plasmid should run at the same height. 
2) Extracting the band containing the linearized plasmids and purification of the DNA with the 
Gel Extraction Kit. 
3) If more than one band was extracted all elutions should be pooled 
4) Heating the Thermo Block to 37°C 
5) Measure the concentration with the NanoDrop 
6) Dephosphorylation of the DNA with Antarctic Phosphatase: 
up to 1 µg plasmid DNA, 2 µL 10x reaction buffer, 1 µL Antarctic Phosphatase, to 20 µL 
ddH20 
7) Incubation for 30 min at 37°C 
8) Stopping the reaction by incubation for 10 min at 65°C 
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8.5.5 Ligation and Transformation 
For the ligation at the beginning the ligation protocol described in 149 (see below) has been 
used. In later attempts, the Blunt/TA-ligation mix (NEB) had been used which is optimized for 
ligations of fragments with blunt ends, following the manufacturer’s instructions. 
 
Needed components: 
• T4-Ligase 
• 10x Ligase Buffer 
• PEG-8000 
• Plasmid, Insert DNA 
Experimental procedure: 
• x µL Plasmid (1µg) 
• y µL Insert DNA (ratio of 1:1.5; calculate the needed amount with Ligation 
Calculator (http://www.insilico.uni-duesseldorf.de/Lig_Input.html)) 
• PEG-8000 (final concentration: 5%) 
• T4-Ligase Buffer (final concentration: 1x) 
• T4 Ligase (2000 U) 
• ad 30 µL H2O 
Incubation at room temperature overnight, afterwards the DAN should be purified prior to 
transformation into electrocompetent DH10β cells (Thermo Scientific). 
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8.6 Cloning of single CRISPRi plasmids 
To construct single CRISPRi plasmids, we followed the protocol by 48. For that, new base 
pairing sequences were designed by identification of PAM sequences of the composition NGG 
within the gene of interest and introduced in the sgRNA expression plasmid pgRNA-bacteria by 
adding the target sequence to the forward primer. With this primer and a reverse primer binding 
on the plasmid backbone the plasmid had been amplified. The endings were subsequently 
phosphorylated with T4 PNK (NEB) and ligated with T4 ligase (NEB) or the Blunt/TA-ligation mix 
(NEB). 
8.7 Cloning of a pooled CRISPRi library 
For the creation of the pooled CRISPRi library (Chapter 6.2.1), target sequences were identified 
and chosen using a Matlab script we wrote for this purpose. Oligonucleotides including the 
target sequence and flanking regions 65 nt upstream and downstream of the variable sequence 
were purchased from Agilent (USA) as pooled oligonucleotide stock. For the construction of the 
library, the oligonucleotides have been amplified in a low cycle PCR (15 cycles, 0.02 pmol 
template) to create double stranded DNA. In parallel the plasmid backbone (pNUT1527) has 
been amplified without the gene targeting sequence. Next, both DNA fragments were 
assembled with Gibson Assembly using the 65 nt flanking regions as overlapping sequence.  
4 Gibson Assembly reactions were pooled, purified, concentrated and transformed into highly 
competent E. coli DH10β cells. The library composition and coverage has been examined with 
Illumina sequencing (Figure 40, page 80). 
8.8 Illumina Sequencing 
For Illumina Sequencing a two-step PCR approach was used to generate DNA fragments that 
are compatible with Illumina sequencing. First, a 300 bp fragment including the sgRNA 
sequence and flanking regions has been amplified using Q5 polymerase (New England Biolabs, 
USA) 150 ng purified library plasmids as template in a 50 μL PCR reaction with following 
settings: 98 °C for 10 s, 12 cycles of 98 °C for 10 s, 65 °C for 30 s and 72 °C for 15 s; final 
extension at 72 °C for 5 min. Afterwards, the PCR products were purified using a NucleoSpin 
Gel and PCR Clean-up Kit (Macherey-Nagel, Germany).  
Second, to add different pairs of indexes (i5 and i7) to each amplicon, a second PCR using 
Phusion High- Fidelity DNA Polymerase (New England BioLabs, USA) has been performed with 
the following conditions: 98 °C for 30 s; 12 cycles of 98 °C for 10 s, 55 °C for 30 s and 72 °C for 
20 s; final extension at 72 °C for 5 min. The PCR products were cleaned up using AMPure XP 
beads (Beckman Coulter). After cleanup, 10 μL of each library was pooled. The concentration of 
the library pool was measured using the Qubit dsDNA BR Assay on a Qubit 2.0 Fluorometer. 
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The pooled sequences were then diluted to a final concentration of 2 nM and loaded on a 
MiniSeq High Output Cartridge following the manufacturer’s instructions. 50% PhiX sample was 
spiked in to ensure sufficient sequence diversity. Sequences were obtained from single-end 
reads and mapped to the 7184 sgRNAs in the library using a Matlab Script. Only sequences 
that mapped to sgRNA guide sequences in the reference library (Table S2 in the publication) 
were used to calculate read counts. Fold changes were calculated as 
(readsafter/readsafter,total)/(readsbefore/readsbefore,total), where “before” and “after” indicate before/after 
enrichment, and “total” the total read counts. Sequences with less than 10 reads before 
enrichment were removed from further analysis. 
8.9 Mass Spectrometry 
Cells were either cultured in 100 mL flasks with 5 – 10 mL culture volume or 12-well flat 
transparent microtiter plates. When cells reached ODs between 0.5 and 1, an equivalent of 1 
mL with OD600 nm = 1 of the culture was vacuum-filtered on a 0.45 μm poresize filter 
(HVLP02500, Merck Millipore). Filters were immediately transferred into 40:40:20 (vol %) 
acetonitrile/methanol/water at −20 °C for extraction. Extracts were centrifuged for 15 min at 
13000 rpm at −9 °C. Centrifuged extracts were analyzed by LC−MS/MS, with an Agilent 6495 
triple quadrupole mass spectrometer (Agilent Technologies) as described previously 104. 
Obtained data sets have been analyzed with Matlab (Mathworks, USA) and MassHunter 
software (Agilent, USA). 
8.10 Flow Cytometry 
8.10.1 Sample preparation and Data Analysis 
Cells were diluted in fresh medium or 1xTB buffer prior to analysis and sorting of fractions if 
needed. For fluorescence- activated cell analysis a BD LSRFortessa SORP flow-cytometer (BD 
Biosciences, USA) was used. Fluorescence-activated cell sorting was carried out on a BD 
FACS Aria Fusion (BD Biosciences, USA). 561 nm lasers, 502 long pass and 532/ 22 bandpass 
filters were used for the detection of the red fraction of TIMER. 488 nm lasers, 600 long pass 
and a 520/30 band-pass filters were used for green fluorescent TIMER. To identify cells in the 
forward/side scatter plot, 488 nm lasers were used. 10 000 or 100 000 cells were sorted per 
sample according to the red/green fluorescence ratio. BD FACSDiva software version 8.0 (BD 
Biosciences, USA) and FlowJo v10.4.1 (FlowJo LLC, USA) were used for analysis of the 
acquired data. 
Chapter 8 - Materials and Methods 
 
126 
8.10.2 Enrichment of slow growing cells 
For the enrichment of slow growing cells with a metabolic bottleneck in a pathway required for 
growth in absence of amino acids (Chapter 6.2.2), cells were grown under two different 
conditions. For the first culture several 100 mL flasks each with 5 mL M9-Glucose medium 
supplemented with 1 mM of each amino acid has been inoculated with defined volumes of the 
cryo stock with dilutions between 1:1000 and 1:1,000,000. The cultures were then incubated at 
37°C and shaking for 6 hours.  
Desired was a culture with an optical density between 0.3 and 0.7 (mid-exponential phase). 0.5 
mL of such a culture has been filtered, washed with 10 mL prewarmed M9 glucose medium 
without amino acids and resuspended in 5 mL prewarmed M9 glucose medium without amino 
acids.  
With this suspension several 100 mL flasks with M9 glucose medium have been inoculated with 
final dilutions between 1:50 and 1:100.000 and total volumes of 5 mL to ensure sufficient 
aeration. The resulting cultures have been incubated for 6 hours shaking at 37°C, a culture with 
an optical density of about 0.2 has then subsequently been used for sorting. 
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